Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
36000.0 | 2018-05-04 00:00:00 UTC | Health Care Sector Update for 05/04/2018: SRPT, ACAD, PTLA, CELG | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-05042018-srpt-acad-ptla-celg-2018-05-04 | nan | nan | Top Health Care Stocks
JNJ +0.89%
PFE +0.19%
ABT +1.23%
MRK +0.30%
AMGN +1.04%
Health care stocks were moderately higher in late trading Friday afternoon, including a nearly 0.6% gain for the NYSE Health Care Index in recent trade. Also today, shares of health care companies in the S&P 500 were up more than 0.7% as a group while the Nasdaq Biotechnology index was rising over 1.1% today.
Among health care stocks moving on news:
+ Sarepta Therapeutics ( SRPT ) jumped out to its best share price in more than 18 years on Friday, climbing over 16% to $90.99 a share, after more than halving its adjusted Q1 net loss compared with year-ago levels and racing to a nearly four-fold year-over-year increase in quarterly revenue. Excluding one-time items, the specialty drugmaker recorded a $0.28 per share net loss during the three months ended March 31, improving on a $0.57 per share net loss during the year-ago period, while revenue rose 296% to $64.6 million from 16.3 million last year. Analysts, on average, had been expecting a $0.26 per share non-GAAP net loss on $65.31 million in revenue, with the below-consensus Q1 results prompting a downgrade of its stock to Perform from Outperform. Separately, Sarepta late Thursday announced an an exclusive partnership with Myonexus Therapeutics, adding five gene therapy candidates to treat various forms of Limb-girdle muscular dystrophies to its product pipeline.
In other sector news:
+ Portola Pharmaceuticals ( PTLA ) climbed as much as 33% on Friday after U.S. regulators approved the company's Andexxa medication, which was developed to reverse the anticoagulation effect of certain drugs in order to stop life-threatening or uncontrolled bleeding. The U.S. Food and Drug Administration decision follows two successful Phase III clinical trials evaluating the safety and efficacy of Andexxa in healthy patients who were being treated with either Factor Xa inhibitors rivaroxaban or apixaban.
+ ACADIA Pharmaceuticals ( ACAD ) still was about 12% higher this afternoon, staying within close range of its intra-day high, after Friday reporting a narrower-than-expected Q1 net loss on above-consensus sales. Net loss for the three months ended March 31 was $0.44 per share, trimming a $0.72 per share net loss from the same quarter last year and beating the Capital IQ consensus expecting a $0.56 per share net loss. Net sales grew to $48.9 million from $15.3 million last year, also topping the $47.1 million analyst mean. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million.
- Celgene ( CELG ) spent Friday on positive ground after reporting adjusted Q1 net income of $2.05 per share on $3.54 billion in revenue, beating the Capital IQ consensus expecting a $1.96 per share non-GAAP profit on $3.47 billion in revenue.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | + ACADIA Pharmaceuticals ( ACAD ) still was about 12% higher this afternoon, staying within close range of its intra-day high, after Friday reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Separately, Sarepta late Thursday announced an an exclusive partnership with Myonexus Therapeutics, adding five gene therapy candidates to treat various forms of Limb-girdle muscular dystrophies to its product pipeline. | + ACADIA Pharmaceuticals ( ACAD ) still was about 12% higher this afternoon, staying within close range of its intra-day high, after Friday reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Health care stocks were moderately higher in late trading Friday afternoon, including a nearly 0.6% gain for the NYSE Health Care Index in recent trade. | + ACADIA Pharmaceuticals ( ACAD ) still was about 12% higher this afternoon, staying within close range of its intra-day high, after Friday reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Among health care stocks moving on news: + Sarepta Therapeutics ( SRPT ) jumped out to its best share price in more than 18 years on Friday, climbing over 16% to $90.99 a share, after more than halving its adjusted Q1 net loss compared with year-ago levels and racing to a nearly four-fold year-over-year increase in quarterly revenue. | ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. + ACADIA Pharmaceuticals ( ACAD ) still was about 12% higher this afternoon, staying within close range of its intra-day high, after Friday reporting a narrower-than-expected Q1 net loss on above-consensus sales. Health care stocks were moderately higher in late trading Friday afternoon, including a nearly 0.6% gain for the NYSE Health Care Index in recent trade. |
36001.0 | 2018-05-04 00:00:00 UTC | Health Care Sector Update for 05/04/2018: ACAD,PTLA,CELG | ACAD | https://www.nasdaq.com/articles/health-care-sector-update-05042018-acadptlacelg-2018-05-04 | nan | nan | Top Health Care Stocks
JNJ +0.41%
PFE +0.17%
ABT +1.10%
MRK +0.10%
AMGN +0.86%
Health care stocks were moderately higher Friday afternoon, including a nearly 0.2% gain for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up more than 0.4% as a group while the Nasdaq Biotechnology index was rising over 0.9%.
Among health care stocks moving on news:
+ ACADIA Pharmaceuticals ( ACAD ) was almost 12% higher Friday afternoon, staying within close range of its intra-day high, after reporting a narrower-than-expected Q1 net loss on above-consensus sales. Net loss for the three months ended March 31 was $0.44 per share, trimming a $0.72 per share net loss from the same quarter last year and beating the Capital IQ consensus expecting a $0.56 per share net loss. Net sales grew to $48.9 million from $15.3 million last year, also topping the $47.1 million analyst mean. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million.
In other sector news:
+ Portola Pharmaceuticals ( PTLA ) climbed as much as 33% on Friday after US regulators cleared the company's Andexxa medication developed to reverse the anticoagulation effect of certain drugs to stop life-threatening or uncontrolled bleeding. The US Food and Drug Administration decision follows two successful phase III clinical trials that evaluated the safety and efficacy of Andexxa in patients being treated with Factor Xa inhibitors rivaroxaban and apixaban.
- Celgene ( CELG ) has spent Friday trading on positive ground after reporting adjusted Q1 net income of $2.05 per share on $3.54 billion revenue, beating the Capital IQ consensus expecting a $1.96 per share non-GAAP profit on $3.47 billion in revenue.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: + ACADIA Pharmaceuticals ( ACAD ) was almost 12% higher Friday afternoon, staying within close range of its intra-day high, after reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. In other sector news: + Portola Pharmaceuticals ( PTLA ) climbed as much as 33% on Friday after US regulators cleared the company's Andexxa medication developed to reverse the anticoagulation effect of certain drugs to stop life-threatening or uncontrolled bleeding. | Among health care stocks moving on news: + ACADIA Pharmaceuticals ( ACAD ) was almost 12% higher Friday afternoon, staying within close range of its intra-day high, after reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Net loss for the three months ended March 31 was $0.44 per share, trimming a $0.72 per share net loss from the same quarter last year and beating the Capital IQ consensus expecting a $0.56 per share net loss. | Among health care stocks moving on news: + ACADIA Pharmaceuticals ( ACAD ) was almost 12% higher Friday afternoon, staying within close range of its intra-day high, after reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Net loss for the three months ended March 31 was $0.44 per share, trimming a $0.72 per share net loss from the same quarter last year and beating the Capital IQ consensus expecting a $0.56 per share net loss. | Among health care stocks moving on news: + ACADIA Pharmaceuticals ( ACAD ) was almost 12% higher Friday afternoon, staying within close range of its intra-day high, after reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Top Health Care Stocks |
36002.0 | 2018-05-01 00:00:00 UTC | Will ACADIA (ACAD) Disappoint Investors This Earnings Season? | ACAD | https://www.nasdaq.com/articles/will-acadia-acad-disappoint-investors-this-earnings-season-2018-05-01 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD is expected to release first-quarter 2018 results on May 8. In the last reported quarter, ACADIA delivered a positive earnings surprise of 5.17%. The company delivered an average positive earnings surprise of 11.24% in the last four quarters.
ACADIA's shares have tumbled 47.5% year to date compared with the industry 's decline of 10.7%.
Let's see how things are shaping up for this announcement.
Factors at Play
ACADIA is focused on developing products for treating unmet medical needs in central nervous system ("CNS"). The performance of its first approved drug, Nuplazid (pimavanserin), for treating hallucinations and delusions associated with Parkinson's disease ("PD") psychosis, has been impressive since its launch in April 2016.
The company is also on track with its multi-year plans of developing Nuplazid in indications beyond PD psychosis. The company is studying the drug in five clinical programs for Nuplazid - Alzheimer's disease agitation, Alzheimer's disease psychosis, Schizophrenia inadequate response, Schizophrenia negative symptoms and major depressive disorders.
In October 2017, the company initiated a phase III HARMONY study in dementia-related psychosis or DRP. The company also received Breakthrough Therapy Designation from the FDA for Nuplazid for the treatment of DRP. Following an End-of-Phase II meeting with the FDA, robust positive results from one phase III study, together with supported data from prior studies with Nuplazid could serve as the basis of a supplementary new drug application.
We expect the company to provide further update on the progress of this study during first-quarter earnings call.
The company expects that full-year Nuplazid net product sales for 2018 will be between $255 million and $270 million, with net sales for the first quarter of 2018 between $45 million and $48 million. The company expects strong volume growth for Nuplazid.
What Our Model Indicates
Our proven model does not show an earnings beat for ACADIA this quarter. This is because a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - for this to happen. However, that is not the case here as you will see below.
Zacks ESP: ACADIA has an Earnings ESP of -0.36%. This is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 56 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: ACADIA currently has a Zacks Rank #2 which increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into an earnings announcement especially when the company is seeing negative estimate revisions.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Celgene Corporation CELG is scheduled to release its first quarter 2018 results on May 4. The company has an Earnings ESP of +0.63% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here .
Adverum Biotechnologies, Inc. ADVM has an Earnings ESP of +6.9% and currently carries a Zacks Rank #3. The company is expected to release first-quarter results on May 8.
Emergent Biosolutions Inc. EBS has an Earnings ESP of +61.8% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 3.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celgene Corporation (CELG): Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Factors at Play ACADIA is focused on developing products for treating unmet medical needs in central nervous system ("CNS"). ACADIA Pharmaceuticals Inc.ACAD is expected to release first-quarter 2018 results on May 8. In the last reported quarter, ACADIA delivered a positive earnings surprise of 5.17%. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks That Warrant a Look Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to release first-quarter 2018 results on May 8. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks That Warrant a Look Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to release first-quarter 2018 results on May 8. | ACADIA Pharmaceuticals Inc.ACAD is expected to release first-quarter 2018 results on May 8. In the last reported quarter, ACADIA delivered a positive earnings surprise of 5.17%. ACADIA's shares have tumbled 47.5% year to date compared with the industry 's decline of 10.7%. |
36003.0 | 2018-04-26 00:00:00 UTC | Implied IWF Analyst Target Price: $157 | ACAD | https://www.nasdaq.com/articles/implied-iwf-analyst-target-price-157-2018-04-26 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 1000 Growth ETF (Symbol: IWF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $157.11 per unit.
With IWF trading at a recent price near $135.05 per unit, that means that analysts see 16.33% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IWF's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and L Brands, Inc (Symbol: LB). Although ACAD has traded at a recent price of $15.20/share, the average analyst target is 238.82% higher at $51.50/share. Similarly, BMRN has 40.17% upside from the recent share price of $81.53 if the average analyst target price of $114.28/share is reached, and analysts on average are expecting LB to reach a target price of $46.84/share, which is 32.09% above the recent price of $35.46. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and LB:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $15.20/share, the average analyst target is 238.82% higher at $51.50/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and LB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWF's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and L Brands, Inc (Symbol: LB). | Three of IWF's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and L Brands, Inc (Symbol: LB). Although ACAD has traded at a recent price of $15.20/share, the average analyst target is 238.82% higher at $51.50/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and LB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and LB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWF's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and L Brands, Inc (Symbol: LB). Although ACAD has traded at a recent price of $15.20/share, the average analyst target is 238.82% higher at $51.50/share. | Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and LB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWF's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and L Brands, Inc (Symbol: LB). Although ACAD has traded at a recent price of $15.20/share, the average analyst target is 238.82% higher at $51.50/share. |
36004.0 | 2018-04-25 00:00:00 UTC | RSI Alert: Acadia Pharmaceuticals (ACAD) Now Oversold | ACAD | https://www.nasdaq.com/articles/rsi-alert-acadia-pharmaceuticals-acad-now-oversold-2018-04-25 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $14.51 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 40.4. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $14.51 per share, with $41.20 as the 52 week high point - that compares with a last trade of $15.20.
According to the ETF Finder at ETF Channel, ACAD makes up 2.34% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 1.1% on the day Wednesday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $14.51 per share. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $14.51 per share, with $41.20 as the 52 week high point - that compares with a last trade of $15.20. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $14.51 per share, with $41.20 as the 52 week high point - that compares with a last trade of $15.20. In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $14.51 per share. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $14.51 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $14.51 per share, with $41.20 as the 52 week high point - that compares with a last trade of $15.20. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $14.51 per share. According to the ETF Finder at ETF Channel, ACAD makes up 2.34% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 1.1% on the day Wednesday. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36005.0 | 2018-04-25 00:00:00 UTC | This Explains Why Acadia Pharmaceuticals Is Selling Off Today | ACAD | https://www.nasdaq.com/articles/explains-why-acadia-pharmaceuticals-selling-today-2018-04-25 | nan | nan | What happened
Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) dropped 19% as of 3:00 p.m. EDT on Wednesday after a news report was published on CNN stating that the Food and Drug Administration (FDA) will re-examine the safety profile of its Parkinson's Disease Psychosis (PDP) drug Nuplazid.
So what
CNN is reporting that FDA Commissioner Scott Gottlieb was asked about Nuplazid last week during a budget hearing with Congress. At the time, he promised Congress that he would "take another look" at the drug.
CNN confirmed today in a news report that the agency had already begun conducting a new evaluation of the drug. In fact, the report states that the review had begun several weeks ago, which coincides perfectly with the timing of another CNN report that highlighted a growing number of patient deaths and adverse events that may be related to the use of Nuplazid.
This news report isn't sitting well with traders, which is why shares are being mauled today.
Now what
Hearing that the FDA has opened up an investigation to re-examine Nuplazid certainly isn't good news for investors. The best-case scenario is that the FDA takes another look at the drug and does nothing. The worst case is that they determine that the benefits of using Nuplazid do not outweigh the risks and they decide to pull the drug from the market. If that happens, then the bull case for owning Acadia will be obliterated.
Which way the agency is going to lean at this point is anyone's guess. Bulls and bears alike should proceed with caution.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 2, 2018
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) dropped 19% as of 3:00 p.m. EDT on Wednesday after a news report was published on CNN stating that the Food and Drug Administration (FDA) will re-examine the safety profile of its Parkinson's Disease Psychosis (PDP) drug Nuplazid. If that happens, then the bull case for owning Acadia will be obliterated. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) dropped 19% as of 3:00 p.m. EDT on Wednesday after a news report was published on CNN stating that the Food and Drug Administration (FDA) will re-examine the safety profile of its Parkinson's Disease Psychosis (PDP) drug Nuplazid. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. If that happens, then the bull case for owning Acadia will be obliterated. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) dropped 19% as of 3:00 p.m. EDT on Wednesday after a news report was published on CNN stating that the Food and Drug Administration (FDA) will re-examine the safety profile of its Parkinson's Disease Psychosis (PDP) drug Nuplazid. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. If that happens, then the bull case for owning Acadia will be obliterated. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) dropped 19% as of 3:00 p.m. EDT on Wednesday after a news report was published on CNN stating that the Food and Drug Administration (FDA) will re-examine the safety profile of its Parkinson's Disease Psychosis (PDP) drug Nuplazid. If that happens, then the bull case for owning Acadia will be obliterated. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. |
36006.0 | 2018-04-19 00:00:00 UTC | Diamond Stocks Aren't Forever -- Your Shot At An Easy 35.8% Gain | ACAD | https://www.nasdaq.com/articles/diamond-stocks-arent-forever-your-shot-easy-358-gain-2018-04-19 | nan | nan | Any man who's gone through it will tell you that a lot of work, money and stress go into buying a diamond. I mean, behind your house and your car, this little rock is one of the most expensive purchases in life. Retailers are fighting for your business, and competition among jewelers is beyond fierce -- and given the potential profits involved, it has to be.
According to the Houston Chronicle , diamonds can be easily marked up 100% or more by brick-and-mortar jewelers like Tiffany and Cartier. And gone are the days of walking to your local jeweler -- the guy your parents went to when you were growing up. If you're not one of society's elite, chances are you're headed to a jewelry chain or looking online.
Online diamond retailers like Blue Nile, which may mark up a diamond only 18% or so, have made deep cuts into everyone else's profit margins. From eBay to Amazon, e-tailers are hitting the diamond game hard. The industry is being diluted further by the rise of niche, handcrafted jewelry available for sale on sites like Etsy, which only further threatens the profits of traditional jewelry retailers.
It's this rising trend of online, direct jewelers -- along with tighter wallets in general -- that could spell more pain for diamond and jewelry giant Signet (NYSE: SIG ) , a company already experiencing problems.
Diamonds Aren't This Stock's Best Friend
If you're not familiar, Signet Jewelers is the world's largest retailer of diamond jewelry and the largest specialty jewelry retailer in the United States, the U.K. and Canada. Under brands like Jared, Kay Jewelers, Zales and others, the company operates 3,500 stores that dominate North America and the U.K.
The company caters to the middle class (as it's lacking the cache of higher-end brands), with many locations in and around malls or suburban shopping centers.
But as you may know, home prices have been skyrocketing ... interest rates are increasing... fuel prices are rising ... and consumer debt is jumping. And since most middle-class folks just want the best diamond at the cheapest price, the internet may be the place they go to shop.
As broad consumer costs build exponentially, the above factors are squeezing our wallets and purses. This leaves less room for excess, i.e., big, expensive diamonds and jewelry -- the kind that used to mean fat margins for Signet.
Signet also derives $0 in revenue from Asia, the region where the jewelry market share is growing the most .
Shares have nearly reached analysts' forward target of $38.44, and with only two of 14 analysts listing the stock as a "buy." I think shares have gotten ahead of themselves in this last rally.
As problems persist and revenues continue to decline, Signet's shares are likely to start moving in that same direction.
Now, some investors may be satisfied with shorting the stock. That's fine. If SIG drops 12.5% to hit that level, then it'll be a good trade. But my Profit Amplifier subscribers and I could see a potential 35.8% gain by July if the stock falls to this level by using call options. That's 131% annualized.
Sounds crazy right? It isn't -- Wall Street uses the same strategy every day. If this still sounds risky to you, maybe because you're new to options trading , know that this trade breaks even if SIG hits $36.90. That's just about 5% below recent prices, a move I think we'll see sooner rather than later given the faltering market and the accelerating rise of online diamond sales.
How You Can Get In On This Trade
It wouldn't be fair to my premium Profit Amplifier subscribers to reveal the specifics of this options trade in this article. But my proven strategy could be just what you need to make more on your trades than you thought possible.
While the rest of the crowd is simply buying stocks and hoping for the best, my subscribers and I have spent years "raiding" the market with our simple options trades, taking more than our fair share of gains.
I'm talking about returns of 31%, 35%, and more -- all in a matter of weeks rather than months or years. In fact, we just closed a trade on TripAdvisor (Nasdaq: TRIP ) for a clean 26.3% in just 10 days .
Bottom line, my stock market raiding technique is the best way to increase your returns while preserving capital and reducing risk. Of course, that's only if it's done correctly.
That's why I created a special report that will walk you through the steps I take when going on market raids, which should help you avoid the costly mistakes many new traders experience. If you'd like to make trades like the one I described today -- or even potentially make 80% when a stock only moves 8% -- go here .
Related Articles
3 Sectors And Stocks Primed For First-Quarter Earnings
The Secret To Matching 2017's Gains In 2018
This Overlooked Sector Is On The Move
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2016 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's this rising trend of online, direct jewelers -- along with tighter wallets in general -- that could spell more pain for diamond and jewelry giant Signet (NYSE: SIG ) , a company already experiencing problems. The company caters to the middle class (as it's lacking the cache of higher-end brands), with many locations in and around malls or suburban shopping centers. While the rest of the crowd is simply buying stocks and hoping for the best, my subscribers and I have spent years "raiding" the market with our simple options trades, taking more than our fair share of gains. | Diamonds Aren't This Stock's Best Friend If you're not familiar, Signet Jewelers is the world's largest retailer of diamond jewelry and the largest specialty jewelry retailer in the United States, the U.K. and Canada. Related Articles 3 Sectors And Stocks Primed For First-Quarter Earnings The Secret To Matching 2017's Gains In 2018 This Overlooked Sector Is On The Move The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. © Copyright 2001-2016 StreetAuthority, LLC. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's this rising trend of online, direct jewelers -- along with tighter wallets in general -- that could spell more pain for diamond and jewelry giant Signet (NYSE: SIG ) , a company already experiencing problems. Diamonds Aren't This Stock's Best Friend If you're not familiar, Signet Jewelers is the world's largest retailer of diamond jewelry and the largest specialty jewelry retailer in the United States, the U.K. and Canada. While the rest of the crowd is simply buying stocks and hoping for the best, my subscribers and I have spent years "raiding" the market with our simple options trades, taking more than our fair share of gains. | Signet also derives $0 in revenue from Asia, the region where the jewelry market share is growing the most . If this still sounds risky to you, maybe because you're new to options trading , know that this trade breaks even if SIG hits $36.90. That's just about 5% below recent prices, a move I think we'll see sooner rather than later given the faltering market and the accelerating rise of online diamond sales. |
36007.0 | 2018-04-11 00:00:00 UTC | Close Update: U.S. Equities Post First Slide in Three Days as Global Political Worries Dent Sentiment | ACAD | https://www.nasdaq.com/articles/close-update-us-equities-post-first-slide-three-days-global-political-worries-dent | nan | nan | Wall Street retreated for the first time in three days in a choppy mid-week session that saw the major equity indexes reclaim some losses but still end lower as heightened geopolitical tensions dented investor sentiment heading into earnings season.
President Donald Trump's tweets warning Russia to expect missiles to be fired on Syria had markets in the red from the open. While gains in Facebook ( FB ) as CEO Mark Zuckerberg testified to U.S. lawmakers for a second day helped the Nasdaq spend part of the session in the green, the selling tone was back in play late as the benchmarks weakened into the close.
On the S&P 500 Wednesday just two of 11 sectors managed gained, with energy leading on a 1% rise amid a surge in oil prices amid the political tensions. Losses were led by telecommunications and financials. The Dow saw almost all of its 30 blue chip components retreat, by just three advancing. Boeing ( BA ) and UnitedHealth ( UNH ) were both down about 2.2%.
Markets slightly extended the selling tone after minutes from the Federal Open Market Committee's meeting last month that showed all members viewed economic data as positive and said they expect further rate hikes, while a strong majority of Fed officials saw the trade war as a downside risk.
While politics has driven much of the moves in markets lately, investors were awaiting the unofficial start of the first-quarter reporting season, with Goldman Sachs projecting in a note earlier that earnings per share are seen rising 17% on the S&P 500, according to the consensus.
But Wells Fargo said EPS growth for the S&P 500 might have peaked in the first quarter and could slow through the rest of 2018.
Here's where the markets stood by the close:
US MARKETS
Dow Jones Industrial Average was down 218.55 points (-0.90%)
S&P 500 was down 14.68 points (-0.55%)
Nasdaq Composite Index was down 25.27 points (-0.36%)
GLOBAL SENTIMENT
FTSE 100 was down 0.13%
Nikkei 225 was down 0.49%
Hang Seng Index was up 0.55%
Shanghai China Composite Index was up 0.56%
UPSIDE MOVERS
(+) EYEG (+26.6%) Granted patent for iontophoretic contact lens
(+) ACAD (+7.67%) FDA approves risk disclosure for Nuplazid
(+) MAT (+6.58%) Jefferies raises to hold from underperform, lifts PT to $13 vs $12
(+) HLT (+6.13%) Prices senior notes and secondary offering
(+) NFLX (+1.88%) Cowen boosts PT to $325 from $275
DOWNSIDE MOVERS
(-) LBCC (-37.14%) Will be delisted on Nasdaq for failing to maintain market cap above $35 mln
(-) NTEC (-17.97%) Plans stock offering
(-) QNST (-17.69%) Short seller Kerrisdale calls company an "outdated online marketer...with bad business model"
(-) FAST (-6.19%) Fiscal Q1 results meet Street expectations
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) EYEG (+26.6%) Granted patent for iontophoretic contact lens (+) ACAD (+7.67%) FDA approves risk disclosure for Nuplazid (+) MAT (+6.58%) Jefferies raises to hold from underperform, lifts PT to $13 vs $12 (+) HLT (+6.13%) Prices senior notes and secondary offering (+) NFLX (+1.88%) Cowen boosts PT to $325 from $275 Wall Street retreated for the first time in three days in a choppy mid-week session that saw the major equity indexes reclaim some losses but still end lower as heightened geopolitical tensions dented investor sentiment heading into earnings season. While gains in Facebook ( FB ) as CEO Mark Zuckerberg testified to U.S. lawmakers for a second day helped the Nasdaq spend part of the session in the green, the selling tone was back in play late as the benchmarks weakened into the close. | (+) EYEG (+26.6%) Granted patent for iontophoretic contact lens (+) ACAD (+7.67%) FDA approves risk disclosure for Nuplazid (+) MAT (+6.58%) Jefferies raises to hold from underperform, lifts PT to $13 vs $12 (+) HLT (+6.13%) Prices senior notes and secondary offering (+) NFLX (+1.88%) Cowen boosts PT to $325 from $275 Dow Jones Industrial Average was down 218.55 points (-0.90%) S&P 500 was down 14.68 points (-0.55%) Nasdaq Composite Index was down 25.27 points (-0.36%) (-) LBCC (-37.14%) Will be delisted on Nasdaq for failing to maintain market cap above $35 mln (-) NTEC (-17.97%) Plans stock offering (-) QNST (-17.69%) Short seller Kerrisdale calls company an "outdated online marketer...with bad business model" (-) FAST (-6.19%) Fiscal Q1 results meet Street expectations The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) EYEG (+26.6%) Granted patent for iontophoretic contact lens (+) ACAD (+7.67%) FDA approves risk disclosure for Nuplazid (+) MAT (+6.58%) Jefferies raises to hold from underperform, lifts PT to $13 vs $12 (+) HLT (+6.13%) Prices senior notes and secondary offering (+) NFLX (+1.88%) Cowen boosts PT to $325 from $275 Wall Street retreated for the first time in three days in a choppy mid-week session that saw the major equity indexes reclaim some losses but still end lower as heightened geopolitical tensions dented investor sentiment heading into earnings season. Markets slightly extended the selling tone after minutes from the Federal Open Market Committee's meeting last month that showed all members viewed economic data as positive and said they expect further rate hikes, while a strong majority of Fed officials saw the trade war as a downside risk. | (+) EYEG (+26.6%) Granted patent for iontophoretic contact lens (+) ACAD (+7.67%) FDA approves risk disclosure for Nuplazid (+) MAT (+6.58%) Jefferies raises to hold from underperform, lifts PT to $13 vs $12 (+) HLT (+6.13%) Prices senior notes and secondary offering (+) NFLX (+1.88%) Cowen boosts PT to $325 from $275 Wall Street retreated for the first time in three days in a choppy mid-week session that saw the major equity indexes reclaim some losses but still end lower as heightened geopolitical tensions dented investor sentiment heading into earnings season. President Donald Trump's tweets warning Russia to expect missiles to be fired on Syria had markets in the red from the open. |
36008.0 | 2018-04-10 00:00:00 UTC | Don't Try to Catch This Falling Knife | ACAD | https://www.nasdaq.com/articles/dont-try-catch-falling-knife-2018-04-10 | nan | nan | Acadia Pharmaceuticals ' (NASDAQ: ACAD) stock got walloped yesterday after a CNN report suggested that Nuplazid, the company's Parkinson's disease psychosis medication (PDP), may be tied to an increased rate of mortality among patients, and that the drug may not even be all that effective at treating hallucinations, as advertised. My Foolish colleague Brian Feroldi provided an excellent summary of yesterday's events here .
As a bargain hunter who loves a good sale, I'm generally all ears whenever a biotech stock drops by over 20% in a single session, especially when it craters on over-the-top reporting. And make no bones about it, this CNN report definitely has some serious flaws. But that doesn't mean Acadia is now a screaming buy. Let's take a deeper look.
The controversy
Personally, I don't see how it's newsworthy to report that patients who are 81.9 years old on average, and taking several medications with an advanced neurological disease, are passing away at an elevated rate when a new drug is added to their regimen. And the Food and Drug Administration (FDA), in its pointed response to CNN, stated as much.
Moreover, the agency has been closely monitoring Nuplazid's emerging real-world risk-to-benefit profile. And so far, regulators haven't seen fit to issue any type of new safety warning. This drug already has a highly restrictive label, after all. Acadia was quick to note these facts in its rebuttal to CNN yesterday.
Long story short, CNN's reporters took the overwhelmingly minority view of Nuplazid's risk-to-reward profile to argue that regulators were too quick to approve a potentially dangerous drug. In doing so, they left out the context in which this drug is being used, namely elderly patients with a number of co-morbidities. They also didn't provide any background about the serious unmet medical need posed by PDP, which is a key reason why regulators felt compelled to approve Nuplazid's New Drug Application on a single positive late-stage trial in the first place.
Point blank: Acadia's shareholders should take this report with a rather large grain of salt, to put it mildly. There is no evidence that the FDA is about to pull Nuplazid from the market, or change its label.
But this falling knife still isn't a buy
That being said, I don't think Acadia's shares are a compelling buy here, even after yesterday's bloodbath. The underlying reason is that Acadia's valuation has long built in a hefty premium under the assumption that the company would be acquired. I've discussed this issue at length here .
If anything, Acadia is now trading at fair value after this pullback, and that's assuming that Nuplazid's sales keep growing organically at a steady pace. In recent quarters, however, there have been some worrying signs that Nuplazid's sales are starting to flatten out. Acadia, after all, took multiple price increases on the drug last year and the company still missed consensus revenue estimates in the fourth quarter .
So, at best, Acadia is properly valued at present, but it could also be a value trap in the event Nuplazid's growth tapers off.
The other big issue is that a buyout scenario now seems to be a pipe dream. Nuplazid's efficacy has long been under question, so it'll probably need to produce stellar results in its ongoing dementia-related psychosis trial to change this perception. Big pharmas aren't going to open the checkbook for a controversial drug with a middling risk-to-reward ratio.
So while I do agree with Acadia bulls that the CNN piece was off base, I also think the drugmaker's radical revaluation yesterday was justified from a fundamental standpoint.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 2, 2018
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals ' (NASDAQ: ACAD) stock got walloped yesterday after a CNN report suggested that Nuplazid, the company's Parkinson's disease psychosis medication (PDP), may be tied to an increased rate of mortality among patients, and that the drug may not even be all that effective at treating hallucinations, as advertised. But that doesn't mean Acadia is now a screaming buy. Acadia was quick to note these facts in its rebuttal to CNN yesterday. | Acadia Pharmaceuticals ' (NASDAQ: ACAD) stock got walloped yesterday after a CNN report suggested that Nuplazid, the company's Parkinson's disease psychosis medication (PDP), may be tied to an increased rate of mortality among patients, and that the drug may not even be all that effective at treating hallucinations, as advertised. But that doesn't mean Acadia is now a screaming buy. Acadia was quick to note these facts in its rebuttal to CNN yesterday. | Acadia Pharmaceuticals ' (NASDAQ: ACAD) stock got walloped yesterday after a CNN report suggested that Nuplazid, the company's Parkinson's disease psychosis medication (PDP), may be tied to an increased rate of mortality among patients, and that the drug may not even be all that effective at treating hallucinations, as advertised. But this falling knife still isn't a buy That being said, I don't think Acadia's shares are a compelling buy here, even after yesterday's bloodbath. But that doesn't mean Acadia is now a screaming buy. | Acadia Pharmaceuticals ' (NASDAQ: ACAD) stock got walloped yesterday after a CNN report suggested that Nuplazid, the company's Parkinson's disease psychosis medication (PDP), may be tied to an increased rate of mortality among patients, and that the drug may not even be all that effective at treating hallucinations, as advertised. But that doesn't mean Acadia is now a screaming buy. Acadia was quick to note these facts in its rebuttal to CNN yesterday. |
36009.0 | 2018-04-09 00:00:00 UTC | Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher | ACAD | https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-over-2-therapix-biosciences-shares-spike-higher-2018 | nan | nan | Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The S&P also rose, gaining 1.70 percent to 2,648.67.
Leading and Lagging Sectors
Monday afternoon, the information technology shares climbed 2.56 percent. Meanwhile, top gainers in the sector included The Meet Group, Inc. (NASDAQ: MEET ), up 19 percent, and Baozun Inc. (NASDAQ: BZUN ), up 9 percent.
In trading on Monday, telecommunication services shares fell 0.20 percent.
Top Headline
Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash.
The offer price of $218 per share represents an 88 percent premium over AveXis' closing price on Friday.
Equities Trading UP
Turtle Beach Corporation (NASDAQ: HEAR ) shares shot up 33 percent to $3.40 after the company raised its guidance for the first quarter.
Shares of AveXis, Inc. (NASDAQ: AVXS ) got a boost, shooting up 79 percent to $207.70 after the company agreed to be acquired by Novartis AG (NYSE: NVS ) for $8.7 billion.
Therapix Biosciences Ltd. (NASDAQ: TRPX ) shares were also up, gaining 30 percent to $6.485. The Israel-based cannabinoid biopharmaceutical company announced encouraging phase 2a results at Yale University exploring its THX-110 among adults with Tourette syndrome. The company said its THX-100 therapy significantly improved symptoms over time in adult subjects.
Equities Trading DOWN
Menlo Therapeutics Inc. (NASDAQ: MNLO ) shares dropped 72 percent to $9.96. The late-stage biopharmaceutical company announced disappointing results from a phase 2 trial of its serlopitant therapy for the treatment of pruritus. The study failed to meet its primary and key secondary efficacy endpoints of showing statistically significant difference between patients who received serlopitant and those who received a placebo.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31.
NMI Holdings, Inc. (NASDAQ: NMIH ) was down, falling around 22 percent to $13.875.
Commodities
In commodity news, oil traded up 2.16 percent to $63.40 while gold traded up 0.06 percent to $1,336.70.
Silver traded up 0.42 percent Monday to $16.43, while copper rose 0.49 percent to $3.0735.
Eurozone
European shares closed mixed today. The eurozone's STOXX 600 climbed 0.13 percent, the Spanish Ibex Index climbed 0.62 percent, while Italy's FTSE MIB Index gained 0.53 percent. Meanwhile the German DAX climbed 0.17 percent, and the French CAC 40 rose 0.10 percent while U.K. shares rose 0.15 percent.
Economics
On the economics calendar Monday, there is no important data due out.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Top Headline Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash. Equities Trading UP Turtle Beach Corporation (NASDAQ: HEAR ) shares shot up 33 percent to $3.40 after the company raised its guidance for the first quarter. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Top Headline Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash. The late-stage biopharmaceutical company announced disappointing results from a phase 2 trial of its serlopitant therapy for the treatment of pruritus. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The eurozone's STOXX 600 climbed 0.13 percent, the Spanish Ibex Index climbed 0.62 percent, while Italy's FTSE MIB Index gained 0.53 percent. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The S&P also rose, gaining 1.70 percent to 2,648.67. |
36010.0 | 2018-04-09 00:00:00 UTC | Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher | ACAD | https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-over-2-therapix-biosciences-shares-spike-higher-0 | nan | nan | Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The S&P also rose, gaining 1.70 percent to 2,648.67.
Leading and Lagging Sectors
Monday afternoon, the information technology shares climbed 2.56 percent. Meanwhile, top gainers in the sector included The Meet Group, Inc. (NASDAQ: MEET ), up 19 percent, and Baozun Inc. (NASDAQ: BZUN ), up 9 percent.
In trading on Monday, telecommunication services shares fell 0.20 percent.
Top Headline
Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash.
The offer price of $218 per share represents an 88 percent premium over AveXis' closing price on Friday.
Equities Trading UP
Turtle Beach Corporation (NASDAQ: HEAR ) shares shot up 33 percent to $3.40 after the company raised its guidance for the first quarter.
Shares of AveXis, Inc. (NASDAQ: AVXS ) got a boost, shooting up 79 percent to $207.70 after the company agreed to be acquired by Novartis AG (NYSE: NVS ) for $8.7 billion.
Therapix Biosciences Ltd. (NASDAQ: TRPX ) shares were also up, gaining 30 percent to $6.485. The Israel-based cannabinoid biopharmaceutical company announced encouraging phase 2a results at Yale University exploring its THX-110 among adults with Tourette syndrome. The company said its THX-100 therapy significantly improved symptoms over time in adult subjects.
Equities Trading DOWN
Menlo Therapeutics Inc. (NASDAQ: MNLO ) shares dropped 72 percent to $9.96. The late-stage biopharmaceutical company announced disappointing results from a phase 2 trial of its serlopitant therapy for the treatment of pruritus. The study failed to meet its primary and key secondary efficacy endpoints of showing statistically significant difference between patients who received serlopitant and those who received a placebo.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31.
NMI Holdings, Inc. (NASDAQ: NMIH ) was down, falling around 22 percent to $13.875.
Commodities
In commodity news, oil traded up 2.16 percent to $63.40 while gold traded up 0.06 percent to $1,336.70.
Silver traded up 0.42 percent Monday to $16.43, while copper rose 0.49 percent to $3.0735.
Eurozone
European shares closed mixed today. The eurozone's STOXX 600 climbed 0.13 percent, the Spanish Ibex Index climbed 0.62 percent, while Italy's FTSE MIB Index gained 0.53 percent. Meanwhile the German DAX climbed 0.17 percent, and the French CAC 40 rose 0.10 percent while U.K. shares rose 0.15 percent.
Economics
On the economics calendar Monday, there is no important data due out.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Top Headline Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash. Equities Trading UP Turtle Beach Corporation (NASDAQ: HEAR ) shares shot up 33 percent to $3.40 after the company raised its guidance for the first quarter. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Top Headline Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash. The late-stage biopharmaceutical company announced disappointing results from a phase 2 trial of its serlopitant therapy for the treatment of pruritus. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The eurozone's STOXX 600 climbed 0.13 percent, the Spanish Ibex Index climbed 0.62 percent, while Italy's FTSE MIB Index gained 0.53 percent. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The S&P also rose, gaining 1.70 percent to 2,648.67. |
36011.0 | 2018-04-09 00:00:00 UTC | Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide | ACAD | https://www.nasdaq.com/articles/mid-day-market-update-dow-rises-250-points-menlo-therapeutics-shares-slide-2018-04-09-0 | nan | nan | Midway through trading Monday, the Dow traded up 1.06 percent to 24,186.09 while the NASDAQ climbed 1.51 percent to 7,019.36. The S&P also rose, gaining 1.08 percent to 2,632.51.
Leading and Lagging Sectors
On Monday, the information technology shares climbed 2.1 percent. Meanwhile, top gainers in the sector included The Meet Group, Inc. (NASDAQ: MEET ), up 19 percent, and FRONTEO, Inc. (NASDAQ: FTEO ), up 8 percent.
In trading on Monday, telecommunication services shares fell 0.60 percent.
Top Headline
Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash.
The offer price of $218 per share represents an 88 percent premium over AveXis' closing price on Friday.
Equities Trading UP
Turtle Beach Corporation (NASDAQ: HEAR ) shares shot up 52 percent to $3.90 after the company raised its guidance for the first quarter.
Shares of AveXis, Inc. (NASDAQ: AVXS ) got a boost, shooting up 77 percent to $205.50 after the company agreed to be acquired by Novartis AG (NYSE: NVS ) for $8.7 billion.
Therapix Biosciences Ltd. (NASDAQ: TRPX ) shares were also up, gaining 32 percent to $6.5792. The Israel-based cannabinoid biopharmaceutical company announced encouraging phase 2a results at Yale University exploring its THX-110 among adults with Tourette syndrome. The company said its THX-100 therapy significantly improved symptoms over time in adult subjects.
Equities Trading DOWN
Menlo Therapeutics Inc. (NASDAQ: MNLO ) shares dropped 71 percent to $10.18. The late-stage biopharmaceutical company announced disappointing results from a phase 2 trial of its serlopitant therapy for the treatment of pruritus. The study failed to meet its primary and key secondary efficacy endpoints of showing statistically significant difference between patients who received serlopitant and those who received a placebo.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 23 percent to $16.68.
Schmitt Industries, Inc. (NASDAQ: SMIT ) was down, falling around 9 percent to $2.43. Schmitt reported Q3 earnings of $0.00 per share, versus a year-ago loss of $0.04 per share. Its total sales rose 1.2 percent to $3.23 million.
Commodities
In commodity news, oil traded up 2.16 percent to $63.40 while gold traded up 0.05 percent to $1,336.80.
Silver traded up 0.42 percent Monday to $16.43, while copper rose 0.25 percent to $3.066.
Eurozone
European shares were mixed today. The eurozone's STOXX 600 slipped 0.03 percent, the Spanish Ibex Index climbed 0.73 percent, while Italy's FTSE MIB Index gained 0.53 percent. Meanwhile the German DAX fell 0.09 percent, and the French CAC 40 rose 0.02 percent while U.K. shares fell 0.02 percent.
Economics
On the economics calendar Monday, there is no important data due out.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 23 percent to $16.68. Top Headline Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash. Equities Trading UP Turtle Beach Corporation (NASDAQ: HEAR ) shares shot up 52 percent to $3.90 after the company raised its guidance for the first quarter. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 23 percent to $16.68. Top Headline Novartis AG (NYSE: NVS ) announced plans to buy AveXis Inc (NASDAQ: AVXS ) for $8.7 billion in cash. The late-stage biopharmaceutical company announced disappointing results from a phase 2 trial of its serlopitant therapy for the treatment of pruritus. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 23 percent to $16.68. Midway through trading Monday, the Dow traded up 1.06 percent to 24,186.09 while the NASDAQ climbed 1.51 percent to 7,019.36. The eurozone's STOXX 600 slipped 0.03 percent, the Spanish Ibex Index climbed 0.73 percent, while Italy's FTSE MIB Index gained 0.53 percent. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 23 percent to $16.68. Midway through trading Monday, the Dow traded up 1.06 percent to 24,186.09 while the NASDAQ climbed 1.51 percent to 7,019.36. The S&P also rose, gaining 1.08 percent to 2,632.51. |
36012.0 | 2018-04-03 00:00:00 UTC | Better Buy: Acadia Pharmaceuticals vs. Eli Lilly | ACAD | https://www.nasdaq.com/articles/better-buy-acadia-pharmaceuticals-vs-eli-lilly-2018-04-03 | nan | nan | While there are hundreds of publicly traded biotech and pharma companies for investors to choose from, they all fall into two general categories. One group is the pharma giants that are big and stable but tend to offer limited growth potential. The other group is comprised of the up-and-coming biopharmas that promise massive upside if things work out, but tend to be highly speculative.
In today's matchup, we'll pit companies from both ends of this spectrum against each other. In one corner is Acadia Pharmaceuticals (NASDAQ: ACAD) , a one-drug company that it is currently in hyper-growth mode. In the other corner is Eli Lilly (NYSE: LLY ), a big pharma company that was founded almost 150 years ago. Which is the better bet for new money today?
The case for Acadia Pharmaceuticals
Once upon a time, Acadia Pharmaceuticals was as red-hot as biotech stocks can be. The company's share price jumped from the mid-single-digits to more than $45 per share between 2013 and 2015 over soaring enthusiasm for its lead compound called pimavanserin (which is now known as Nuplazid).
Expectations were running high when Nuplazid officially won FDA approval in April of 2016. Nuplazid was the first and only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis (PDP). About 40% of the 1 million patients with Parkinson's disease in the U.S. suffer from PDP, so the patient population is very large. What's more, Acadia priced Nuplazid at $24,000 per year, so it's understandable why Wall Street expected the drug to eventually reach blockbuster status.
However, while Nuplazid got off to a fast start right out of the gate -- sales blew past expectations in the first three quarters after launch -- results came in a bit shy of what Wall Street had wanted to see in the final quarter of 2017 . Furthermore, Acadia reported mixed results from a phase 2 study that was testing Nuplazid as a hopeful treatment for Alzheimer's disease psychosis . Add in the fact that the company set fire to $289 million in 2017 as it launched Nuplazid and its sky-high valuation, and it's understandable why shareholders have had to endure a painful downward roller-coaster over the last couple of years.
Fast-forward to today, and Acadia is now trading for about 11 times current-year expected sales. That number falls to about 7 if you use next year's projected numbers. While that's still certainly not cheap, it might not be that outrageous either given that Nuplazid is still posting triple-digit revenue growth and still holds blockbuster potential. Acadia is also set to report data from a several phases 2 trials over the next 18 months that are studying Nuplaizd as a treatment for major depressive disorder and schizophrenia. Good news from any of those trials could easily translate into a soaring share price.
The case for Eli Lilly
Eil Lilly has been in turnaround mode for a few years now, but the company's efforts look to be finally paying off. Lilly struggled in the early 2010s as it dealt with patent protection losses on several key drugs including Zyprexa, Cymbalta, and Evista. A handful of other top sellers could start facing generic competition in the short term, too.
Thankfully, Lilly is having success with a few recent launches that should help to offset the gap. Recent winners include diabetes treatment Trulicity, psoriasis drug Taltz, and soft tissue sarcoma drug Latruvo. These drugs helped Lilly post an overall revenue growth rate of 8% in 2017, which is pretty good when considering the company's size.
Lilly also boasts a robust pipeline that should help it keep its growth rate up over the next few years. The company boasts 18 programs in late-stage clinical trials or already under regulatory review, some of which promise billion dollar sales potential .
Another potential catalyst for Lilly's investors to look forward to is the possible sale of its Elanco animal health division. Quick math shows us that a sale could bring in more than $10 billion , which Eli Lilly could use to reinvest in R&D, make an acquisition, pay down debt, or reward shareholders. That would also represent a tidy profit from the $5.4 billion it spent to acquire the division from Novartis a few years ago.
In total, Wall Street expects Eli Lilly to post earnings growth in excess of 11% annually over the next five years. That's quite high when considering Eli Lilly's age and size. Shares also offer up a dividend yield of 2.9%, and the payments consume less than half of full-year profit estimates, so it looks quite secure.
Double-digit profit growth and a market-beating yield are an attractive combination, especially when considering that shares trade for less than 15 times next year's earnings estimates.
The better buy
If forced to choose, I'd have to give the edge to Eli Lilly, because I generally favor investing in companies that are cranking out profits as opposed to those that are consuming capital. However, which company you choose for yourself speaks more about what kind of investment you're looking for. If you want the potential to earn multibagger returns -- and have an iron stomach for risk -- then Acadia is clearly the better bet. If you are after income and slow but steady growth, then Eli Lilly is likely to be the superior choice.
10 stocks we like better than Eli Lilly and Company
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Eli Lilly and Company wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In one corner is Acadia Pharmaceuticals (NASDAQ: ACAD) , a one-drug company that it is currently in hyper-growth mode. The case for Acadia Pharmaceuticals Once upon a time, Acadia Pharmaceuticals was as red-hot as biotech stocks can be. What's more, Acadia priced Nuplazid at $24,000 per year, so it's understandable why Wall Street expected the drug to eventually reach blockbuster status. | What's more, Acadia priced Nuplazid at $24,000 per year, so it's understandable why Wall Street expected the drug to eventually reach blockbuster status. Furthermore, Acadia reported mixed results from a phase 2 study that was testing Nuplazid as a hopeful treatment for Alzheimer's disease psychosis . In one corner is Acadia Pharmaceuticals (NASDAQ: ACAD) , a one-drug company that it is currently in hyper-growth mode. | In one corner is Acadia Pharmaceuticals (NASDAQ: ACAD) , a one-drug company that it is currently in hyper-growth mode. The case for Acadia Pharmaceuticals Once upon a time, Acadia Pharmaceuticals was as red-hot as biotech stocks can be. What's more, Acadia priced Nuplazid at $24,000 per year, so it's understandable why Wall Street expected the drug to eventually reach blockbuster status. | What's more, Acadia priced Nuplazid at $24,000 per year, so it's understandable why Wall Street expected the drug to eventually reach blockbuster status. In one corner is Acadia Pharmaceuticals (NASDAQ: ACAD) , a one-drug company that it is currently in hyper-growth mode. The case for Acadia Pharmaceuticals Once upon a time, Acadia Pharmaceuticals was as red-hot as biotech stocks can be. |
36013.0 | 2018-03-29 00:00:00 UTC | ACAD May 11th Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-may-11th-options-begin-trading-2018-03-29 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 11th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new May 11th contracts and identified one put and one call contract of particular interest.
The put contract at the $22.00 strike price has a current bid of 70 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $22.00, but will also collect the premium, putting the cost basis of the shares at $21.30 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $22.19/share today.
Because the $22.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 3.18% return on the cash commitment, or 27.01% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $23.00 strike price has a current bid of 10 cents. If an investor was to purchase shares of ACAD stock at the current price level of $22.19/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $23.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.10% if the stock gets called away at the May 11th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $23.00 strike highlighted in red:
Considering the fact that the $23.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.45% boost of extra return to the investor, or 3.83% annualized, which we refer to as the YieldBoost .
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $22.19) to be 50%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $23.00 strike highlighted in red: Considering the fact that the $23.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 11th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $23.00 strike highlighted in red: Considering the fact that the $23.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 11th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new May 11th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $23.00 strike price has a current bid of 10 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $23.00 strike highlighted in red: Considering the fact that the $23.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 11th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new May 11th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $23.00 strike highlighted in red: Considering the fact that the $23.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 11th expiration. |
36014.0 | 2018-03-20 00:00:00 UTC | Is Acadia Pharmaceuticals a Buy? | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-buy-2018-03-20 | nan | nan | Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing treatments for diseases of the central nervous system, has had an exceedingly rough go of it this year, with the company's stock falling by a whopping 14.5% year to date. Wall Street, however, clearly thinks that Acadia's sizable downturn presents an outsize buying opportunity.
The Street's low end 12-month price target of $40, after all, indicates an attractive upside potential of about 55% from current levels. Analysts' average and high-end price targets, on the other hand, imply even greater upside potentials of 95% and 136%, respectively.
I think that these various price targets are unrealistic, and that the stock's march southward is indeed justified. In fact, I think Acadia's shares will continue to struggle in the days and weeks ahead. Here's why.
Too much depends on a single drug
The core issue is that Acadia's valuation depends entirely on the commercial trajectory of its Parkinson's disease psychosis medication, Nuplazid. Although the drug has gotten off to a quick start since its commercial launch in May 2016, the fact remains that Acadia's lofty valuation clearly assumed an even greater penetration rate . The biotech's stock, after all, is presently trading at a price-to-sales ratio in excess of 24 -- even after this latest downturn.
Nuplazid's sales would thus need to rise by 128% from current levels simply to bring the company's valuation in line with most other biopharmas (an average price-to-sales ratio of around 5). In a similar manner, the drug's sales would need to rise by perhaps 265%, relative to its projected haul of $263 million for 2018, to make the Street's low-end price target a fundamentally sound projection.
The current consensus, by contrast, has Nuplazid's sales growing by a far more modest 68% for the whole of 2019 compared to this year. So, as you can see, the Street's price targets for Acadia's stock don't match up with the company's near-term growth prospects.
Compounding matters further, Nuplazid's rapid growth rate has been due in part to a very aggressive pricing strategy over the past year. Regular price increases, however, have been a good way to draw the ire of payers, leading to reimbursement issues.
So, at a bare minimum, the company probably can't continue to rely on price increases to meet quarterly estimates. Nuplazid's sales growth may therefore start to taper off significantly soon -- that is, unless management is right in its assumption that script volume will pave the way for growth this year and next.
A capital raise is looming
Another good reason to avoid this pricey biotech stock is the fact that the company is set to continue incurring heavy losses for the foreseeable future due to both the promotion of Nuplazid and the drug's development for other indications like dementia-related psychosis. Even with Nupazid's sales heading higher, Acadia is on track to burn through over $151 million in 2018, bringing its cash and cash equivalents down to about $190 million by the end of the year.
To be fair, Acadia believes it will exit 2018 with a cash buffer of more than $200 million. But that rosy forecast appears to assume that Nuplazid's sales will come in on the high side of its estimated range for the year, and the drug's clinical development costs won't increase even more in the near term. As Nuplazid's all-important late-stage trial for dementia-related psychosis is just getting underway, and the company is arguably running out of room to drive growth via price increases, I think these estimates are questionable, to put it mildly.
The key takeaway here is that Acadia is perhaps less than a year away from having to issue a large secondary offering in the area of $200 million or so. Nuplazid, after all, is about three full years away from a possible label expansion for dementia-related psychosis, and the drug's sales for Parkinson's disease psychosis are showing signs of hitting a plateau . If they were growing organically, after all, Acadia probably wouldn't have set three price increases over the course of 2017.
Investing takeaway
All things considered, I think Wall Street's sky-high price targets are actually assuming a buyout at a ginormous premium. The company, as things stand now, doesn't have the growth drivers in place to meet these targets organically.
Another glaring problem with the buyout assumption is that Acadia's valuation arguably isn't a compelling bargain for would-be suitors. Nuplazid needs to expand into other high-value indications to unlock Acadia's deeper value, and there's no guarantee when it comes to clinical trials.
All told, I think there are far too many moving parts to Acadia's growth story to have confidence that things will work out exactly as planned. And if Acadia does run into trouble in the clinic or with payers, the market could very well revalue this single-drug biotech in a dramatic fashion.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing treatments for diseases of the central nervous system, has had an exceedingly rough go of it this year, with the company's stock falling by a whopping 14.5% year to date. Wall Street, however, clearly thinks that Acadia's sizable downturn presents an outsize buying opportunity. In fact, I think Acadia's shares will continue to struggle in the days and weeks ahead. | Too much depends on a single drug The core issue is that Acadia's valuation depends entirely on the commercial trajectory of its Parkinson's disease psychosis medication, Nuplazid. Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing treatments for diseases of the central nervous system, has had an exceedingly rough go of it this year, with the company's stock falling by a whopping 14.5% year to date. Wall Street, however, clearly thinks that Acadia's sizable downturn presents an outsize buying opportunity. | Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing treatments for diseases of the central nervous system, has had an exceedingly rough go of it this year, with the company's stock falling by a whopping 14.5% year to date. So, as you can see, the Street's price targets for Acadia's stock don't match up with the company's near-term growth prospects. Wall Street, however, clearly thinks that Acadia's sizable downturn presents an outsize buying opportunity. | So, as you can see, the Street's price targets for Acadia's stock don't match up with the company's near-term growth prospects. If they were growing organically, after all, Acadia probably wouldn't have set three price increases over the course of 2017. Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing treatments for diseases of the central nervous system, has had an exceedingly rough go of it this year, with the company's stock falling by a whopping 14.5% year to date. |
36015.0 | 2018-03-12 00:00:00 UTC | Is Acadia Pharmaceuticals Stock Now a Strong Buy? | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-stock-now-strong-buy-2018-03-12 | nan | nan | What happened
Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing novel treatments for disorders of the central nervous system, saw its shares fall by a noteworthy 17.7% last month, according to S&P Global Market Intelligence .
What's going on? The company's fourth-quarter sales of its drug for Parkinson's disease psychosis, Nuplazid, came in slightly below consensus for the three-month period, triggering a mass exodus among shareholders.
So what
Acadia's stock has shed more than a third of its value since Nuplazid's approval by the Food and Drug Administration roughly two years ago. The underlying reason is that early shareholders seemed to believe that Nuplazid would go supernova, from a sales standpoint, right out of the gate.
While the drug is performing admirably, with a projected run rate of between $255 million and $270 million for 2018, these sales forecasts are well below the $3 billion or more that some investors and analysts were touting prior to FDA approval.
Now what
The silver lining is that Nuplazid has been far from the total flop some analysts were predicting early on. In fact, the drug's sales are expected to reach a healthy $443 million in 2019.
The downside, however, is that even this stately annual haul still equates to Acadia's shares trading at a forward price-to-sales ratio in excess of 7. That's among the highest in the biopharmaceutical space -- suggesting that Acadia's stock remains on the expensive side.
When is it time to buy? My view is that Acadia won't be in bargain territory until it either loses another 20% (at a minimum), or the company addresses its long-term financing needs by striking a front-loaded licensing deal for Nuplazid's other potential indications. As things stand now, Acadia will probably have to resort to a massive secondary offering in early 2019 to pay for Nuplazid's other clinical trials.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing novel treatments for disorders of the central nervous system, saw its shares fall by a noteworthy 17.7% last month, according to S&P Global Market Intelligence . My view is that Acadia won't be in bargain territory until it either loses another 20% (at a minimum), or the company addresses its long-term financing needs by striking a front-loaded licensing deal for Nuplazid's other potential indications. So what Acadia's stock has shed more than a third of its value since Nuplazid's approval by the Food and Drug Administration roughly two years ago. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What happened Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing novel treatments for disorders of the central nervous system, saw its shares fall by a noteworthy 17.7% last month, according to S&P Global Market Intelligence . So what Acadia's stock has shed more than a third of its value since Nuplazid's approval by the Food and Drug Administration roughly two years ago. | So what Acadia's stock has shed more than a third of its value since Nuplazid's approval by the Food and Drug Administration roughly two years ago. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! | What happened Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing novel treatments for disorders of the central nervous system, saw its shares fall by a noteworthy 17.7% last month, according to S&P Global Market Intelligence . So what Acadia's stock has shed more than a third of its value since Nuplazid's approval by the Food and Drug Administration roughly two years ago. The downside, however, is that even this stately annual haul still equates to Acadia's shares trading at a forward price-to-sales ratio in excess of 7. |
36016.0 | 2018-03-08 00:00:00 UTC | Interesting ACAD Put And Call Options For April 27th | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-april-27th-2018-03-08 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 27th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 27th contracts and identified one put and one call contract of particular interest.
The put contract at the $23.00 strike price has a current bid of 20 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $23.00, but will also collect the premium, putting the cost basis of the shares at $22.80 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $25.25/share today.
Because the $23.00 strike represents an approximate 9% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 0.87% return on the cash commitment, or 6.35% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $23.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of 20 cents. If an investor was to purchase shares of ACAD stock at the current price level of $25.25/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $26.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 3.76% if the stock gets called away at the April 27th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red:
Considering the fact that the $26.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.79% boost of extra return to the investor, or 5.79% annualized, which we refer to as the YieldBoost .
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $25.25) to be 50%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 27th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 27th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 27th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $23.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of 20 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 27th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 27th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 27th expiration. |
36017.0 | 2018-02-28 00:00:00 UTC | Mid-Morning Market Update: Markets Open Higher; Lowe's Profit Misses Views | ACAD | https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-lowes-profit-misses-views-2018-02-28 | nan | nan | Following the market opening Wednesday, the Dow traded up 0.46 percent to 25,527.05 while the NASDAQ climbed 0.54 percent to 7,370.15. The S&P also rose, gaining 0.49 percent to 2,757.81.
Leading and Lagging Sectors
Wednesday morning, the technology shares gained 0.79 percent. Meanwhile, top gainers in the sector included TiVo Corp (NASDAQ: TIVO ), up 15 percent, and Agilysys, Inc. (NASDAQ: AGYS ), up 6 percent.
In trading on Wednesday, basic materials shares tumbled 0.40 percent. Meanwhile, top losers in the sector included Synalloy Corporation (NASDAQ: SYNL ), down 5 percent, and Albemarle Corporation (NYSE: ALB ) down 6 percent.
Top Headline
Lowe's Companies, Inc. (NYSE: LOW ) reported weaker-than-expected earnings for its fourth quarter.
The company said it earned $0.74 per share in the fourth quarter on revenue of $15.49 billion versus expectations of $0.87 per share on revenue of $15.33 billion.
Lowe's expects FY18 sales to rise 4 percent and earnings of $5.40 to $5.50 per share.
Equities Trading UP
PHH Corporation (NYSE: PHH ) shares shot up 26 percent to $10.69 after the company agreed to be purchased by Ocwen Financial for $11 per share in cash.
Shares of Student Transportation Inc (NASDAQ: STB ) got a boost, shooting up 25 percent to $7.50 after the company agreed to be acquired by a group of investors led by CDPQ.
Axon Enterprise Inc (NASDAQ: AAXN ) shares were also up, gaining 23 percent to $33.42 following a surprise earnings beat.
Equities Trading DOWN
Frontier Communications Corp (NASDAQ: FTR ) shares dropped 25 percent to $6.92 following its fourth quarter report. The company sees FY18 adjusted EBITDA of $3.6 billion.
Shares of Huron Consulting Group (NASDAQ: HURN ) were down 18 percent to $33.70 after the company posted weaker-than-expected quarterly results. . ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) was down, falling around 15 percent to $26.53 after the company reported results for its fourth quarter.
Commodities
In commodity news, oil traded down 0.08 percent to $62.96 while gold traded up 0.08 percent to $1,319.60.
Silver traded down 0.05 percent Wednesday to $16.425, while copper fell 0.71 percent to $3.164.
Eurozone
European shares were lower today. The eurozone's STOXX 600 fell 0.33 percent, the Spanish Ibex Index fell 0.52 percent, while Italy's FTSE MIB Index declined 0.12 percent. Meanwhile the German DAX dropped 0.13 percent, and the French CAC 40 fell 0.27 percent while U.K. shares fell 0.08 percent.
Economics
U.S. economy expanded at an annual pace of 2.5 percent in the fourth quarter, versus a prior reading of 2.6 percent growth. Economists were expecting a 2.5 percent growth.
The Chicago PMI dropped to a reading of 61.9 in February, versus a reading of 65.7 in January.
Pending-home sales declined 4.7 percent to 104.6 for January.
The Energy Information Administration's weekly report on petroleum inventories will be released at 10:30 a.m. ET.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) was down, falling around 15 percent to $26.53 after the company reported results for its fourth quarter. Shares of Student Transportation Inc (NASDAQ: STB ) got a boost, shooting up 25 percent to $7.50 after the company agreed to be acquired by a group of investors led by CDPQ. Equities Trading DOWN Frontier Communications Corp (NASDAQ: FTR ) shares dropped 25 percent to $6.92 following its fourth quarter report. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) was down, falling around 15 percent to $26.53 after the company reported results for its fourth quarter. Top Headline Lowe's Companies, Inc. (NYSE: LOW ) reported weaker-than-expected earnings for its fourth quarter. The company said it earned $0.74 per share in the fourth quarter on revenue of $15.49 billion versus expectations of $0.87 per share on revenue of $15.33 billion. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) was down, falling around 15 percent to $26.53 after the company reported results for its fourth quarter. Meanwhile, top gainers in the sector included TiVo Corp (NASDAQ: TIVO ), up 15 percent, and Agilysys, Inc. (NASDAQ: AGYS ), up 6 percent. The eurozone's STOXX 600 fell 0.33 percent, the Spanish Ibex Index fell 0.52 percent, while Italy's FTSE MIB Index declined 0.12 percent. | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) was down, falling around 15 percent to $26.53 after the company reported results for its fourth quarter. The company said it earned $0.74 per share in the fourth quarter on revenue of $15.49 billion versus expectations of $0.87 per share on revenue of $15.33 billion. Silver traded down 0.05 percent Wednesday to $16.425, while copper fell 0.71 percent to $3.164. |
36018.0 | 2018-02-27 00:00:00 UTC | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 62.5% Follow-Through Indicator, 8.3% Sensitive | ACAD | https://www.nasdaq.com/articles/earnings-reaction-history-acadia-pharmaceuticals-inc-625-follow-through-indicator-83 | nan | nan | Expected Earnings Release: 02/27/2018, After-hours
Avg. Extended-Hours Dollar Volume: $4,965,797
ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 60%
Average next regular session additional gain: 3.5%
Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 100%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,965,797 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,965,797 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,965,797 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $4,965,797 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. |
36019.0 | 2018-02-22 00:00:00 UTC | Interesting ACAD Put And Call Options For April 6th | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-april-6th-2018-02-22 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 6th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 6th contracts and identified one put and one call contract of particular interest.
The put contract at the $30.00 strike price has a current bid of $1.30. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $28.70 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $31.19/share today.
Because the $30.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 4.33% return on the cash commitment, or 36.82% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $32.00 strike price has a current bid of $1.30. If an investor was to purchase shares of ACAD stock at the current price level of $31.19/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $32.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 6.76% if the stock gets called away at the April 6th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $32.00 strike highlighted in red:
Considering the fact that the $32.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.17% boost of extra return to the investor, or 35.41% annualized, which we refer to as the YieldBoost .
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $31.19) to be 44%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $32.00 strike highlighted in red: Considering the fact that the $32.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 6th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $32.00 strike highlighted in red: Considering the fact that the $32.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 6th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 6th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $32.00 strike price has a current bid of $1.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $32.00 strike highlighted in red: Considering the fact that the $32.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 6th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 6th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $32.00 strike highlighted in red: Considering the fact that the $32.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 6th expiration. |
36020.0 | 2018-02-20 00:00:00 UTC | George Soros Just Dumped These 2 Healthcare Stocks. Should You? | ACAD | https://www.nasdaq.com/articles/george-soros-just-dumped-these-2-healthcare-stocks-should-you-2018-02-20 | nan | nan | George Soros, the billionaire hedge fund guru, may have turned the bulk of his attention toward the political arena lately, but his namesake fund, Soros Fund Management, is still a focal point for investors. The Soros Fund Management, after all, has consistently beat the broader markets since its inception in 1969.
What key moves has the Soros Fund Management been making in the most recent quarter? In the high-flying healthcare sector, the fund reportedly dumped its entire holdings of Acadia Pharmaceuticals (NASDAQ: ACAD) and Shire plc (NASDAQ: SHPG) in the fourth quarter of 2017, according to the latest 13F filings.
Should shareholders of these top healthcare companies be worried? Let's dig deeper to find out.
Too high, too fast
Acadia's stock has been steadily reverting to the mean ever since the FDA approval of its Parkinson's disease psychosis medicine, Nuplazid, in mid-2016. In fact, the biotech's shares have now fallen by more than 21% over just the last 12 months.
What's the problem? The key issue is that Nuplazid's sales are doing well, but arguably not well enough to justify Acadia's present market cap of $3.84 billion. In 2018, for example, the drug is expected to generate around $261 million in sales, which translates to a forward-looking price to sales ratio of 14.71. Put simply, Acadia sports one of the richest valuations in the entire healthcare sector.
Bargain hunters shouldn't necessarily write off Acadia's stock just yet, though. Acadia, after all, is striving to expand Nuplazid's label to include other high-value indications such as dementia-related psychosis. So, there's still a really good chance that Nuplazid will eventually reach blockbuster status. And if this turns out to be the case, Acadia's shares are actually undervalued right now -- despite the stock's unsightly near-term valuation metrics.
The downside is that investors appear to be in for a fairly lengthy wait to find out either way. Nuplazid's late-stage trial for dementia-related psychosis isn't scheduled to readout until the second quarter of 2020, and that'll be the drug's first opportunity to tack on an additional indication.
So, given the lack of any near-term catalysts, Acadia's shares are probably going to continue to slide for the foreseeable future.
Bad timing
Shire, an orphan drug specialist, has had an extremely rough go of it of late -- evidenced by the stock's eye-popping 43% drop over the past three years. The underlying reason is that the company has taken on a substantial amount of debt in order to bring new growth products into the fold. Shire, for instance, paid a stately $32 billion to acquire Baxalta for its hemophilia drug portfolio roughly two years ago. Unfortunately, the drugmaker decided to lever up at perhaps the worst possible time.
Around the same time Shire was gobbling up rare disease companies, Valeant Pharmaceuticals was busy imploding thanks to the company's overly aggressive growth-by-acquisition strategy. The trickle-down effect, if you will, is that investors have largely shied away from serial acquirers with heavy debt loads like Shire ever since -- even though Valeant had a multitude of other problems, beyond a distressed balance sheet, that precipitated its downfall.
On the bright side, Shire has been rapidly de-levering to directly address this issue. The company also sports a fairly robust late-stage clinical pipeline that should help to boost its free cash flows within a reasonable time frame. That being said, Shire is presently spending the bulk of its free cash flows on its underlying debt problem, leaving next to nothing for shareholder rewards.
In all, Shire still has a lot of work to do to clean up its balance sheet, but its stock is probably near a bottom at this stage. The company's price to sales ratio of 2.45, after all, is about as low as it gets for a large-cap pharma stock.
Are either of these stocks worth buying?
Acadia's only realistic hope of rebounding this year is arguably a buyout. The market clearly expected too much out of Nuplazid too soon. The good news is that a buyout is a real possibility here, thanks to Nuplazid's sizable commercial opportunity over the course of its life cycle. But the reality is that there doesn't seem to be all that much interest from possible suitors, which may be directly due to the company's bloated valuation.
Shire, on the other hand, comes across as a decent bargain for investors with a long-term outlook. The company is staring down some tough patent expires in the years ahead, but its pipeline is starting to bear fruit. That bodes well for the company's ability to both pay off its long-term debt and boost shareholder rewards going forward.
10 stocks we like better than Shire
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Shire wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the high-flying healthcare sector, the fund reportedly dumped its entire holdings of Acadia Pharmaceuticals (NASDAQ: ACAD) and Shire plc (NASDAQ: SHPG) in the fourth quarter of 2017, according to the latest 13F filings. Too high, too fast Acadia's stock has been steadily reverting to the mean ever since the FDA approval of its Parkinson's disease psychosis medicine, Nuplazid, in mid-2016. The key issue is that Nuplazid's sales are doing well, but arguably not well enough to justify Acadia's present market cap of $3.84 billion. | In the high-flying healthcare sector, the fund reportedly dumped its entire holdings of Acadia Pharmaceuticals (NASDAQ: ACAD) and Shire plc (NASDAQ: SHPG) in the fourth quarter of 2017, according to the latest 13F filings. Too high, too fast Acadia's stock has been steadily reverting to the mean ever since the FDA approval of its Parkinson's disease psychosis medicine, Nuplazid, in mid-2016. The key issue is that Nuplazid's sales are doing well, but arguably not well enough to justify Acadia's present market cap of $3.84 billion. | In the high-flying healthcare sector, the fund reportedly dumped its entire holdings of Acadia Pharmaceuticals (NASDAQ: ACAD) and Shire plc (NASDAQ: SHPG) in the fourth quarter of 2017, according to the latest 13F filings. Too high, too fast Acadia's stock has been steadily reverting to the mean ever since the FDA approval of its Parkinson's disease psychosis medicine, Nuplazid, in mid-2016. The key issue is that Nuplazid's sales are doing well, but arguably not well enough to justify Acadia's present market cap of $3.84 billion. | In the high-flying healthcare sector, the fund reportedly dumped its entire holdings of Acadia Pharmaceuticals (NASDAQ: ACAD) and Shire plc (NASDAQ: SHPG) in the fourth quarter of 2017, according to the latest 13F filings. Too high, too fast Acadia's stock has been steadily reverting to the mean ever since the FDA approval of its Parkinson's disease psychosis medicine, Nuplazid, in mid-2016. The key issue is that Nuplazid's sales are doing well, but arguably not well enough to justify Acadia's present market cap of $3.84 billion. |
36021.0 | 2018-02-20 00:00:00 UTC | Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings? | ACAD | https://www.nasdaq.com/articles/will-acadia-acad-disappoint-investors-in-q4-earnings-2018-02-20 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD is expected to release fourth-quarter 2017 results on Feb 27. In the last quarter, ACADIA delivered a positive surprise of 15.87%. The company delivered an average positive earnings surprise of 9.95% in the last four quarters.
ACADIA's shares have tumbled 21.3% year to date compared with the industry 's decline of 2.5%.
Let's see how things are shaping up for this announcement.
Factors at Play
ACADIA is focused on developing products for treating unmet medical needs in central nervous system ("CNS"). The growth of its first approved drug, Nuplazid (pimavanserin), for treating hallucinations and delusions associated with Parkinson's disease ("PD") psychosis, has been impressive since its launch in April 2016.
The drugs sales have been impressive and has helped the company to garner 32% revenues in the third quarter. The company expects the trend to continue this time around as well and in the fourth quarter of 2017. The number of patients receiving Nuplazid treatment continues to grow and banking on this trend, the company increased its 2017 guidance for Nuplazid net sales between $124 million and $127 million.
The company is also on track with its multi-year plans of developing Nuplazid in indications beyond PD psychosis. The company is studying the drug in five clinical programs for Nuplazid - Alzheimer's disease agitation, Alzheimer's disease psychosis, Schizophrenia inadequate response, Schizophrenia negative symptoms and major depressive disorders.
In October 2017, the company initiated a phase III HARMONY Study in dementia-related psychosis or DRP. The company also received Breakthrough Therapy Designation from the FDA for Nuplazid for the treatment of DRP. Following an End-of-Phase II meeting with the FDA, robust positive results from one phase III study, together with supported data from prior studies with Nuplazid could serve as the basis of a supplementary new drug application.
We expect the company to provide further update on the progress of this study during fourth-quarter earnings call.
The company expects research and operating expenses to be in the mid-$40 million range and SG&A to be in the high-$60 million to low-$70 million range due to higher clinical costs related to studies and to support its commercial activities for Nuplazid.
What Our Model Indicates
Our proven model does not conclusively show an earnings beat for ACADIA this quarter. This is because a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - for this to happen. However, that is not the case here as you will see below.
Zacks ESP: ACADIA has an Earnings ESP of -3.75%. This is because the Most Accurate estimate stands at a loss of 60 cents, while the Zacks Consensus Estimate is pegged at a loss of 58 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: ACADIA currently has a Zacks Rank #4 (Sell). Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into an earnings announcement especially when the company is seeing negative estimate revisions.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to deliver an earnings beat this quarter.
Exelixis EXEL is scheduled to release fourth quarter 2017 results on Feb 26 after the market closes . The company has an Earnings ESP of +8.94% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Gemphire Therapeutics GEMP is expected to release fourth quarter 2017 results on Mar 21. The company has an Earnings ESP of +6.62% and a Zacks Rank #2.
Atara Biotherapeutics ATRA is expected to release fourth quarter 2017 results on Mar 8. The company has an Earnings ESP of +7.42% and a Zacks Rank #3.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL): Free Stock Analysis Report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Gemphire Therapeutics Inc. (GEMP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Factors at Play ACADIA is focused on developing products for treating unmet medical needs in central nervous system ("CNS"). ACADIA Pharmaceuticals Inc.ACAD is expected to release fourth-quarter 2017 results on Feb 27. In the last quarter, ACADIA delivered a positive surprise of 15.87%. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks That Warrant a Look Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to deliver an earnings beat this quarter. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Gemphire Therapeutics Inc. (GEMP): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to release fourth-quarter 2017 results on Feb 27. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks That Warrant a Look Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to deliver an earnings beat this quarter. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Gemphire Therapeutics Inc. (GEMP): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to release fourth-quarter 2017 results on Feb 27. | ACADIA Pharmaceuticals Inc.ACAD is expected to release fourth-quarter 2017 results on Feb 27. In the last quarter, ACADIA delivered a positive surprise of 15.87%. ACADIA's shares have tumbled 21.3% year to date compared with the industry 's decline of 2.5%. |
36022.0 | 2018-02-14 00:00:00 UTC | Interesting ACAD Put And Call Options For April 20th | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-april-20th-2018-02-14 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 20th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 20th contracts and identified one put and one call contract of particular interest.
The put contract at the $30.00 strike price has a current bid of $1.90. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $28.10 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $30.72/share today.
Because the $30.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 6.33% return on the cash commitment, or 35.59% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $1.80. If an investor was to purchase shares of ACAD stock at the current price level of $30.72/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $31.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 6.77% if the stock gets called away at the April 20th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red:
Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.86% boost of extra return to the investor, or 32.92% annualized, which we refer to as the YieldBoost .
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $30.72) to be 43%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 20th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 20th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 20th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $1.80. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 20th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new April 20th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 20th expiration. |
36023.0 | 2018-02-08 00:00:00 UTC | Interesting ACAD Put And Call Options For March 29th | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-march-29th-2018-02-08 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the March 29th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 29th contracts and identified one put and one call contract of particular interest.
The put contract at the $29.00 strike price has a current bid of $1.70. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $29.00, but will also collect the premium, putting the cost basis of the shares at $27.30 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $29.38/share today.
Because the $29.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 5.86% return on the cash commitment, or 43.70% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $29.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $30.00 strike price has a current bid of $1.60. If an investor was to purchase shares of ACAD stock at the current price level of $29.38/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $30.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.56% if the stock gets called away at the March 29th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red:
Considering the fact that the $30.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.45% boost of extra return to the investor, or 40.60% annualized, which we refer to as the YieldBoost .
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $29.38) to be 44%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red: Considering the fact that the $30.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the March 29th expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red: Considering the fact that the $30.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the March 29th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 29th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $29.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $30.00 strike price has a current bid of $1.60. Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red: Considering the fact that the $30.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the March 29th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 29th contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red: Considering the fact that the $30.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the March 29th expiration. |
36024.0 | 2018-02-01 00:00:00 UTC | March 23rd Options Now Available For Acadia Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/march-23rd-options-now-available-acadia-pharmaceuticals-acad-2018-02-01 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 23rd expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 23rd contracts and identified one put and one call contract of particular interest.
The put contract at the $30.00 strike price has a current bid of $1.90. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $28.10 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $30.25/share today.
Because the $30.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 6.33% return on the cash commitment, or 46.27% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $1.45. If an investor was to purchase shares of ACAD stock at the current price level of $30.25/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $31.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.27% if the stock gets called away at the March 23rd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red:
Considering the fact that the $31.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 4.79% boost of extra return to the investor, or 35.02% annualized, which we refer to as the YieldBoost .
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $30.25) to be 42%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 23rd expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 23rd expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 23rd contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $1.45. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 23rd expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 23rd contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 23rd expiration. |
36025.0 | 2018-01-22 00:00:00 UTC | FBT's Holdings Imply 17% Gain Potential | ACAD | https://www.nasdaq.com/articles/fbts-holdings-imply-17-gain-potential-2018-01-22 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $155.11 per unit.
With FBT trading at a recent price near $133.08 per unit, that means that analysts see 16.55% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Ultragenyx Pharmaceutical Inc (Symbol: RARE), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $26.92/share, the average analyst target is 85.74% higher at $50.00/share. Similarly, RARE has 40.63% upside from the recent share price of $49.16 if the average analyst target price of $69.13/share is reached, and analysts on average are expecting BMRN to reach a target price of $115.28/share, which is 29.35% above the recent price of $89.12. Below is a twelve month price history chart comparing the stock performance of ACAD, RARE, and BMRN:
Combined, ACAD, RARE, and BMRN represent 8.57% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $26.92/share, the average analyst target is 85.74% higher at $50.00/share. Below is a twelve month price history chart comparing the stock performance of ACAD, RARE, and BMRN: Combined, ACAD, RARE, and BMRN represent 8.57% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Ultragenyx Pharmaceutical Inc (Symbol: RARE), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). | Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Ultragenyx Pharmaceutical Inc (Symbol: RARE), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $26.92/share, the average analyst target is 85.74% higher at $50.00/share. Below is a twelve month price history chart comparing the stock performance of ACAD, RARE, and BMRN: Combined, ACAD, RARE, and BMRN represent 8.57% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Ultragenyx Pharmaceutical Inc (Symbol: RARE), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $26.92/share, the average analyst target is 85.74% higher at $50.00/share. Below is a twelve month price history chart comparing the stock performance of ACAD, RARE, and BMRN: Combined, ACAD, RARE, and BMRN represent 8.57% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Below is a twelve month price history chart comparing the stock performance of ACAD, RARE, and BMRN: Combined, ACAD, RARE, and BMRN represent 8.57% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Ultragenyx Pharmaceutical Inc (Symbol: RARE), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $26.92/share, the average analyst target is 85.74% higher at $50.00/share. |
36026.0 | 2018-01-12 00:00:00 UTC | Noteworthy Friday Option Activity: MYL, MCD, ACAD | ACAD | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-myl-mcd-acad-2018-01-12 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mylan NV (Symbol: MYL), where a total of 36,109 contracts have traded so far, representing approximately 3.6 million underlying shares. That amounts to about 54.8% of MYL's average daily trading volume over the past month of 6.6 million shares. Particularly high volume was seen for the $50 strike call option expiring April 20, 2018 , with 22,545 contracts trading so far today, representing approximately 2.3 million underlying shares of MYL. Below is a chart showing MYL's trailing twelve month trading history, with the $50 strike highlighted in orange:
McDonald's Corp (Symbol: MCD) options are showing a volume of 15,268 contracts thus far today. That number of contracts represents approximately 1.5 million underlying shares, working out to a sizeable 53.2% of MCD's average daily trading volume over the past month, of 2.9 million shares. Particularly high volume was seen for the $175 strike call option expiring January 19, 2018 , with 2,459 contracts trading so far today, representing approximately 245,900 underlying shares of MCD. Below is a chart showing MCD's trailing twelve month trading history, with the $175 strike highlighted in orange:
And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 8,804 contracts thus far today. That number of contracts represents approximately 880,400 underlying shares, working out to a sizeable 52.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $31 strike call option expiring June 15, 2018 , with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $31 strike highlighted in orange:
For the various different available expirations for MYL options , MCD options , or ACAD options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $31 strike call option expiring June 15, 2018 , with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD. Below is a chart showing MCD's trailing twelve month trading history, with the $175 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 8,804 contracts thus far today. That number of contracts represents approximately 880,400 underlying shares, working out to a sizeable 52.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. | That number of contracts represents approximately 880,400 underlying shares, working out to a sizeable 52.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing MCD's trailing twelve month trading history, with the $175 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 8,804 contracts thus far today. Especially high volume was seen for the $31 strike call option expiring June 15, 2018 , with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD. | Below is a chart showing MCD's trailing twelve month trading history, with the $175 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 8,804 contracts thus far today. That number of contracts represents approximately 880,400 underlying shares, working out to a sizeable 52.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $31 strike call option expiring June 15, 2018 , with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD. | That number of contracts represents approximately 880,400 underlying shares, working out to a sizeable 52.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $31 strike highlighted in orange: For the various different available expirations for MYL options , MCD options , or ACAD options , visit StockOptionsChannel.com. Below is a chart showing MCD's trailing twelve month trading history, with the $175 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 8,804 contracts thus far today. |
36027.0 | 2018-01-11 00:00:00 UTC | Interesting ACAD Put And Call Options For March 2nd | ACAD | https://www.nasdaq.com/articles/interesting-acad-put-and-call-options-march-2nd-2018-01-11 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 2nd expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 2nd contracts and identified one put and one call contract of particular interest.
The put contract at the $26.00 strike price has a current bid of 45 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $26.00, but will also collect the premium, putting the cost basis of the shares at $25.55 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $27.77/share today.
Because the $26.00 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 1.73% return on the cash commitment, or 12.63% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of $1.10. If an investor was to purchase shares of ACAD stock at the current price level of $27.77/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $28.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.79% if the stock gets called away at the March 2nd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red:
Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.96% boost of extra return to the investor, or 28.92% annualized, which we refer to as the YieldBoost .
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $27.77) to be 42%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 2nd expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 2nd expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 2nd contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of $1.10. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 2nd expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new March 2nd contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 2nd expiration. |
36028.0 | 2018-01-10 00:00:00 UTC | 3 Keys for Acadia Pharmaceuticals to Succeed in 2018 | ACAD | https://www.nasdaq.com/articles/3-keys-acadia-pharmaceuticals-succeed-2018-2018-01-10 | nan | nan | In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017 . The launch for Nuplazid in treating Parkinson's disease (PD) psychosis went better than expected, with sales beating Wall Street estimates. Acadia moved ahead with its late-stage studies for the drug in other indications. The FDA granted breakthrough therapy designation to Nuplazid for dementia-related psychosis. Despite all of this good news, Acadia stock finished the year up only 4%.
Acadia CEO Stephen Davis didn't mention the underwhelming performance of the stock when he spoke at the J.P. Morgan Healthcare Conference on Tuesday. Instead, his focus was more on the future. Davis provided the path that Acadia intends to take to achieve greater success in 2018 and beyond. Here are three of the keys for success he identified.
1. Increase patient awareness of Nuplazid
Although Nuplazid enjoyed solid momentum in 2017, Davis acknowledged one challenge for Acadia. Although more than half of PD patients experience PD psychosis, many of them aren't aware that they do. Others realize that they experience symptoms but don't tell their healthcare providers. It's estimated that 10% to 20% of all PD patients fit one of these two categories.
Acadia's game plan, therefore, is to do all it can to increase patient and caregiver awareness of Nuplazid. Davis said the company is trying to accomplish this goal in three ways.
First, Acadia began an integrated communications campaign, which included TV commercials and a website containing doctor discussion guides, videos targeted toward caregivers and patients, and a physician finder application for patients. Davis also stated that Acadia has trained speakers to present at Parkinson's disease patient advocacy groups. Acadia's third approach for increasing patient awareness is placing media and educational tools in healthcare providers' offices.
2. Increase long-term care penetration
PD psychosis is a leading cause of nursing home admissions among patients with PD. Acadia knew even before it launched Nuvazid that targeting long-term care (LTC) would need to be a top priority. Davis stated that the results so far for this effort have been good. However, he also said Acadia needs to increase its LTC penetration.
One important factor behind the company's success so far is its sales team dedicated to the LTC market. Davis noted that this team expanded in size in April 2017.
This sales team now has a little help in its efforts. The Centers for Medicare and Medicaid Services (CMS) have pressured nursing homes to reduce the number of psychotropic drugs patients take. However, CMS provided new regulatory guidance for nursing homes that allows prescribers to continue treatment with Nuplazid as long as the patient is demonstrating a benefit from the drug.
3. Achieve positive results in clinical studies
The third key for Acadia's success is to achieve positive results in clinical studies evaluating Nuplazid in treating other indications. Acadia expects to announce results from a phase 2 study targeting major depressive disorder in the second half of 2018. There is a significant unmet medical need for this indication: Only around half of the 16 million Americans with major depressive disorder receive treatment -- and the majority of these patients don't respond to initial antidepressant therapy.
Acadia anticipates announcing results from two other studies in 2019. The company's late-stage study of Nuplazid in treating schizophrenia in patients who inadequately respond to treatment could be a big catalyst. One-third of adults treated for schizophrenia don't respond to treatment, with another third only partially responding. Data from a phase 2 study of Nuplazid as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia are also expected to be released next year.
The biggie for Acadia could be its late-stage study targeting dementia-related psychosis. This indication includes psychosis associated with Alzheimer's disease and PD. There are no approved treatments right now, and current drugs used off-label for treating dementia-related psychosis come with serious side effects. This study is scheduled to conclude in 2020.
Can Acadia deliver?
These are the three things Acadia needs to do to be successful, but can the company deliver on these goals? I think so.
Of course, the first two are largely within Acadia's control. My view is that the company is on the right track in its efforts to increase patient awareness of Nuplazid and increase its LTC penetration. All Acadia needs to do now is to keep things going and execute effectively.
How well Nuplazid performs in treating additional indications is a different story. All we have to go on in judging Acadia's chances are prior clinical studies. There's certainly a significant level of risk that Nuplazid won't be effective. However, earlier studies were generally positive. My hunch is that Acadia will rack up more successes with its clinical program.
The biggest challenge for Acadia is playing the Wall Street expectations game. For example, the company reported pretty good results in the third quarter of 2017, but they weren't enough to meet analysts' estimates. Acadia stock tanked as a result .
But investors are better off focusing on the long term instead of temporary dips and fluctuations. In the PD psychosis indication alone, many expect Nuplazid to reach peak annual sales of around $1 billion by 2021. That level by itself is enough to justify Acadia's current market cap of $3.5 billion. And if Acadia's clinical studies go well, the stock should be worth a whole lot more. Acadia's success in 2018 isn't a sure thing, but I think the risk-reward proposition for the stock looks intriguing.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
Keith Speights owns shares of JPMorgan Chase. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia CEO Stephen Davis didn't mention the underwhelming performance of the stock when he spoke at the J.P. Morgan Healthcare Conference on Tuesday. In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017 . Acadia moved ahead with its late-stage studies for the drug in other indications. | Achieve positive results in clinical studies The third key for Acadia's success is to achieve positive results in clinical studies evaluating Nuplazid in treating other indications. Acadia expects to announce results from a phase 2 study targeting major depressive disorder in the second half of 2018. In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017 . | Increase patient awareness of Nuplazid Although Nuplazid enjoyed solid momentum in 2017, Davis acknowledged one challenge for Acadia. Acadia's game plan, therefore, is to do all it can to increase patient and caregiver awareness of Nuplazid. Achieve positive results in clinical studies The third key for Acadia's success is to achieve positive results in clinical studies evaluating Nuplazid in treating other indications. | Achieve positive results in clinical studies The third key for Acadia's success is to achieve positive results in clinical studies evaluating Nuplazid in treating other indications. These are the three things Acadia needs to do to be successful, but can the company deliver on these goals? In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017 . |
36029.0 | 2018-01-04 00:00:00 UTC | Noteworthy Thursday Option Activity: ACAD, V, NXPI | ACAD | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-acad-v-nxpi-2018-01-04 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 6,964 contracts has been traded thus far today, a contract volume which is representative of approximately 696,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.9% of ACAD's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $30 strike put option expiring January 19, 2018 , with 4,336 contracts trading so far today, representing approximately 433,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange:
Visa Inc (Symbol: V) options are showing a volume of 37,558 contracts thus far today. That number of contracts represents approximately 3.8 million underlying shares, working out to a sizeable 47.1% of V's average daily trading volume over the past month, of 8.0 million shares. Especially high volume was seen for the $115 strike call option expiring January 19, 2018 , with 2,502 contracts trading so far today, representing approximately 250,200 underlying shares of V. Below is a chart showing V's trailing twelve month trading history, with the $115 strike highlighted in orange:
And NXP Semiconductors NV (Symbol: NXPI) options are showing a volume of 10,438 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 44.8% of NXPI's average daily trading volume over the past month, of 2.3 million shares. Particularly high volume was seen for the $105 strike put option expiring January 17, 2020 , with 5,075 contracts trading so far today, representing approximately 507,500 underlying shares of NXPI. Below is a chart showing NXPI's trailing twelve month trading history, with the $105 strike highlighted in orange:
For the various different available expirations for ACAD options , V options , or NXPI options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $30 strike put option expiring January 19, 2018 , with 4,336 contracts trading so far today, representing approximately 433,600 underlying shares of ACAD. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 6,964 contracts has been traded thus far today, a contract volume which is representative of approximately 696,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.9% of ACAD's average daily trading volume over the past month, of 1.4 million shares. | Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: Visa Inc (Symbol: V) options are showing a volume of 37,558 contracts thus far today. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 6,964 contracts has been traded thus far today, a contract volume which is representative of approximately 696,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.9% of ACAD's average daily trading volume over the past month, of 1.4 million shares. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 6,964 contracts has been traded thus far today, a contract volume which is representative of approximately 696,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.9% of ACAD's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $30 strike put option expiring January 19, 2018 , with 4,336 contracts trading so far today, representing approximately 433,600 underlying shares of ACAD. | Particularly high volume was seen for the $30 strike put option expiring January 19, 2018 , with 4,336 contracts trading so far today, representing approximately 433,600 underlying shares of ACAD. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 6,964 contracts has been traded thus far today, a contract volume which is representative of approximately 696,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.9% of ACAD's average daily trading volume over the past month, of 1.4 million shares. |
36030.0 | 2017-12-29 00:00:00 UTC | TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise | ACAD | https://www.nasdaq.com/articles/therapeuticsmd-submits-nda-for-vms-candidate-shares-rise-2017-12-29 | nan | nan | Shares of TherapeuticsMD, Inc.TXMD were up 4.4% in after-market trading on Dec 28, following the submission of a new drug application ("NDA") to the FDA for pipeline candidate, TX-001HR.
In fact, TherapeuticsMD's share price has increased 12.5% in the past six months, outperforming the industry 's gain of 5.4%.
Data from the study showed that TX-001HR achieved statistically significant and clinically meaningful reduction in frequency and severity of VMS (hot flashes) from baseline compared to placebo.
TX-001HR is the first investigational bio-identical combination hormone therapy of estradiol and progesterone. The company believes there is significant demand for a bio-identical hormone therapy for treating VMS, which is currently being treated with unapproved combinations made by independent and community pharmacies.
A potential approval to TX-001HR will help patients to use proven safe and effective treatment and the cost may also get reimbursed through insurance.
The company expects a decision from the FDA on the acceptance of the NDA by March 2018.
We remind investors that last week, the FDA also accepted TherapeuticsMD's resubmission of the NDA for TX-004HR seeking approval to treat dyspareunia. A decision is expected in May 2018.
The company currently earns from manufacture and distribution of branded and generic prescription prenatal vitamins. Approval of the NDAs will likely boost the company's revenues.
TherapeuticsMD, Inc. Price
TherapeuticsMD, Inc. Price | TherapeuticsMD, Inc. Quote
Zacks Rank & Stocks to Consider
TherapeuticsMD carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Celldex's loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents in the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company's shares have returned 5.7% so far this year. The stock is up 8.1% so far this year.
Corcept's earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The stock is up 150.2% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days. Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days. | Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days. | Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days. |
36031.0 | 2017-12-27 00:00:00 UTC | 4 Biotech Stocks Ready to Crush the Market in 2018 | ACAD | https://www.nasdaq.com/articles/4-biotech-stocks-ready-to-crush-the-market-in-2018-2017-12-27 | nan | nan | The year 2017 has been quite a impressive one for the biotech sector as evident from the 19.4% gain registered so far by the NASDAQ Biotechnology Index (^ NBI . This is surely welcome news for investors since the industry suffered a decline of 19.2% last year.
While drug pricing issue, competition and a slowdown in growth of key drugs dented the sector's 2016 performance, new drug approvals and encouraging outlook by the companies boosted investor sentiment in 2017.
Immuno-oncology continued to remain in spotlight in 2017. The FDA's approval of CAR-T (chimeric antigen T-cell receptor) therapies like Kymriah and Gilead Sciences' GILD Yescarta for leukemia and lymphoma shifted investors' attention toward small biotechs companies developing these therapies. Investors also kept tab of key candidates' data.
The slowdown in mature products forced bigwigs like Gilead to undertake acquisitions to bolster pipelines. Gilead acquired erstwhile Kite Pharma to add Yescarta to its kitty. The company also inked an agreement to acquire Cell Design Labs. Celgene Corporation CELG too might be on the look-out for acquisitions to bolster its portfolio.
Approval of new drugs like Dupixient, Kevzara, Idhifa, Tremfya among others along with label expansion of existing drugs like Cabometyx boosted the respective companies' portfolios. We note that 2017 saw a larger number of drug approvals from the FDA than 2016.
Although the threat of biosimilars loom large on the sector, we expect a further boost in performance from the sector in 2018. Notably, the Medical - Biomed/Genetics sub-industry carries a Zacks Industry Rank of 114, which places it at the top 45% of the 250 plus Zacks industries.
While the smaller biotechs have performed impressively in 2017, the bigwigs weren't far behind and we expect the momentum to continue in 2018 as well. Here we list a few biotech companies which should outperform the market in 2018:
ACADIA Pharmaceuticals Inc . ACAD 's lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The drug was approved in 2016 by the FDA. Notably, it is the only drug approved in the United States for this condition. The drug generated sales of $81.3 million in the first nine months of 2017 and the company is looking to expand the drug's label further. 2017 was a roller-coaster ride for Acadia. Shares of the company have moved up 5.6% year-to-date compared with the industry's gain of 4.8%. We believe this Zacks Rank #2 (Buy) company should perform well in 2018 boosted by Nulpazid. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
(Looking for the Best Stocks for 2018? Be among the first to see our Top Ten Stocks for 2018 portfolio here .)
Sangamo Therapeutics, Inc . SGMO focuses on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo is conducting phase I/II clinical trials in Hemophilia A and B, and lysosomal storage disorders MPS I and MPS II. The company has collaborated with leading global companies for various pipeline candidates. This Zacks Rank #2 company had a phenomenal run in 2017 with the stock soaring 455.7% year-to-date compared with the industry's gain of 5.2%.
AnaptysBio ANAB is a clinical-stage biotechnology company. Its anti-inflammatory pipeline includes anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis. The company also has a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated, which have demonstrated efficacy in an animal model of graft-versus-host disease. The company is expected to report top-line data from its on-going phase IIa studies on ANB020 in severe adult peanut allergy and severe adult eosinophilic asthma during the first and second quarters of 2018, respectively. This Zacks Rank #2 company had a phenomenal run in 2017 with the stock soaring 488.4% compared with the industry's gain of 5.2%.
Sino Biopharmaceutical LimitedSBMFF researches, develops, manufactures and markets a wide array of Chinese medicines and chemical medicines for two major therapeutic categories - hepatitis and cardio-cerebral diseases. The company also actively develops medicines for treating tumors, analgesia, orthopedic diseases, anti-infection, parenteral nutrition, respiratory system diseases, anorectal diseases, diabetes and other diseases to meet the increasing demand of the market, medical practitioners and patients. The lead products include Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules along with cardio-cerebral medicines such as Yilunping and Tuotuo tablets. The company currently carries a Zacks Rank #2.
We expect investors to remain focussed on this dynamic sector eying new drug approvals and important data read-outs.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
SINO PHARMACEUT (SBMFF): Free Stock Analysis Report
AnaptysBio, Inc. (ANAB): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here we list a few biotech companies which should outperform the market in 2018: ACADIA Pharmaceuticals Inc . ACAD 's lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 2017 was a roller-coaster ride for Acadia. | Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report SINO PHARMACEUT (SBMFF): Free Stock Analysis Report AnaptysBio, Inc. (ANAB): Free Stock Analysis Report To read this article on Zacks.com click here. Here we list a few biotech companies which should outperform the market in 2018: ACADIA Pharmaceuticals Inc . ACAD 's lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. | Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report SINO PHARMACEUT (SBMFF): Free Stock Analysis Report AnaptysBio, Inc. (ANAB): Free Stock Analysis Report To read this article on Zacks.com click here. Here we list a few biotech companies which should outperform the market in 2018: ACADIA Pharmaceuticals Inc . ACAD 's lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. | Here we list a few biotech companies which should outperform the market in 2018: ACADIA Pharmaceuticals Inc . ACAD 's lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 2017 was a roller-coaster ride for Acadia. |
36032.0 | 2017-12-26 00:00:00 UTC | Why the Earnings Streak Will Continue for ACADIA Pharmaceuticals (ACAD) | ACAD | https://www.nasdaq.com/articles/why-the-earnings-streak-will-continue-for-acadia-pharmaceuticals-acad-2017-12-26 | nan | nan | Looking for a stock that might be in a good position to beat earnings at its next report? Consider ACADIA Pharmaceuticals Inc.ACAD , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat.
This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ACAD has beaten estimates by at least 15% in both cases, suggesting it has a nice short-term history of crushing expectations.
Earnings in Focus
Two quarters ago, ACAD was expected to post a loss of 71 cents per share, while it actually produced a loss of 55 cents per share, a beat of 22.5%. Meanwhile, for the most recent quarter, the company looked to deliver a loss of 63 cents per share, when it actually saw a loss of 53 cents per share instead, representing a 15.9% positive surprise.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Thanks in part to this history, recent estimates have been moving higher for ACADIA Pharmaceuticals. In fact, the Earnings ESP for ACAD is positive, which is a great sign of a coming beat.
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company's earnings prospects. This is the case for ACAD, as the firm currently has a Zacks Earnings ESP of 4.03%, so another beat could be around the corner.
This is particularly true when you consider that ACAD has a great Zacks Rank #2 (Buy), which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ACAD could see another beat at its next report, especially if recent trends are any guide.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Consider ACADIA Pharmaceuticals Inc.ACAD , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat. In fact, in these reports, ACAD has beaten estimates by at least 15% in both cases, suggesting it has a nice short-term history of crushing expectations. This is particularly true when you consider that ACAD has a great Zacks Rank #2 (Buy), which can be a harbinger of outperformance and a signal for a strong earnings profile. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Thanks in part to this history, recent estimates have been moving higher for ACADIA Pharmaceuticals. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Consider ACADIA Pharmaceuticals Inc.ACAD , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Thanks in part to this history, recent estimates have been moving higher for ACADIA Pharmaceuticals. When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ACAD could see another beat at its next report, especially if recent trends are any guide. Consider ACADIA Pharmaceuticals Inc.ACAD , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat. | In fact, in these reports, ACAD has beaten estimates by at least 15% in both cases, suggesting it has a nice short-term history of crushing expectations. When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ACAD could see another beat at its next report, especially if recent trends are any guide. Consider ACADIA Pharmaceuticals Inc.ACAD , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat. |
36033.0 | 2017-12-20 00:00:00 UTC | Minerva Initiates Phase III Study on Schizophrenia Candidate | ACAD | https://www.nasdaq.com/articles/minerva-initiates-phase-iii-study-on-schizophrenia-candidate-2017-12-20 | nan | nan | Minerva Neurosciences, Inc.NERV announced that it has initiated a phase III study, MIN-101C07, to evaluate its lead pipeline candidate as monotherapy for the treatment of negative symptoms in patients diagnosed with schizophrenia.
Minerva's share price has declined 51.9% so far this year, while the industry witnessed a gain of 7.5%.
The primary endpoint of the study is to achieve an improvement in PANSS score. Top-line data from the study is expected in the first half of 2019.
The 12-week study will be followed by an open-label extension study for period of 40 weeks.
The design of the phase III study is similar to the successfully completed phase IIb study. The phase IIb study showed improvement in schizophrenic patients with negative symptoms treated with MIN-101 compared to placebo.
With no approved products in its portfolio, Minerva is dependent on the progress of its pipeline. Moreover, with no major collaboration agreements the company doesn't have a source of funds while it continues to burn cash for the research and development process. The company expects to incur operating losses going forward. The cash available is expected to fund operations for the next 12 months only.
Any setback in the development of MIN-101 will adversely impact Minerva's shares.
Meanwhile, Minerva has a license agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson JNJ , for co-development of orexin-2 receptor antagonist, MIN-202, for treating schizophrenia.
Minerva Neurosciences, Inc Price
Minerva Neurosciences, Inc Price | Minerva Neurosciences, Inc Quote
Zacks Rank & Stocks to Consider
Minerva Neurosciences carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Celldex's loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. | ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . |
36034.0 | 2017-12-20 00:00:00 UTC | First Week of ACAD February 2018 Options Trading | ACAD | https://www.nasdaq.com/articles/first-week-acad-february-2018-options-trading-2017-12-20 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.
The put contract at the $28.00 strike price has a current bid of $1.60. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $28.00, but will also collect the premium, putting the cost basis of the shares at $26.40 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $28.38/share today.
Because the $28.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 57%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 5.71% return on the cash commitment, or 35.96% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $28.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $29.00 strike price has a current bid of $1.50. If an investor was to purchase shares of ACAD stock at the current price level of $28.38/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $29.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 7.47% if the stock gets called away at the February 2018 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $29.00 strike highlighted in red:
Considering the fact that the $29.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 51%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.29% boost of extra return to the investor, or 33.26% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 45%, while the implied volatility in the call contract example is 44%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $28.38) to be 44%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $29.00 strike highlighted in red: Considering the fact that the $29.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 2018 expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $29.00 strike highlighted in red: Considering the fact that the $29.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new February 2018 contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $28.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $29.00 strike price has a current bid of $1.50. Below is a chart showing ACAD's trailing twelve month trading history, with the $29.00 strike highlighted in red: Considering the fact that the $29.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 2018 expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new February 2018 contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $29.00 strike highlighted in red: Considering the fact that the $29.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 2018 expiration. |
36035.0 | 2017-12-20 00:00:00 UTC | TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why | ACAD | https://www.nasdaq.com/articles/therapeuticsmd-falls-despite-acceptance-of-nda%3A-heres-why-2017-12-20 | nan | nan | TherapeuticsMD, Inc.TXMD announced that the FDA has accepted the resubmission of the New Drug Application ("NDA") for its dyspareunia candidate, TX-004HR. The FDA also set a PDUFA date of May 29, 2018.
Shares of the company however fell 6.8% in after-hours trading on Dec 19, presumably due to classification of resubmission as a Class 2 response by the FDA. Classification as a Class 1 response would have shortened the timeframe for a potential approval from six months to two months.
We remind investors that the company had received a complete response letter ("CRL") from the FDA in May for the same.
However, TherapeuticsMD's share price has increased 6.4% in the past six months, outperforming the industry 's decline 0.4%.
The resubmission was supported by data from phase III Rejoice study, which demonstrated statistically significant and clinically meaningful improvements in dyspareunia and vaginal dryness from baseline compared to a placebo.
We note that the resubmission includes data only for two dosages - 4 mcg and 10 mcg - of the candidate.
The CRL was a major setback for the company. Any issue with the resubmission may further delay the candidate's approval and result in a decline in shares.
According to the press release, an estimated 32 million women are currently suffering from symptoms of VVA in the United States.
We note that in April 2017, AMAG Pharmaceuticals, Inc. AMAG had acquired commercial rights to Intrarosa, the only FDA-approved non-estrogen product for the treatment of moderate-to-severe dyspareunia from privately held Endoceutics, Inc.
TherapeuticsMD, Inc. Price
TherapeuticsMD, Inc. Price | TherapeuticsMD, Inc. Quote
Zacks Rank & Stocks to Consider
TherapeuticsMD carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Celldex's loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report
Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. | A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. | Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. | A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36036.0 | 2017-12-14 00:00:00 UTC | Shire's New Formulation of Oncaspar Gets Approval in Europe | ACAD | https://www.nasdaq.com/articles/shires-new-formulation-of-oncaspar-gets-approval-in-europe-2017-12-14 | nan | nan | Shire plcSHPG announced that the European Commission ("EC") has granted marketing authorization to its new freeze-dried formulation of Oncaspar for treating acute lymphoblastic leukemia ("ALL") in Europe. The new lyophilized formulation is approved as a component of a multi-agent chemotherapeutic regimen in pediatric patients (from birth to 18 years) as well as adult patients.
The approval in EU was expected as the drug was recommended by the Committee for Medicinal Products for Human Use ("CHMP") in October. Presently, the drug is approved in liquid form for treating the same indication. The approval of the new formulation will increase the shelf life of Oncaspar up to three times to 24 months.
Shire's shares have underperformed the industry so far this year. The company's shares have lost 13.8% against the industry's gain of 6.2%.
The formulation is now approved in all 28 European Union ("EU") member countries plus Iceland, Norway and Liechtenstein.
Lyophilized Oncaspar works in a similar way as liquid Oncaspar and has the same dosing regimen as well.
Shire's oncology segment witnessed growth of 24% in the third quarter of 2017 driven by strong sales of Oncaspar and pancreatic cancer drug, Onivyde. The increase in shelf life with this new formulation is expected to help the company improve the supply of this critical drug. Moreover, the new formulation will improve the accessibility of the drug to ALL patients in countries where the liquid form is not allowed.
The company expects the new formulation of Oncaspar to be available in Europe in the first half of 2018.
Shire PLC Price
Shire PLC Price | Shire PLC Quote
Zacks Rank & Stocks to Consider
Shire carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Celldex's loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company's shares have returned 3.8% so far this year.
Corcept's earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The company's stock is up 138.1% so far this year.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Shire PLC (SHPG): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. | Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. |
36037.0 | 2017-12-13 00:00:00 UTC | Glaxo's Nucala Label Expansion Application Gets FDA Approval | ACAD | https://www.nasdaq.com/articles/glaxos-nucala-label-expansion-application-gets-fda-approval-2017-12-13 | nan | nan | GlaxoSmithKline plcGSK announced that the FDA has approved the label expansion of eosinophilic asthma drug, Nucala, to include treatment of eosinophilic granulomatosis with polyangiitis ("EGPA"). With this approval, Nucala becomes the first targeted treatment for EGPA, which was previously known as Churg-Strauss syndrome.
EGPA is a rare autoimmune disease, which causes inflammation in small and medium-sized blood vessels. It can cause damage to lungs, sinuses, skin, heart, gastrointestinal tract, nerves and other organs.
Nucala is presently approved for treating severe eosinophilic asthma.
Shares of Glaxo have decreased 7.8% so far this year, underperforming the industry 's gain of 17.4% in that period.
Data showed that Nucala achieved statistically significant improvement in primary endpoints - accrued time in remission and proportion of patients achieving remission - compared to placebo.
According to principal investigator of MIRRA study, Dr. Michael Wechsler, EGPA patients often suffer from recurrent relapses, which may permanently damage tissue and organ. Data from the study has shown that Nucala has increased accrued time in remission and also reduced the frequency of relapse and flares. The patients were also able to reduce their dose of corticosteroid compared to placebo.
Currently, approved treatments for EGPA generally work by reducing active inflammation and by suppressing the body's immune response.
A supplemental biologics license application for label expansion of Nucala to include treatment of chronic obstructive pulmonary disease is under review in the United States.
GlaxoSmithKline PLC Price
GlaxoSmithKline PLC Price | GlaxoSmithKline PLC Quote
Zacks Rank & Stocks to Consider
Glaxo carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Celldex's loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company's shares have returned 5.7% so far this year.
Corcept's earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The company's stock is up 131.3% so far this year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. | Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. | Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. |
36038.0 | 2017-12-11 00:00:00 UTC | Lilly Reports Mixed Results from Late-Stage Cyramza Study | ACAD | https://www.nasdaq.com/articles/lilly-reports-mixed-results-from-late-stage-cyramza-study-2017-12-11 | nan | nan | Eli Lilly and CompanyLLY announced top-line data from the phase III study - RAINFALL - evaluating Cyramza (ramucirumab) as first-line treatment for patients with advanced gastric cancer. The study met its primary endpoint of progression free survival ("PFS") but failed to improve overall survival ("OS"). The results will be presented at a future medical meeting.
The company has also announced that it will not seek regulatory approval in the first-line setting based on the data from this study.
Cyramza is presently approved as a single agent or in combination with chemotherapy drug, paclitaxel, for treating advanced or metastatic gastric (stomach) or gastroesophageal junction ("GEJ") adenocarcinoma in patients whose disease has progressed after prior therapies. The drug is also approved for treating metastatic non-small cell lung cancer and for metastatic colorectal cancer (with tradename Folfiri).
Shares of Lilly have gained 6.9% in the past six months, outperforming the industry 's rise of 4.5% in that period.
The company was hopeful that the positive PFS would lead to an OS benefit. Treating advanced gastric cancer is a challenge, which is further underscored by the fact that no major advances over chemotherapies have been achieved for treating metastatic gastric cancer.
Moreover, initial data from another phase III study on Cyramza presented at ESMO 2017 Congress showed that the drug met PFS endpoint in patients with advanced urothelial carcinoma.
Per the press release, gastric cancer is the fifth most common form of cancer in the world. The disease is expected to affect 28,000 new patients and cause 11,000 deaths in the United Sates in 2017 alone.
Eli Lilly and Company Price
Eli Lilly and Company Price | Eli Lilly and Company Quote
Zacks Rank & Stocks to Consider
Lilly carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Johnson & Johnson JNJ , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
J&J's earnings estimates increased from $7.19 to $7.28 for 2017 and from $7.75 to $7.85 over the last 60 days. The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 3.12%. The company's shares have returned 22% so far this year.
ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company's shares have returned 5.7% so far this year.
Corcept's earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The company's stock is up 131.3% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector include Johnson & Johnson JNJ , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector include Johnson & Johnson JNJ , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Johnson & Johnson JNJ , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. | Some better-ranked stocks in the pharma sector include Johnson & Johnson JNJ , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. |
36039.0 | 2017-12-08 00:00:00 UTC | 5 Cheap Biotech Stocks to Snag on the Bounce | ACAD | https://www.nasdaq.com/articles/5-cheap-biotech-stocks-snag-bounce-2017-12-08 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
U.S. equities are pushing higher on Friday thanks to a strong non-farm payroll report, the passage of a short-term government funding bill preventing a shutdown tonight and the seasonal tailwinds the bulls enjoy this time of year.
One sector group in particular looks ready to profit from the upward drift are the biotech stocks, which have been on the decline in recent weeks as investors focus on Big Tech stocks and more recently on high-tax issues most likely to benefit from the GOP's corporate tax cut plans.
That's changing now, with the iShares Nasdaq Biotech (NASDAQ: IBB ) looking ready to rise up and out of a three-month holding period taking the fight back toward its 50-day moving average.
7 AI Stocks to Buy to Join the Next Technological Revolution
This sets up a possible return to the highs not seen since October. If so, here are five cheap biotech stocks ready to surge:
Biotech Stocks to Buy: Acadia Pharmaceuticals (ACAD)
Shares of Acadia Pharmacueticals Inc. (NASDAQ: ACAD ) are rising off of support from a multi-year pennant pattern, setting up another run at overhead resistance near the $40-a-share level.
That would be worth a 33%-plus gain from here. In a recent note to clients, Needham analysts highlighted potential sales momentum building for the company.
The company will next report results on Feb. 28. Analysts are looking for a loss of 57 cents per share on revenues of $45 million. When the company last reported Nov. 7, a loss of 53 cents per share beat estimates by 10 cents on a 5.7x rise in revenues from the previous year.
Biotech Stocks to Buy: ImmunoGen (IMGN)
ImmunoGen, Inc. (NASDAQ: IMGN ) shares are creeping higher, rising on support at its 20-day moving average capping a multi-month consolidation from the massive rise off of the lows seen last December.
Watch for a move back to the highs seen in late August, which would be worth a gain of 40% from here.
The company will next report results on Feb. 2 before the bell. Analysts are looking for a loss of 14 cents per share on revenues of $39.6 million.
When the company last reported on Nov. 3, a loss of 61 cents per share missed estimates by 40 cents on a 10.4% Riss in revenues
Biotech Stocks to Buy: Viking Therapeutics (VKTX)
Viking Therapeutics Inc (NASDAQ: VKTX ) shares have more than quadrupled from their summertime low, rising above the $4-a-share threshold returning to levels not seen since January 2016. Just the past month has seen a 33%-plus gain.
The gain hasn't been affected by a float of more than five million shares in a secondary offering this week, priced at $2.50 per share.
10 High-Yield Stocks That Won't Cut Their Dividends in 2018
Positive analyst coverage has helped, with Maxim Group raising their price target to $8 on positive results from a hip fracture study. HC Wainwright has a $7 target.
Biotech Stocks to Buy: Alexion Pharmaceuticals (ALXN)
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) shares are rising off of a three-month consolidation range setting up a run at its 50- and 200-day moving averages.
Shares are down from a peak of $210 set back in 2015 but look ready for a rise in efforts by activist investors to shake up the management team and turn its fortunes around. M&A chatters could bolster prices as well.
The company will next report results on Feb. 15 before the bell. Analysts are looking for earnings of $1.27 per share on revenues of $878 million. When the company last reported on Oct. 26, earnings of $1.44 per share beat estimates by 12 cents on a 7.5% rise in revenues.
Biotech Stocks to Buy: Immunomedics (IMMU)
Immunomedics, Inc. (NASDAQ: IMMU ) shares are rising back toward its September/October highs after hitting support at its 200-day moving average earlier this month. This sets up a breakout out of a five-month consolidation range that's capped a 5x rally off of its 2016 lows.
Merely a return to its October high would be worth a gain of 16% from current levels.
The company will next report results on Feb. 8 after the close. Analysts are looking for a loss of 12 cents per share on revenues of $4.7 million.
7 'Strong Buy' Disruptive Stocks You Should Track Now
When the company last reported on Nov. 9, a loss of 91 cents per share missed estimates by 91 cents on a 6.8% drop in revenues.
Anthony Mirhaydari is the founder of the Edge (ETFs) and Edge Pro (Options) investment advisory newsletters. Free two- and four-week trial offers have been extended to InvestorPlace readers.
The post 5 Cheap Biotech Stocks to Snag on the Bounce appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If so, here are five cheap biotech stocks ready to surge: Biotech Stocks to Buy: Acadia Pharmaceuticals (ACAD) Shares of Acadia Pharmacueticals Inc. (NASDAQ: ACAD ) are rising off of support from a multi-year pennant pattern, setting up another run at overhead resistance near the $40-a-share level. InvestorPlace - Stock Market News, Stock Advice & Trading Tips U.S. equities are pushing higher on Friday thanks to a strong non-farm payroll report, the passage of a short-term government funding bill preventing a shutdown tonight and the seasonal tailwinds the bulls enjoy this time of year. When the company last reported on Nov. 3, a loss of 61 cents per share missed estimates by 40 cents on a 10.4% Riss in revenues Biotech Stocks to Buy: Viking Therapeutics (VKTX) Viking Therapeutics Inc (NASDAQ: VKTX ) shares have more than quadrupled from their summertime low, rising above the $4-a-share threshold returning to levels not seen since January 2016. | If so, here are five cheap biotech stocks ready to surge: Biotech Stocks to Buy: Acadia Pharmaceuticals (ACAD) Shares of Acadia Pharmacueticals Inc. (NASDAQ: ACAD ) are rising off of support from a multi-year pennant pattern, setting up another run at overhead resistance near the $40-a-share level. When the company last reported on Nov. 3, a loss of 61 cents per share missed estimates by 40 cents on a 10.4% Riss in revenues Biotech Stocks to Buy: Viking Therapeutics (VKTX) Viking Therapeutics Inc (NASDAQ: VKTX ) shares have more than quadrupled from their summertime low, rising above the $4-a-share threshold returning to levels not seen since January 2016. Biotech Stocks to Buy: Alexion Pharmaceuticals (ALXN) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) shares are rising off of a three-month consolidation range setting up a run at its 50- and 200-day moving averages. | If so, here are five cheap biotech stocks ready to surge: Biotech Stocks to Buy: Acadia Pharmaceuticals (ACAD) Shares of Acadia Pharmacueticals Inc. (NASDAQ: ACAD ) are rising off of support from a multi-year pennant pattern, setting up another run at overhead resistance near the $40-a-share level. When the company last reported on Nov. 3, a loss of 61 cents per share missed estimates by 40 cents on a 10.4% Riss in revenues Biotech Stocks to Buy: Viking Therapeutics (VKTX) Viking Therapeutics Inc (NASDAQ: VKTX ) shares have more than quadrupled from their summertime low, rising above the $4-a-share threshold returning to levels not seen since January 2016. 7 'Strong Buy' Disruptive Stocks You Should Track Now When the company last reported on Nov. 9, a loss of 91 cents per share missed estimates by 91 cents on a 6.8% drop in revenues. | If so, here are five cheap biotech stocks ready to surge: Biotech Stocks to Buy: Acadia Pharmaceuticals (ACAD) Shares of Acadia Pharmacueticals Inc. (NASDAQ: ACAD ) are rising off of support from a multi-year pennant pattern, setting up another run at overhead resistance near the $40-a-share level. That's changing now, with the iShares Nasdaq Biotech (NASDAQ: IBB ) looking ready to rise up and out of a three-month holding period taking the fight back toward its 50-day moving average. When the company last reported Nov. 7, a loss of 53 cents per share beat estimates by 10 cents on a 5.7x rise in revenues from the previous year. |
36040.0 | 2017-12-04 00:00:00 UTC | Here's How Acadia Pharmaceuticals Crushed It in 2017 | ACAD | https://www.nasdaq.com/articles/heres-how-acadia-pharmaceuticals-crushed-it-2017-2017-12-04 | nan | nan | About 1 million patients in the U.S. suffer from Parkinson's disease. Unfortunately, nearly 40% of them will experience hallucinations and delusions in their daily life, which is a disease state called Parkinson's disease psychosis (PDP).
Caring for a patient who suffers from Parkinson's disease is hard, but adding PDP to the mix elevates their needs to a whole new level. Given the challenge, many patients who develop PDP are sent off to a nursing home.
For decades, there wasn't much that providers could do to treat PDP. However, Acadia Pharmaceuticals (NASDAQ: ACAD) changed all of that in 2016 when the Food and Drug Administration approved its PDP drug Nuplazid for sale. Given the enormous unmet medical need and lack of competition , Acadia had a wide-open market opportunity ahead of it -- if it could successfully execute against its commercialization plan.
A solid year
So how did the company's actual results shake out in 2017? Here's a quick review of the first three quarters:
In the first quarter, Acadia reported total Nuplazid sales of $15.3 million . That figure was comfortably ahead of the $13.8 million that analysts were expecting.
Things got even better in the second quarter. Revenue came in at $30.5 million, blowing past the $19.6 million that Wall Street had expected. The upbeat data gave management enough confidence to share full-year revenue guidance for the first time. The company called for revenue to land between $105 million and $115 million. The midpoint of the range was far ahead of the $94 million in revenue that Wall Street was projecting at the time.
The good times continued into the third quarter, too. Revenue was $35.6 million, which also beat Wall Street's estimate of $31.5 million. The strong results allowed management to significantly raise its full-year guidance to $124 million-$127 million.
The good news wasn't just limited to strong revenue growth, either. In October, Acadia kicked off a phase 3 study designed to test Nuplazid as a treatment for hallucinations and delusions associated with dementia-related psychosis (which can be associated with diseases such as Alzheimer's, Lewy bodies, Parkinson's, and more). The FDA even granted it the drug breakthrough therapy designation, which is a great sign. If all goes well, management believes that winning this label expansion claim could add millions of patients to the company's addressable market.
A roller-coaster ride to nowhere
Given the string of expectation-topping results and upbeat clinical news, you might assume that Acadia's stock would be on fire in 2017. After all, it has been a monster winner over the last couple of years, so shareholders are accustomed to seeing the stock price go up.
But that's not what has happened in 2017 thus far.
ACAD data by YCharts .
What gives? The recent weakness can be traced to a data release from the company's phase 2 study in Alzheimer's disease. While Nuplazid was able to meet the study's primary endpoint -- which was measured as a statistically significant reduction in psychosis versus placebo -- it missed the mark on a handful of secondary endpoints. That could be a cause for concern down the road if it prevents physicians from prescribing the drug (assuming it wins approval).
Another potential negative is that the company's phase 3 dementia-related psychosis study won't be completed until 2020. That catalyst might be viewed as too far away to ignite trader enthusiasm.
Combine these facts with Acadia's lofty valuation -- shares currently trade at 57 times sales -- and it is understandable why 2017 has been a roller-coaster ride to nowhere.
Is Acadia a buy?
Despite the sideways share-price movement and lukewarm clinical results, I can't help but remain bullish on Acadia's long-term potential. Acadia has already proven that Nuplazid is safe to use, so I think that the odds of it winning a label expansion claim into dementia-related psychosis down the road remain excellent. In the meantime, Nuplazid's fast start gives it a decent shot at reaching blockbuster status based on its PDP opportunity alone. If true, then the company's current market cap of $3.6 billion doesn't seem so outrageously rich. Count me as a bull.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 6, 2017
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given the enormous unmet medical need and lack of competition , Acadia had a wide-open market opportunity ahead of it -- if it could successfully execute against its commercialization plan. In October, Acadia kicked off a phase 3 study designed to test Nuplazid as a treatment for hallucinations and delusions associated with dementia-related psychosis (which can be associated with diseases such as Alzheimer's, Lewy bodies, Parkinson's, and more). Acadia has already proven that Nuplazid is safe to use, so I think that the odds of it winning a label expansion claim into dementia-related psychosis down the road remain excellent. | Acadia has already proven that Nuplazid is safe to use, so I think that the odds of it winning a label expansion claim into dementia-related psychosis down the road remain excellent. However, Acadia Pharmaceuticals (NASDAQ: ACAD) changed all of that in 2016 when the Food and Drug Administration approved its PDP drug Nuplazid for sale. Given the enormous unmet medical need and lack of competition , Acadia had a wide-open market opportunity ahead of it -- if it could successfully execute against its commercialization plan. | However, Acadia Pharmaceuticals (NASDAQ: ACAD) changed all of that in 2016 when the Food and Drug Administration approved its PDP drug Nuplazid for sale. Here's a quick review of the first three quarters: In the first quarter, Acadia reported total Nuplazid sales of $15.3 million . In October, Acadia kicked off a phase 3 study designed to test Nuplazid as a treatment for hallucinations and delusions associated with dementia-related psychosis (which can be associated with diseases such as Alzheimer's, Lewy bodies, Parkinson's, and more). | However, Acadia Pharmaceuticals (NASDAQ: ACAD) changed all of that in 2016 when the Food and Drug Administration approved its PDP drug Nuplazid for sale. Given the enormous unmet medical need and lack of competition , Acadia had a wide-open market opportunity ahead of it -- if it could successfully execute against its commercialization plan. Here's a quick review of the first three quarters: In the first quarter, Acadia reported total Nuplazid sales of $15.3 million . |
36041.0 | 2017-11-30 00:00:00 UTC | Medicines Company to Sell Infectious Disease Unit to Melinta | ACAD | https://www.nasdaq.com/articles/medicines-company-to-sell-infectious-disease-unit-to-melinta-2017-11-30 | nan | nan | The Medicines CompanyMDCO announced that it has entered into a definitive agreement with antibiotics company, Melinta Therapeutics, Inc. MLNT , for selling its infectious disease business unit for an upfront payment of $270 million. The agreement will grant Melinta worldwide rights of Orbactiv, Minocin and recently launched Vabomere.
The Medicines Company plans to focus on developing its pivotal pipeline candidate - inclisiran - for treating hypercholesterolemia.
The Medicines Company's shares have fallen 11.1% so far this year, underperforming the industry 's rise of 1.3% in that period.
The Medicine Company will receive royalties in the range of 5%-25% on Vabomere U.S. sales, 5%-15% on U.S. sales of Minocin & Orbactiv, and 15% on international sales of all the drugs.
The Medicine Company plans to focus on the development of inclisiran, which is currently being evaluated in a phase III study for the treatment of hypercholesterolemia. The company has burnt significant cash this year. This deal will help the company to recoup a major portion of it. Moreover, the cash will help to continue the inclisiran study till its anticipated completion in 2019.
The deal is expected to close in the first quarter of 2018.
Meanwhile, the company, as part of its earlier announced restructuring program, will cut its headcount by 60. This will also reduce its annual operating expenses.
The Medicines Company Price
The Medicines Company Price | The Medicines Company Quote
Zacks Rank & Stocks to Consider
The Medicines Company carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc. LGND and ACADIA Pharmaceuticals Inc. ACAD . Both stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Ligand's earnings estimates were increased from $2.96 to $2.97 for 2017 and increased from $3.68 to $3.70 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 8.22%. The company's shares have returned 28.8% so far this year.
ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Medicines Company (MDCO): Free Stock Analysis Report
Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Cempra, Inc. (MLNT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc. LGND and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Cempra, Inc. (MLNT): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Cempra, Inc. (MLNT): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc. LGND and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. | Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Cempra, Inc. (MLNT): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc. LGND and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. | A couple of better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc. LGND and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Cempra, Inc. (MLNT): Free Stock Analysis Report To read this article on Zacks.com click here. |
36042.0 | 2017-11-27 00:00:00 UTC | Spectrum Doubles in 3 Months: What's Driving the Rally? | ACAD | https://www.nasdaq.com/articles/spectrum-doubles-in-3-months%3A-whats-driving-the-rally-2017-11-27 | nan | nan | Shares of Spectrum Pharmaceuticals, Inc.SPPI have been rising over the past year. This biotech company has more than doubled in the past three months surging 110%, significantly outperforming the 5.3% rise of the industry in this period.
Spectrum is focused on acquiring, developing and commercializing products, primarily in the fields of hematology and oncology. The company markets six products, which are utilized to treat several cancer indications including lymphoma, leukemia and myeloma. However, its primary focus focus is on the development of pipeline which includes poziotinib, Qapzola and Rolontis.
Pipeline in Focus
In the last three months, poziotinib has been the driving factor behind the stock's rally. In October, Spectrum announced encouraging preliminary data from a phase II study on poziotinib in non-small-cell lung cancer ("NSCLC") patients with exon 20 insertion mutations in EGFR. The candidate achieved an objective response rate in 73% of patients. The stock witnessed a rise following the news. Spectrum also initiated a multicenter phase II study to evaluate poziotinib in NSCLC patients with exon 20 insertion mutations in EGFR or HER2.
Meanwhile, Spectrum's most advanced candidate, Rolontis, is currently being evaluated in two separate phase III studies - ADVANCE and RECOVER - for treating chemotherapy-induced neutropenia. Top line data from the ADVANCE study is expected in first-quarter 2018. This will be followed by a biologics license application (BLA), likely to be filed by the end of 2018. A phase III study is evaluating Qapzola, another pipeline candidate, in patients with non-muscle invasive bladder cancer.
The lackluster product sales have kept investors focused on pipeline development. Also, Spectrum's cash and cash equivalents rose about $109 million to $247 million in the third quarter of 2017 which should help the company fund the development of candidates. A potential success inthe Rolontis study expected in early 2018 can be the next catalyst for the stock's further rise.
Spectrum Pharmaceuticals, Inc. Price
Spectrum Pharmaceuticals, Inc. Price | Spectrum Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Spectrum carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Incorporated LGND , ACADIA Pharmaceuticals Inc. ACAD and ANI Pharmaceuticals, Inc. ANIP . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Ligand's earnings estimates were flat at $2.96 for 2017 and increased from $3.68 to $3.70 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 8.22%. The company's shares have returned 31.6% year to date.
ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
ANI Pharma's earnings per share estimates increased from $3.87 to $3.93 for 2017 and from $4.56 to $4.67 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 0.13%. The stock has returned 23% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report
Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Incorporated LGND , ACADIA Pharmaceuticals Inc. ACAD and ANI Pharmaceuticals, Inc. ANIP . ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Incorporated LGND , ACADIA Pharmaceuticals Inc. ACAD and ANI Pharmaceuticals, Inc. ANIP . Click to get this free report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. | Some better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Incorporated LGND , ACADIA Pharmaceuticals Inc. ACAD and ANI Pharmaceuticals, Inc. ANIP . Click to get this free report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. | Some better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Incorporated LGND , ACADIA Pharmaceuticals Inc. ACAD and ANI Pharmaceuticals, Inc. ANIP . ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. |
36043.0 | 2017-11-22 00:00:00 UTC | ACAD January 2018 Options Begin Trading | ACAD | https://www.nasdaq.com/articles/acad-january-2018-options-begin-trading-2017-11-22 | nan | nan | Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the January 2018 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.
The put contract at the $27.00 strike price has a current bid of 45 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $27.00, but will also collect the premium, putting the cost basis of the shares at $26.55 (before broker commissions). To an investor already interested in purchasing shares of ACAD, that could represent an attractive alternative to paying $27.77/share today.
Because the $27.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 60%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 1.67% return on the cash commitment, or 13.83% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of 65 cents. If an investor was to purchase shares of ACAD stock at the current price level of $27.77/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $28.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 3.17% if the stock gets called away at the January 2018 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red:
Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 47%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.34% boost of extra return to the investor, or 19.42% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 54%, while the implied volatility in the call contract example is 56%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $27.77) to be 45%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ACAD shares really soar, which is why looking at the trailing twelve month trading history for Acadia Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the January 2018 expiration. | Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the January 2018 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new January 2018 contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of 65 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the January 2018 expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new January 2018 contracts and identified one put and one call contract of particular interest. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the January 2018 expiration. |
36044.0 | 2017-11-20 00:00:00 UTC | Analysts Anticipate 21% Upside For The Holdings of BBH | ACAD | https://www.nasdaq.com/articles/analysts-anticipate-21-upside-holdings-bbh-2017-11-20 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Biotech ETF (Symbol: BBH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $150.36 per unit.
With BBH trading at a recent price near $124.34 per unit, that means that analysts see 20.93% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Tesaro Inc (Symbol: TSRO), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $27.86/share, the average analyst target is 75.43% higher at $48.88/share. Similarly, TSRO has 70.91% upside from the recent share price of $85.90 if the average analyst target price of $146.81/share is reached, and analysts on average are expecting BMRN to reach a target price of $114.05/share, which is 37.61% above the recent price of $82.88. Below is a twelve month price history chart comparing the stock performance of ACAD, TSRO, and BMRN:
Combined, ACAD, TSRO, and BMRN represent 6.73% of the Biotech ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $27.86/share, the average analyst target is 75.43% higher at $48.88/share. Below is a twelve month price history chart comparing the stock performance of ACAD, TSRO, and BMRN: Combined, ACAD, TSRO, and BMRN represent 6.73% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Tesaro Inc (Symbol: TSRO), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Tesaro Inc (Symbol: TSRO), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Below is a twelve month price history chart comparing the stock performance of ACAD, TSRO, and BMRN: Combined, ACAD, TSRO, and BMRN represent 6.73% of the Biotech ETF. Although ACAD has traded at a recent price of $27.86/share, the average analyst target is 75.43% higher at $48.88/share. | Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Tesaro Inc (Symbol: TSRO), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $27.86/share, the average analyst target is 75.43% higher at $48.88/share. Below is a twelve month price history chart comparing the stock performance of ACAD, TSRO, and BMRN: Combined, ACAD, TSRO, and BMRN represent 6.73% of the Biotech ETF. | Below is a twelve month price history chart comparing the stock performance of ACAD, TSRO, and BMRN: Combined, ACAD, TSRO, and BMRN represent 6.73% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Tesaro Inc (Symbol: TSRO), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $27.86/share, the average analyst target is 75.43% higher at $48.88/share. |
36045.0 | 2017-11-08 00:00:00 UTC | Acadia Pharmaceuticals is Now Oversold (ACAD) | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-now-oversold-acad-2017-11-08 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 24.9, after changing hands as low as $28.985 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 73.2. A bullish investor could look at ACAD's 24.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares:
Looking at the chart above, ACAD's low point in its 52 week range is $21.93 per share, with $41.20 as the 52 week high point - that compares with a last trade of $29.97.
According to the ETF Finder at ETF Channel, ACAD makes up 2.94% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading higher by about 0.7% on the day Wednesday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 24.9, after changing hands as low as $28.985 per share. A bullish investor could look at ACAD's 24.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $21.93 per share, with $41.20 as the 52 week high point - that compares with a last trade of $29.97. | The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $21.93 per share, with $41.20 as the 52 week high point - that compares with a last trade of $29.97. In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 24.9, after changing hands as low as $28.985 per share. A bullish investor could look at ACAD's 24.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 24.9, after changing hands as low as $28.985 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $21.93 per share, with $41.20 as the 52 week high point - that compares with a last trade of $29.97. A bullish investor could look at ACAD's 24.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 24.9, after changing hands as low as $28.985 per share. According to the ETF Finder at ETF Channel, ACAD makes up 2.94% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading higher by about 0.7% on the day Wednesday. A bullish investor could look at ACAD's 24.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. |
36046.0 | 2017-11-08 00:00:00 UTC | How to Invest in Biotech Stocks | ACAD | https://www.nasdaq.com/articles/how-invest-biotech-stocks-2017-11-08 | nan | nan | $33,800.
That's how much you'd have if you'd invested $10,000 in Alnylam stock just one year ago .
Sound enticing? How about $154,980?
That's how much a $10,000 investment in Acadia Pharmaceuticals five years ago would be worth today.
With potential returns like that, it's no wonder the biotechnology sector holds unparalleled allure.
Biotech is a sector riddled with heartbreaking failures only to be outdone in drama by unexpected success sending stocks soaring in a single day. This unpredictable nature scares many investors off -- but with a few basic strategies for investing in biotech and an understanding of the trade-off between risk and reward, you can better understand when to be fearful and when to be greedy.
Dip your toes in with an ETF
The easiest and least risky way to get exposure to drugmakers large and small is through an ETF. Exchange-traded funds are baskets of stocks that you can buy under a single ticker symbol. My favorite biotech ETF is the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) , which has 159 different biotech stocks. With the IBB, you can get exposure in your portfolio to the tailwinds benefiting the entire biotech industry (an aging population, for example) without the risk inherent in picking out single stocks.
The SPDR S&P Biotechnology ETF (NYSEMKT: XBI) has a lower expense ratio than the IBB (0.35% vs 0.47%), but all 102 companies in the XBI have equal weighting. I prefer the IBB's method of weighting its holdings by market cap because it weights your exposure toward the large, established players rather than the clinical-stage small caps. After all, the point of choosing an ETF is to minimize risk.
Wade in slowly with big biotech
While an ETF is a great way to avoid much of the potential loss that can come with choosing the wrong individual stocks, you also lose out on some of the eye-popping gains that can come with investing in specific companies. If you're looking to research and invest in individual biotech stocks in hopes of higher returns, you might want to start with the least risky type of company: commercial-stage big biotech.
Large-cap drugmakers like Celgene (NASDAQ: CELG) are mature companies with a long track record of profitability. Their management has proven competent, the marketing teams have established connections, and both researchers and manufacturers have experience under their belts. The stocks of these large companies do not hinge on a single clinical trial because their cash flow comes from many different drugs. Celgene, for example, has eight approved drugs on the market. Revlimid, in particular, reliably brings in billions of dollars per year, and Pomalyst, Imnovid, Otezla, and Abraxane are also on track to clear the coveted billion-dollar blockbuster hurdle for 2017 sales.
Celgene isn't resting on its laurels, though -- the company also has a packed pipeline of drugs it's investigating for indications from multiple sclerosis to blood cancer. My favorite part of Celgene's strategy is the partnerships it's forged with other drugmakers. Celgene doesn't just focus on its internally developed pipeline; the company also loves to invest in smaller companies and early stage drugs while they're still in early innings. Not all of these investments will work out, but the deals are structured in a way that the funding comes via milestone payments. This means that Celgene has little to lose; Celgene only pays up if the drug succeeds in trials, at which point Celgene will usually become eligible for a royalty on sales -- it's a win-win.
None of this is to say that Celgene (or any investment, for that matter) is entirely without risk. Celgene's stock has lost a third of its value in the past month due to a single pipeline setback combined with weak quarterly earnings. However, I believe that an investor with a long-term mindset should see this as a great buying opportunity for a successful company with strong cash flow, a solid balance sheet, and plenty of upside in the years to come.
Take the plunge with small caps
With greater risk comes greater potential reward. Tiny biotechs with small product portfolios (or possibly even no commercial-stage drugs at all!) are the most exciting way to invest in the industry for those with a high tolerance for risk. Stocks whose value proposition rests with a single investigational compound are prone to utter implosion if the drug in question fails its trials. And failure is more likely than not -- greater than 90% of drugs entering trials never make it to approval.
If, however, you're willing to take on the additional risk, it can be smart to make a handful of small investments in early-stage companies because these stocks usually have so much more room to run than their more established brethren. If you choose wisely, you may wind up with the next Acadia Pharmaceuticals on your hands.
One small cap that looks particularly attractive to me right now is Celldex (NASDAQ: CLDX) , which has a market cap of just $325 million (compared to Celgene's $80 billion ). Celldex has given investors a bumpy ride over the years -- its market cap is down 90% from the days of peak optimism surrounding its drug Rintega. This brain cancer drug flopped in clinical trials, and many left the stock for dust, forgetting the rest of Celldex's pipeline.
However, I still see promise in pipeline drugs like Glemba, which aims to provide a cure for a very narrow but underserved population of breast cancer patients. Glemba has shown promise in mid-stage trials, and investors and patients alike are now waiting to see if the drug can impress once again in a late-stage study.
Success here would turn Celldex's fortunes around, as glemba's peak annual sales are estimated to be around $400 million. Since biotechs generally trade at mid-single-digit multiples of their sales figures, an approval for glemba alone would be enough to send Celldex soaring.
Make sure you don't forget...
...to diversify. Whichever strategy you choose, be mindful that you're not over-weighting your portfolio toward any one type of stock -- whether that be small cap, biotech, or even healthcare at large. A well-diversified portfolio is the key to long-term gains that don't put your entire nest egg at risk from a single company, type of stock, or sector falling out of favor.
If you keep diversification in mind, choose the level of risk that's right for you, and buy and hold for the long haul, you're well on your way to investing in biotech the Foolish way.
10 stocks we like better than Celldex Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celldex Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017
Kristine Harjes owns shares of Celldex Therapeutics. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals and Celgene. The Motley Fool recommends Celldex Therapeutics. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That's how much a $10,000 investment in Acadia Pharmaceuticals five years ago would be worth today. If you choose wisely, you may wind up with the next Acadia Pharmaceuticals on your hands. Wade in slowly with big biotech While an ETF is a great way to avoid much of the potential loss that can come with choosing the wrong individual stocks, you also lose out on some of the eye-popping gains that can come with investing in specific companies. | That's how much a $10,000 investment in Acadia Pharmaceuticals five years ago would be worth today. If you choose wisely, you may wind up with the next Acadia Pharmaceuticals on your hands. My favorite biotech ETF is the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) , which has 159 different biotech stocks. | That's how much a $10,000 investment in Acadia Pharmaceuticals five years ago would be worth today. If you choose wisely, you may wind up with the next Acadia Pharmaceuticals on your hands. My favorite biotech ETF is the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) , which has 159 different biotech stocks. | That's how much a $10,000 investment in Acadia Pharmaceuticals five years ago would be worth today. If you choose wisely, you may wind up with the next Acadia Pharmaceuticals on your hands. My favorite biotech ETF is the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) , which has 159 different biotech stocks. |
36047.0 | 2017-11-07 00:00:00 UTC | Nektar, Acadia Pop On Street-Crushing Quarters, But Tesaro Dips | ACAD | https://www.nasdaq.com/articles/nektar-acadia-pop-street-crushing-quarters-tesaro-dips-2017-11-07 | nan | nan | Nektar Therapeutics ( NKTR ) and Acadia Pharmaceuticals ( ACAD ) stocks jumped late Tuesday after beating third-quarter expectations, but Tesaro ( TSRO ) dove despite posting its own analyst-besting quarter.
[ibd-display-video id=2533216 width=50 float=left autostart=true]In after-hours trading on the stock market today , Acadia popped 2.7%, defying its close down 0.3%, at 32.46. Nektar rocketed 8.1%, tacking on to a 10.5% rise to 26.84 during the regular session. Tesaro dipped 2.7% in late trading after closing down 0.4%, at 112.08.
Acadia Beats And Raises
For its third quarter, Acadia reported losses of 53 cents per share, narrowing from a 61-cent loss in the year-ago period, and beating the consensus view for a 63-cent loss. Sales of $35.58 million grew from $5.27 million in the year-ago period and topped analysts' model for $32 million.
Chief Executive Steve Davis credited Nuplazid for Acadia's growth in the quarter. Nuplazid is used to treat hallucinations and delusions associated with Parkinson's disease psychosis.
IBD'S TAKE:Large-cap biotechs have offered largely mixed earnings results with one issuing third-quarter metrics that have been deemed "alarming." Head to IBD Industry Themes for more on this firm and its rivals.
"Our results this quarter reflect strong growth for Nuplazid for Parkinson's disease psychosis," Davis said in a statement. "We also recently advanced our clinical portfolio for the initiation of our Phase 3 study of pimavanserin (Nuplazid) for dementia-related psychosis."
Acadia also boosted its 2017 sales guidance to between $124 million and $127 million, crushing views for $112 million.
Nektar Plans To File Drug Application
Nektar wrapped its third quarter with profit of 39 cents a share on revenue of $152.93 million. Profit broke a streak of quarterly losses, turning around from a year-ago loss of 32 cents and beating forecasts for a 21-cent gain. Sales grew more than fourfold and topped the consensus for $125 million.
Product sales totaled $4.45 million with royalty revenue coming in at $9.3 million. Nektar brought in $131.1 million in license, collaboration and other revenue. The balance of its quarterly sales stemmed from noncash royalty revenue related to the sale of future royalties.
The firm also announced its plan to submit an application to the Food and Drug Administration by April 2018 for its painkiller known as NKTR-181. The drug is designed to provide pain relief without the euphoric and addictive side effects of opioids.
Tesaro's PARP Inhibitor Leads
Tesaro ended with losses of 47 cents a share and sales of $142.8 million. Losses were less severe than expectations for a $1.04 per-share deficit, and narrowed from the year-earlier when it posted a $1.72 per-share loss. Sales grew from $17 million in the year-ago period and topped views for $121 million.
During the quarter, Zejula brought in $39.4 million in sales and Varubi/Varuby generated $2.4 million. Zejula belongs to a class of drugs called PARP inhibitors and is approved to treat some patients with ovarian cancer. Varubi/Varuby is used to treat nausea and vomiting associated with chemotherapy.
AstraZeneca ( AZN ) and Clovis Oncology ( CLVS ) also have PARP inhibitors approved to treat ovarian cancer. But Zejula was the most prescribed PARP inhibitor in the U.S. in the quarter, Tesaro said in a news release. Tesaro is also looking to expand Zejula to other tumor types.
RELATED:
Nektar Rockets To 16-Year High As Analyst Pegs It For Success
Teva Survives Price Cut As Billionaire Reportedly Mulls Stake
Mallinckrodt Dives After Sales Lag, Though Earnings Top Views
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Nektar Therapeutics ( NKTR ) and Acadia Pharmaceuticals ( ACAD ) stocks jumped late Tuesday after beating third-quarter expectations, but Tesaro ( TSRO ) dove despite posting its own analyst-besting quarter. [ibd-display-video id=2533216 width=50 float=left autostart=true]In after-hours trading on the stock market today , Acadia popped 2.7%, defying its close down 0.3%, at 32.46. Acadia Beats And Raises For its third quarter, Acadia reported losses of 53 cents per share, narrowing from a 61-cent loss in the year-ago period, and beating the consensus view for a 63-cent loss. | Acadia Beats And Raises For its third quarter, Acadia reported losses of 53 cents per share, narrowing from a 61-cent loss in the year-ago period, and beating the consensus view for a 63-cent loss. Nektar Therapeutics ( NKTR ) and Acadia Pharmaceuticals ( ACAD ) stocks jumped late Tuesday after beating third-quarter expectations, but Tesaro ( TSRO ) dove despite posting its own analyst-besting quarter. [ibd-display-video id=2533216 width=50 float=left autostart=true]In after-hours trading on the stock market today , Acadia popped 2.7%, defying its close down 0.3%, at 32.46. | Acadia Beats And Raises For its third quarter, Acadia reported losses of 53 cents per share, narrowing from a 61-cent loss in the year-ago period, and beating the consensus view for a 63-cent loss. Acadia also boosted its 2017 sales guidance to between $124 million and $127 million, crushing views for $112 million. Nektar Therapeutics ( NKTR ) and Acadia Pharmaceuticals ( ACAD ) stocks jumped late Tuesday after beating third-quarter expectations, but Tesaro ( TSRO ) dove despite posting its own analyst-besting quarter. | Acadia also boosted its 2017 sales guidance to between $124 million and $127 million, crushing views for $112 million. Nektar Therapeutics ( NKTR ) and Acadia Pharmaceuticals ( ACAD ) stocks jumped late Tuesday after beating third-quarter expectations, but Tesaro ( TSRO ) dove despite posting its own analyst-besting quarter. [ibd-display-video id=2533216 width=50 float=left autostart=true]In after-hours trading on the stock market today , Acadia popped 2.7%, defying its close down 0.3%, at 32.46. |
36048.0 | 2017-11-07 00:00:00 UTC | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 62.5% Follow-Through Indicator, 7.0% Sensitive | ACAD | https://www.nasdaq.com/articles/earnings-reaction-history-acadia-pharmaceuticals-inc-625-follow-through-indicator-70 | nan | nan | Expected Earnings Release: 11/07/2017, After-hours
Avg. Extended-Hours Dollar Volume: $4,510,007
ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 75%
Average next regular session additional gain: 3.5%
Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 75%
Average next regular session additional loss: 2.7%
Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 75% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 75% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,510,007 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 75% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 75% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,510,007 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 75% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 75% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,510,007 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $4,510,007 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 75% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Historical earnings event related premarket and after-hours trading activity in ACAD indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. |
36049.0 | 2017-11-06 00:00:00 UTC | Acadia Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ACAD | ACAD | https://www.nasdaq.com/articles/acadia-pharmaceuticals-breaks-below-200-day-moving-average-notable-acad-2017-11-06 | nan | nan | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $33.07, changing hands as low as $32.15 per share. Acadia Pharmaceuticals Inc shares are currently trading down about 9.2% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average:
Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $41.20 as the 52 week high point - that compares with a last trade of $32.55.
According to the ETF Finder at ETF Channel, ACAD makes up 2.97% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 1.2% on the day Monday.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $33.07, changing hands as low as $32.15 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $41.20 as the 52 week high point - that compares with a last trade of $32.55. Acadia Pharmaceuticals Inc shares are currently trading down about 9.2% on the day. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $33.07, changing hands as low as $32.15 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $41.20 as the 52 week high point - that compares with a last trade of $32.55. Acadia Pharmaceuticals Inc shares are currently trading down about 9.2% on the day. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $33.07, changing hands as low as $32.15 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $41.20 as the 52 week high point - that compares with a last trade of $32.55. Acadia Pharmaceuticals Inc shares are currently trading down about 9.2% on the day. | In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $33.07, changing hands as low as $32.15 per share. According to the ETF Finder at ETF Channel, ACAD makes up 2.97% of the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT) which is trading lower by about 1.2% on the day Monday. Acadia Pharmaceuticals Inc shares are currently trading down about 9.2% on the day. |
36050.0 | 2017-11-03 00:00:00 UTC | Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings? | ACAD | https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-perrigo-prgo-in-q3-earnings-2017-11-03 | nan | nan | We expect Perrigo Company plcPRGO to beat expectations when it reports third-quarter 2017 results before the opening bell on Nov 9.
Perrigo has an average positive surprise of 13.13%. Last quarter, the company delivered a positive surprise of 28.42%.
Perrigo's shares have lost 2.1% so far this year against the industry 's rally of 19.8%.
Factors Influencing This Quarter
Perrigo's product acquisitions and new product launches in the Prescription Pharmaceuticals (Rx) segment are expected to boost sales in the coming quarters. In September, Perrigo announced that it has initiated shipments of the first-to-market over-the-counter store brand equivalent of Nexium capsules to retail customers which is indicated to treat frequent heartburn. During the same month, the company also announced FDA approvals for generic version of Exalgo for management of moderate to severe pain in opioid tolerant patients and the generic version of Acanya for topical treatment of acne vulgaris. These launches and approvals are expected to contribute to the top line in the coming quarters.
Also, the ongoing restructuring initiatives and operating expense discipline are expected to support the bottom line.
However, price erosion and changing market dynamics amid a tough drug pricing environment across Perrigo's Rx segment is likely to continue hurting the segment's performance. It anticipates price erosion of approximately 9-11% at the Rx segment in the coming quarters.
The Branded Consumer Healthcare ("BCH") business, part of Consumer Health Care International ("CHCI") segment, is still being impacted by unfavorable market dynamics in countries like Belgium, France, Germany and Italy. This BCH segment is projected to underperform in the yet-to-be-reported quarter due to lower-than-expected revenues from certain high-margin products.
Earnings Whispers
Our proven model shows that Perrigo is likely to beat on earnings because it has the right combination of the two key ingredients - a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Zacks ESP: Perrigo has an Earnings ESP of +2.53%, indicating a likely positive earnings surprise. The figure also represents the difference between the Most Accurate estimate of $1.15 per share and the Zacks Consensus Estimate of $1.12. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Perrigo has a Zacks Rank #3, which increases the predictive power of ESP.
We caution against all Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Some other health care stocks worth considering with the right combination of elements to surpass estimates this quarter are:
Agenus Inc. AGEN is scheduled to release results on Nov 7. The company has an Earnings ESP of +8.11% and carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Syndax Pharmaceuticals, Inc. SNDX is scheduled to release results on Nov 7. The company has an Earnings ESP of +2.90% and a Zacks Rank of 3.
ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. The Zacks #3 Ranked company has an Earnings ESP of +3.20%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Perrigo Company (PRGO): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Click to get this free report Perrigo Company (PRGO): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. In September, Perrigo announced that it has initiated shipments of the first-to-market over-the-counter store brand equivalent of Nexium capsules to retail customers which is indicated to treat frequent heartburn. | Click to get this free report Perrigo Company (PRGO): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Factors Influencing This Quarter Perrigo's product acquisitions and new product launches in the Prescription Pharmaceuticals (Rx) segment are expected to boost sales in the coming quarters. | Click to get this free report Perrigo Company (PRGO): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Earnings Whispers Our proven model shows that Perrigo is likely to beat on earnings because it has the right combination of the two key ingredients - a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. | ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Click to get this free report Perrigo Company (PRGO): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Influencing This Quarter Perrigo's product acquisitions and new product launches in the Prescription Pharmaceuticals (Rx) segment are expected to boost sales in the coming quarters. |
36051.0 | 2017-11-03 00:00:00 UTC | What's in the Cards for Adverum (ADVM) This Earnings Season? | ACAD | https://www.nasdaq.com/articles/whats-in-the-cards-for-adverum-advm-this-earnings-season-2017-11-03 | nan | nan | Adverum Biotechnologies, Inc.ADVM is expected to report third-quarter 2017 results on Nov 14.
The company has a dismal track record as it missed estimates in three of the last four quarters, resulting in an average negative earnings surprise of 11.95%. In the last reported quarter, Adverum beat estimates, delivering a positive surprise of 27.03%.
Also, Adverum's share price movement year to date indicates that the stock has outperformed the industry . The company's shares have gained 12.1% compared with the industry's gain of 2.3%.
Factors to Consider
Adverum is a development-stage biotech company with no approved product in its portfolio.
Adverum's pipeline consists of gene therapy programs for rare diseases, alpha 1 antitrypsin (A1AT) deficiency, wet AMD and hereditary angioedema ("HAE"). However, all the candidates are in pre-clinical studies.
The company added multiple early-stage candidates including ANN-043 (ADVM-001), ANN-053 (ANN-002) and ANN-003 among others with the acquisition of Annapurna Therapeutics in May 2016.
Based on pre-clinical development results, the company is planning to advance its anti-VEGF gene therapy candidate, ADVM-022. The candidate is being developed for treating wet age-related macular degeneration ("AMD"). Adverum is in the process of filing a pre-investigational new drug (IND), following its meeting with the FDA in the first quarter of 2017. The company is also developing another anti-VEGF gene therapy, ADVM-032.
Adverum expects to initiate a phase I/II study on ADVM-043 for the treatment of A1AT deficiency by the end of this year. The company filed an IND with the FDA and also met the agency in July for a review of the development plan.
Moreover, it is evaluating ADVM-053 to treat HAE and discussed a development plan with the FDA in the first quarter. It is preparing to file an IND.
Adverum extended its collaboration agreement with Regeneron Pharmaceuticals, Inc. REGN by three years till May 1, 2020. The companies will developeight distinct ocular therapeutic targets, including AVA-311, which is being developed for treating juvenile X-Linked Retinoschisis.
The company has also collaborated with Editas Medicine, Inc. EDIT for developing treatment for inherited retinal diseases using the latter's CRISPR-based genome editing technologies.
We expect investor focus to remain on pipeline updates on the third-quarter earnings call.
Earnings Whispers
Our proven model does not conclusively show that Adverum is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -3.33%. This is because the Most Accurate estimate is at a loss of 31 cents while the Zacks Consensus Estimate stands at a loss of 30 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Adverum's Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings surprise.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Adverum Biotechnologies, Inc. Price and EPS Surprise
Adverum Biotechnologies, Inc. Price and EPS Surprise | Adverum Biotechnologies, Inc. Quote
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. The company has an Earnings ESP of +3.2% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. Adverum's pipeline consists of gene therapy programs for rare diseases, alpha 1 antitrypsin (A1AT) deficiency, wet AMD and hereditary angioedema ("HAE"). | Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Based on pre-clinical development results, the company is planning to advance its anti-VEGF gene therapy candidate, ADVM-022. | Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -3.33%. | Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Based on pre-clinical development results, the company is planning to advance its anti-VEGF gene therapy candidate, ADVM-022. |
36052.0 | 2017-11-02 00:00:00 UTC | Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised) | ACAD | https://www.nasdaq.com/articles/horizon-pharma-hznp-q3-earnings%3A-a-disappointment-in-store-revised-2017-11-02 | nan | nan | Horizon Pharma plcHZNP is scheduled to report third-quarter 2017 results before the opening bell on Nov 6.
Last quarter, the company missed expectations by 16%. Let's see how things are shaping up for this quarter.
Horizon Pharma's shares have declined 12% in the year so far, underperforming the industry 's gain of 0.9%.
Factors Likely to Impact This Quarter
Concurrent with the second-quarter earnings, the company raised its outlook for 2017 and now expects sales in the range of $1.010-$1.045 billion, compared to the earlier estimate of $985-$1.020 billion.
Horizon Pharma is significantly increasing investments in one of its key growth drivers, Krystexxa, and projects peak sales of around $400 million in 2017 driven by higher demand. The guidance includes assumption of lower net average net realized price from the U.S. Government's Health Resource and Services Administration's Final Rule on 340B drug ceiling price implementation scheduled for Oct 1.
The company expects continued double-digit net sales growth for Ravicti in 2017, with room for additional uptake due to the recent label expansion. The drug is also expected to be launched in Europe in the second half. However, sales of Procysbi will decline due to the divestiture of European rights. Sales of Actimmune are projected to grow in low single-digits driven by a year-over-year growth in the second half.
Meanwhile, Horizon Pharma's primary care business is under pressure due to the implementation of a new commercial model, where the company is teaming up with pharmacy benefit managers and payers to help patients obtain access to its medicines.
During the third-quarter earnings call, focus will be on the performance of the business units, along with that of products like Actimmune and Krystexxa.
Earnings Whispers
Our proven model does not conclusively show that Horizon Pharma is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -8.48%. This is because both the Most Accurate estimate is 21 cents while the Zacks Consensus Estimate is currently pegged at 22 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter ..
Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). As it is, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Horizon Pharma PLC Price and EPS Surprise
Horizon Pharma PLC Price and EPS Surprise | Horizon Pharma PLC Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Agenus Inc. AGEN has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 7. You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The company is expected to release third-quarter results on Nov 7.
Mylan N.V. MYL has an Earnings ESP of +3.9% and currently carries a Zacks Rank #2. The company is expected to release third-quarter results on Nov 6.
(NOTE: We are republishing this article to correct a mistake. The original version, published earlier today, Thursday, November 2, 2017, should no longer be relied upon.)
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Horizon Pharma PLC (HZNP): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Horizon Pharma is significantly increasing investments in one of its key growth drivers, Krystexxa, and projects peak sales of around $400 million in 2017 driven by higher demand. | Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .. Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). | Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .. Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company missed expectations by 16%. |
36053.0 | 2017-11-02 00:00:00 UTC | Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? | ACAD | https://www.nasdaq.com/articles/horizon-pharma-hznp-q3-earnings%3A-a-disappointment-in-store-2017-11-02 | nan | nan | Horizon Pharma plcHZNP is scheduled to report third-quarter 2017 results before the opening bell on Nov 6.
Last quarter, the company missed expectations by 16%. Let's see how things are shaping up for this quarter.
Horizon Pharma's shares have declined 12% in the year so far, underperforming the industry 's gain of 0.9%.
Factors Likely to Impact This Quarter
Concurrent with the second-quarter earnings, the company raised its outlook for 2017 and now expects sales in the range of $1.010-$1.045 billion, compared to the earlier estimate of $985-$1.020 billion.
Horizon Pharma is significantly increasing investments in one of its key growth drivers, Krystexxa and expects net sales for the same to be around $400 million in 2017 driven by higher demand. The guidance includes assumption of lower net average net realized price from the U.S. Government's Health Resource and Services Administration's Final Rule on 340B drug ceiling price implementation scheduled for Oct 1.
The company expects continued double-digit net sales growth for Ravicti in 2017, with room for additional uptake due to the recent label expansion. The drug is also expected to be launched in Europe in the second half. However, sales of Procysbi will decline due to the divestiture of European rights. Sales of Actimmune are projected to grow in low single-digits driven by a year-over-year growth in the second half.
Meanwhile, Horizon Pharma's primary care business is under pressure due to the implementation of a new commercial model, where the company is teaming up with pharmacy benefit managers and payers to help patients obtain access to its medicines.
During the third-quarter earnings call, focus will be on the performance of the business units, along with that of products like Actimmune and Krystexxa.
Earnings Whispers
Our proven model does not conclusively show that Horizon Pharma is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -8.48%. This is because both the Most Accurate estimate is 21 cents while the Zacks Consensus Estimate is currently pegged at 22 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter ..
Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). As it is, Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Horizon Pharma PLC Price and EPS Surprise
Horizon Pharma PLC Price and EPS Surprise | Horizon Pharma PLC Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Agenus Inc. AGEN has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 7. You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The company is expected to release third-quarter results on Nov 7.
Mylan N.V. MYL has an Earnings ESP of +3.9% and currently carries a Zacks Rank #2. The company is expected to release third-quarter results on Nov 6.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Horizon Pharma PLC (HZNP): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Horizon Pharma is significantly increasing investments in one of its key growth drivers, Krystexxa and expects net sales for the same to be around $400 million in 2017 driven by higher demand. | Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .. Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). | Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .. Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company missed expectations by 16%. |
36054.0 | 2017-10-31 00:00:00 UTC | Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3? | ACAD | https://www.nasdaq.com/articles/is-acadia-acad-likely-to-beat-earnings-estimates-in-q3-2017-10-31 | nan | nan | We expect ACADIA Pharmaceuticals Inc.ACAD to beat expectations when it reports its third-quarter 2017 results expectedly on Nov 6. In the last reported quarter, ACADIA delivered a positive surprise of 22.54%. It has an average positive earnings surprise of 7.97% in the last four quarters.
ACADIA's share price has increased 21.9% year to date compared with the industry 's gain of 3.9%.
Factors at Play
ACADIA is focused on developing products for treating unmet medical needs in central nervous system (CNS) disorders. The growth of its first approved drug, Nuplazid, for treating hallucinations and delusions associated with Parkinson's disease ("PD") psychosis, has been impressive since its launch in April 2016.
Sales of the drug almost doubled sequentially in the second quarter. It generated revenues of $45.8 million in the first half of 2017 and $17.3 million in 2016. The company expects the trend to continue this time around as well and in the remainder of 2017. Moreover, reimbursement and access trends for Nuplazid remained strong during the last quarter. The company had increased price at the start of the second quarter. Also, the drug witnessed strong demand from new as well as old patients in the second quarter. Continued positive demand trends despite the price increase should further boost sales.
The company is also on track with its multiyear plans of developing Nuplazid in indications beyond PD psychosis. The company is studying the drug in five clinical programs for Nuplazid - Alzheimer's disease agitation, Alzheimer's disease (AD) psychosis, Schizophrenia inadequate response, Schizophrenia negative symptoms and major depressive disorders.
This month, the company initiated a phase III study to evaluate Nuplazid in treating hallucinations and delusions associated with dementia-related psychosis. The company also said that the FDA has granted Breakthrough Therapy Designation to the drug for this indication, which should speed up the development process.
We expect the company to provide further update on the progress of this study in its third-quarter earnings call.
The company expects research and operating expenses to increase in the third quarter due to higher clinical costs related to studies and to support its commercial activities for Nuplazid.
Why a Likely Positive Surprise?
Our proven model shows that ACADIA is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate (loss of 61 cents) and the Zacks Consensus Estimate (loss of 63 cents), stands at +3.2%. This is a leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Acadia currently has a Zacks Rank #3. The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
ACADIA Pharmaceuticals Inc. Price and EPS Surprise
ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote
Other Stocks That Warrant a Look
Here are some health care stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Clovis Oncology, Inc. CLVS is scheduled to release results on Nov 1 after market close. The company has an Earnings ESP of +2.01% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Myriad Genetics, Inc. MYGN has an Earnings ESP of +1.04% and a Zacks Rank #2. The company is scheduled to release results on Nov 7.
Syndax Pharmaceuticals, Inc. SNDX has an Earnings ESP of +2.9% and a Zacks Rank #3. The company is expected to release results on Nov 9.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Factors at Play ACADIA is focused on developing products for treating unmet medical needs in central nervous system (CNS) disorders. We expect ACADIA Pharmaceuticals Inc.ACAD to beat expectations when it reports its third-quarter 2017 results expectedly on Nov 6. In the last reported quarter, ACADIA delivered a positive surprise of 22.54%. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Other Stocks That Warrant a Look Here are some health care stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. Click to get this free report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. We expect ACADIA Pharmaceuticals Inc.ACAD to beat expectations when it reports its third-quarter 2017 results expectedly on Nov 6. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Other Stocks That Warrant a Look Here are some health care stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. Click to get this free report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. We expect ACADIA Pharmaceuticals Inc.ACAD to beat expectations when it reports its third-quarter 2017 results expectedly on Nov 6. | We expect ACADIA Pharmaceuticals Inc.ACAD to beat expectations when it reports its third-quarter 2017 results expectedly on Nov 6. ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Other Stocks That Warrant a Look Here are some health care stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. In the last reported quarter, ACADIA delivered a positive surprise of 22.54%. |
36055.0 | 2017-10-31 00:00:00 UTC | Will Endocyte (ECYT) Disappoint This Earnings Season? | ACAD | https://www.nasdaq.com/articles/will-endocyte-ecyt-disappoint-this-earnings-season-2017-10-31 | nan | nan | Endocyte, Inc.ECYT is expected to report third-quarter 2017 results on Nov 6 after the market closes .
Endocyte recorded a negative surpirise of 12.00% in the last quarter. The company has a mixed track record as it surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed the same in two quarters . Overall, the company delivered an average positive surprise of 2.45%.
Notably, Endocyte's share price has increased 78.5% year to date, as against the industry 's decline of 1.3%.
Factors at Play
Endocyte is a development-stage biopharmaceutical company, focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market.
In Jun 2017, Endocyte announced plans to reduce its workforce by about 40% in order to better focus its resources on the more valuable opportunities. The company also looks forward to shift its focus on its most promising programs, which include its CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 and the cohort of taxane-exposed patients receiving EC1169.The restructuring will help the company to have increased cash balance at the end of 2017
Although several companies are aggressively working on bringing new cancer treatments to market, demand for improved and targeted therapies makes this a space with high commercial potential. In fact, Endocyte uses its proprietary technology platform to develop various new SMDCs for a range of diseases.
Currently, EC1456 is being evaluated in a small number of patients in an ovarian cancer surgical study.
Endocyte also filed an Investigational New Drug (IND) application with the FDA for EC2629 and is planning to initiate a phase I study in patients selected as positive for the folate receptor in cancers where tumor associated macrophages (TAMs) are known to be prevalent in the tumor micro-environment.
The company is also enrolling patients in the second part of the study of EC1169, which will evaluate radiographic progression free survival in mCRPC patients with PSMA-positive. The enrollment is expected to be completed in the to-be-reported quarter.
However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth.
The investors can expect some news about the pipeline candidates EC1456 and EC2629 in the third quarter.
Earnings Whispers
Our proven model does not conclusively show earnings beat for Endocyte this quarter. This is because a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Endocyte's has an Earnings ESP of - 45.71% as the Most Accurate estimate is 51 cents while Zacks Consensus Estimate is pegged at a loss of 35 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Endocyte's carries a Zacks Rank #4 (Sell).
As it is we caution against stocks with Zacks Ranks #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing a negative estimate revision.
Endocyte, Inc. Price and EPS Surprise
Endocyte, Inc. Price and EPS Surprise | Endocyte, Inc. Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Clovis Oncology, Inc. CLVS is scheduled to release results on Nov 1, after market close. The company has an Earnings ESP of +2.01% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Agenus Inc. AGEN has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is scheduled to release results on Nov 7.
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.20% and a Zacks Rank #3. The company is scheduled to release results on Nov 6.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Endocyte, Inc. (ECYT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.20% and a Zacks Rank #3. Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Endocyte is a development-stage biopharmaceutical company, focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market. | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.20% and a Zacks Rank #3. This is because a stock needs to have both - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) - to be able to beat estimates. | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.20% and a Zacks Rank #3. Zacks ESP: Endocyte's has an Earnings ESP of - 45.71% as the Most Accurate estimate is 51 cents while Zacks Consensus Estimate is pegged at a loss of 35 cents. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.20% and a Zacks Rank #3. Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report To read this article on Zacks.com click here. Endocyte, Inc.ECYT is expected to report third-quarter 2017 results on Nov 6 after the market closes . |
36056.0 | 2017-10-31 00:00:00 UTC | Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store? | ACAD | https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q3-earnings%3A-a-beat-in-store-2017-10-31 | nan | nan | We expect Jazz Pharmaceuticals plcJAZZ to beat expectations when it reports third-quarter 2017 results on Nov 7, after the market closes .
Jazz's shares have outperformed the industry so far this year. The stock has rallied 25.1% compared with the industry's 1.3% decrease during the period.
Jazz's earnings history has been disappointing. The company missed estimates in three of the last four quarters and surpassed in one with an average negative earnings surprise of 1.53%. Last quarter, the company lagged expectations with a negative earnings surprise of 5.54%.
Jazz Pharmaceuticals PLC Price and EPS Surprise
Jazz Pharmaceuticals PLC Price and EPS Surprise | Jazz Pharmaceuticals PLC Quote
Let's see, how things have shaped up for this quarter:
Factors at Play
At the third-quarter conference call, investors' focus will be on the performance of Jazz's lead product, Xyrem, for cataplexy and excessive daytime sleepiness ("EDS"). Investors will also be looking out for the company's pipeline progress. Its business development plans are also expected to draw attention.
Xyrem should deliver a strong performance in the third quarter, given a continuous increase in active Xyrem patients. The company is striving to expand Xyrem's label and currently conducting a phase II/III EXPRESS study on children and adolescents, suffering from cataplexy with narcolepsy. It is planning to submit an sNDA for Xyrem to include the pediatric phase III study results, later in 2017. The Zacks Consensus Estimate for Xyrem is $313 million for the third quarter.
The company's another drug Defitelio (veno-occlusive disease) was launched in the United States in early April 2016. Though the drug witnessed a sequential decline in sales in second-quarter 2017, the company's commercialization efforts are expected to boost its sales in the to-be-reported quarter. The Zacks Consensus Estimate for Defitelio is $38.3 million for the third quarter.
Presently, the company is enrolling patients for a phase III clinical trial on Defitelio for the potential prevention of veno-occlusive disease ("VOD") on high-risk adults and pediatric patients. Also, the company is working to initiate a phase II proof-of-concept study for the prevention of acute graft versus host disease, later this year.
However, Jazz has been facing challenges in building sufficient inventory levels for another product, Erwinaze, due to constrained manufacturing capacity. The company may further continue to experience supply disruptions in certain markets this quarter, including the United States and beyond.
Notably, the company drug Vyxeos received an FDA approval earlier in August for treatment of adults with acute myeloid leukemia ("AML") and was launched in the market soon after the approval. The company is expected to recognize revenues for the first time from Vyxeos in the to-be-reported quarter. We expect management to update on commercialization/launch plans of Vyxeos at the third-quarter conference call. The company is also planning to submit regulatory applications in the EU later this year.
Earnings Whispers
Our proven model shows that Jazz is likely to beat on earnings this quarter because it has the right combination of the two key ingredients - a positive Earnings ESP and a bullish Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Zacks ESP: Jazz has an Earnings ESP of +0.73%, representing the difference between the Most Accurate estimate ($2.91 per share) and the Zacks Consensus Estimate ($2.89 per share). A positive ESP indicates a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Jazz has a Zacks Rank #3, which increases the predictive power of ESP.
We caution against all Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks That Warrant a Look
Here are some other health care stocks worth considering as per our model, these have the right combination of elements to beat estimates this quarter:
Clovis Oncology, Inc. CLVS is scheduled to release results on Nov 1. The company has an Earnings ESP of +2.01% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Agenus Inc. AGEN is scheduled to release results on Nov 7. The company has an Earnings ESP of +8.11% and carries a Zacks Rank of 2 as well.
ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. The company has an Earnings ESP of +3.20% and also carries a Zacks Rank of 3.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. The company is striving to expand Xyrem's label and currently conducting a phase II/III EXPRESS study on children and adolescents, suffering from cataplexy with narcolepsy. | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC Price and EPS Surprise | Jazz Pharmaceuticals PLC Quote Let's see, how things have shaped up for this quarter: Factors at Play At the third-quarter conference call, investors' focus will be on the performance of Jazz's lead product, Xyrem, for cataplexy and excessive daytime sleepiness ("EDS"). | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC Price and EPS Surprise | Jazz Pharmaceuticals PLC Quote Let's see, how things have shaped up for this quarter: Factors at Play At the third-quarter conference call, investors' focus will be on the performance of Jazz's lead product, Xyrem, for cataplexy and excessive daytime sleepiness ("EDS"). | ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. We expect Jazz Pharmaceuticals plcJAZZ to beat expectations when it reports third-quarter 2017 results on Nov 7, after the market closes . |
36057.0 | 2017-10-31 00:00:00 UTC | Is a Beat in the Cards for Mylan (MYL) This Earnings Season? | ACAD | https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-mylan-myl-this-earnings-season-2017-10-31 | nan | nan | Mylan N.V.MYL is scheduled to report third-quarter 2017 results on Nov 6, before the market opens.
The company's performance has been mixed so far, having topped earnings estimates in two of the trailing four quarters and in missing in other two. The company delivered an average negative earnings surprise of 0.59% in the trailing four quarters.
Last quarter, the company missed earnings estimates by 6.78%. Let's see how things are shaping up for this announcement.
Mylan's stock has increased 0.3% year-to-date compared with the industry's decline of 27.8%. The stock got a boost with the approval of generic Copaxone 40mg.
Why a Likely Positive Surprise?
Our proven model shows that Mylan is likely to beat estimates this quarter because it has the right combination of two key ingredients.
Zacks ESP : The Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +3.92%. This is because the Most Accurate estimate is pegged at $1.25 while the Zacks Consensus Estimate is pegged at $1.21. A positive ESP serves as a meaningful and leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Mylan currently carries a Zacks Rank #2 (Buy). Note that stocks with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) have a significantly higher chance of beating earnings estimates. The combination of Zacks Rank #3 and a positive ESP makes us confident of an earnings beat.
Conversely, Sell-rated stocks (#4 or 5) should never be considered going into an earnings announcement especially when the company is seeing negative estimate revisions.
Factors to Consider This Quarter
Concurrent with the second-quarter results, Mylan lowered its revenue guidance. The company now expects revenues of $11.5-$12.5 billion in 2017, down from the earlier projection of $12.25-$13.75 billion. The company now projects earnings in the range of $4.30-$4.70, down from the previous projected range of $5.15-$5.55. The guidance was lowered as a result of expected delays in the timing of certain new key product launches. Ongoing challenges in the United States and uncertain regulatory environment has led the company to defer all major launches in the United States from 2017 to 2018 including generic Advair and generic Copaxone. Pricing in generics is expected to decline in mid-single digits globally, with high-single-digit erosion expected in North America.
Nevertheless, newly launched products are likely to perform well and aid the top line, while the acquisitions of Meda and the Renaissance Topicals Business should continue to boost the top line in the generics segment.
In a major boost, Mylan received FDA approval for a generic version of multiple sclerosis (MS) drug Copaxone 40mg. This is the first generic of Copaxone that has been approved. The company being one of the first filers, will also enjoy 180 days of exclusivity. According to QuintilesIMS, sales of Copaxone 20mg/mL dose was approximately $700 million and for the 40 mg/mL dose was $3.64 billion for the 12 months period ending July 31, 2017.
However, Mylan's Specialty segment, of which EpiPen is the most significant product, continues to be weak. Sales of EpiPen Auto-Injector are anticipated to continue to decline in the current quarter as a result of increased competition and the impact of the authorized generic launch. Meanwhile, the company's efforts to get Advair's generic approved suffered a blow when the FDA issued a complete response letter to its ANDA for generic Advair Diskus. The FDA Oncologic Drugs Advisory Committee recently unanimously recommended approval of its biosimilar version of Roche Holdings RHHBY Herceptin. However, the anticipated FDA goal date set under the Biosimilar User Fee Act has been deferred to December from September 2017.
During the earnings call, we expect investors to focus on the performance of EpiPen, newly launched drugs and progress with the biosimilars pipeline.
Mylan N.V. Price and EPS Surprise
Mylan N.V. Price and EPS Surprise | Mylan N.V. Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Agenus Inc. AGEN has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 7. You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The company is expected to release third-quarter results on Nov 6.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius. Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Sales of EpiPen Auto-Injector are anticipated to continue to decline in the current quarter as a result of increased competition and the impact of the authorized generic launch. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Ongoing challenges in the United States and uncertain regulatory environment has led the company to defer all major launches in the United States from 2017 to 2018 including generic Advair and generic Copaxone. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Zacks ESP : The Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +3.92%. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Note that stocks with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) have a significantly higher chance of beating earnings estimates. |
36058.0 | 2017-10-31 00:00:00 UTC | What's in the Cards for Prothena (PRTA) in Q3 Earnings? | ACAD | https://www.nasdaq.com/articles/whats-in-the-cards-for-prothena-prta-in-q3-earnings-2017-10-31 | nan | nan | Prothena Corporation plcPRTA is expected to report third-quarter 2017 results on Nov 7.
Last quarter, the company reported a narrower-than-expected loss resulting in a positive earnings surprise of 48.31%. Notably, Prothena's track record has been decent so far. The company reported a narrower-than-expected loss in two of the trailing four quarters, with an average positive surprise of 14.3%.
Prothena's share price has increased 17.1% in the year so far, better than the industry 's gain of 5.4%.
Let's see how things are shaping up for this announcement.
Pipeline Progress in Focus
Prothena's top line primarily comprises collaboration revenues earned through its license, development and commercialization agreements. In fact, the company earns collaboration revenues mainly under its license agreement with Roche Holding AG RHHBY for PRX002.
We expect, investors focus to remain on pipeline updates as it has no approved product in its portfolio.
The company is evaluating its lead candidate NEOD001 in the phase III VITAL Amyloidosis study in newly diagnosed treatment-naïve patients with AL amyloidosis and cardiac dysfunction. Prothena is also evaluating the candidate in a phase IIb study, PRONTO, in previously treated patients with AL amyloidosis and persistent cardiac dysfunction. The company completed enrolment in this study and top-line results from the study are expected following the 12-month study period in second-quarter 2018.
Moreover, Prothena is evaluating PRX002, in collaboration with Roche, for the treatment of Parkinson's disease and other related synucleinopathies. The company initiated a phase II study, PASADENA, in patients suffering from Parkinson`s disease in second-quarter 2017.The initiation triggered a $30 million milestone from Roche to Prothena.
Earlier in the month, Prothena announced disappointing results from a phase Ib multiple ascending dose (MAD) study of pipeline candidate, PRX003 in psoriasis patients. The primary objectives of the study were achieved. However, advancing PRX003 into mid-stage clinical development required a well-defined relationship between biological activity and meaningful clinical effects and these prerequisites were not met.
Prothena is also working to advance PRX004 in a phase I study in patients with ATTR amyloidosis. The candidate is expected to enter clinic in 2018.
Moving ahead, like any other development-stage biotechnology company, Prothena is likely to see an increase in research and development expenses due to higher spending on pipeline.
Prothena Corporation PLC Price and EPS Surprise
Prothena Corporation PLC Price and EPS Surprise | Prothena Corporation PLC Quote
Earnings Whispers
Our proven model doesn't conclusively show that Prothena is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat earnings. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate is pegged at a loss of $1.40. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Prothena currently carries a Zacks Rank #3. Although the rank is favourable, the company's 0.00% ESP makes surprise prediction difficult.
Conversely, Sell-rated stocks (#4 or 5) should never be considered going into an earnings announcement especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Agenus Inc. AGEN has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 7. You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The company is expected to release third-quarter results on Nov 6.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius. Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Prothena Corporation PLC (PRTA): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Prothena is also evaluating the candidate in a phase IIb study, PRONTO, in previously treated patients with AL amyloidosis and persistent cardiac dysfunction. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. In fact, the company earns collaboration revenues mainly under its license agreement with Roche Holding AG RHHBY for PRX002. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Prothena Corporation PLC Price and EPS Surprise Prothena Corporation PLC Price and EPS Surprise | Prothena Corporation PLC Quote Earnings Whispers Our proven model doesn't conclusively show that Prothena is likely to beat estimates this quarter. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company reported a narrower-than-expected loss resulting in a positive earnings surprise of 48.31%. |
36059.0 | 2017-10-30 00:00:00 UTC | Is a Beat in Store for Zoetis (ZTS) This Earnings Season? | ACAD | https://www.nasdaq.com/articles/is-a-beat-in-store-for-zoetis-zts-this-earnings-season-2017-10-30 | nan | nan | Zoetis Inc.ZTS is scheduled to report third-quarter 2017 results on Nov 2 before the market opens.
Zoetis' performance over the last four quarters has been mixed, with the company surpassing expectations thrice and meeting the same once. The average positive earnings surprise over the last four quarters is 6.98%. Let's see how things are shaping up for this announcement.
Zoetis' share price movement year to date shows that the stock has outperformed the industry . The stock has moved up 19.7% compared with the industry's decline of 2.2% during this period.
Why a Likely Positive Surprise?
Our proven model shows that Zoetis is likely to beat estimates this quarter because it has the right combination of two key ingredients.
Zacks ESP:Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +0.33%. A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Zoetis currently carries a Zacks Rank #2 (Buy). Note that stocks with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) have a significantly higher chance of beating earnings estimates.
The combination of Zoetis' Zacks Rank #2 and a positive ESP makes us confident of an earnings beat in the upcoming release.
Conversely, Sell-rated stocks (#4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Factors to Consider
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company continues to strengthen its diverse products portfolio through lifecycle innovations, strong customer relationships and access to new markets and technologies.
Concurrent with the second earnings call, Zoetis increased its 2017 outlook. The company expects earnings in the range of $2.30-$2.37 per share and revenues of $5.15 billion-$5.25 billion. The improved outlook also suggest a better results in the third quarter. The company's companion animal business has been boosted by further penetration of new products in key countries outside the United States. Apoquel and Cytopoint and new oral parasiticide Simparica are driving growth.
The company received approval for Clavamox Chewable in the United States in May 2017 and for Cytopoint in the European Union in April 2017 and in Canada in March 2017. The approvals strengthened its canine dermatology portfolio, thus providing a boost to its top line.
Zoetis completed the acquisition of Nexvet Biopharma, an innovator in monoclonal antibody therapies for companion animals, in July. The acquisition is expected to strengthen Zoetis' pipeline of solutions for chronic pain management in dogs and cats, which represents an area of high-need in companion animal health.
We expect management to throw more light on its acquisition strategy.
Zoetis Inc. Price and EPS Surprise
Zoetis Inc. Price and EPS Surprise | Zoetis Inc. Quote
Other Stocks That Warrant a Look
Here are some health care stocks that you may also want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter.
Clovis Oncology, Inc. CLVS has an Earnings ESP of +2.01% and a Zacks Rank #2. The company is scheduled to release results on Nov 1. You can see the complete list of today's Zacks #1 Rank stocks here .
Agenus Inc. AGEN has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 7.
ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The company is expected to release third-quarter results on Nov 6.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Zoetis Inc. (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Zoetis Inc. Price and EPS Surprise Zoetis Inc. Price and EPS Surprise | Zoetis Inc. Quote Other Stocks That Warrant a Look Here are some health care stocks that you may also want to consider, as our model shows that they too have the right combination of elements to post an earnings beat this quarter. | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The combination of Zoetis' Zacks Rank #2 and a positive ESP makes us confident of an earnings beat in the upcoming release. | ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The combination of Zoetis' Zacks Rank #2 and a positive ESP makes us confident of an earnings beat in the upcoming release. |
36060.0 | 2017-10-30 00:00:00 UTC | What's in the Cards for Arena (ARNA) This Earnings Season? | ACAD | https://www.nasdaq.com/articles/whats-in-the-cards-for-arena-arna-this-earnings-season-2017-10-30 | nan | nan | Arena Pharmaceuticals, Inc.ARNA is scheduled to report third-quarter 2017 earnings on Nov 7, after the market closes .
Year to date, Arena's shares have soared 96% compared with the industry 's 3.9% increase.
Arena's earnings performance is a mixed bag. While the company surpassed expectations in two of the last four quarters, it missed estimates in the other two. Overall, the company delivered an average positive surprise of 70.15% in the trailing four quarters.
Arena Pharmaceuticals, Inc. Price and EPS Surprise
Arena Pharmaceuticals, Inc. Price and EPS Surprise | Arena Pharmaceuticals, Inc. Quote
Last quarter, the company missed expectations with a negative earnings surprise of 13.24%.
Let's see, how things are shaping up for this announcement.
Factors at Play
The only approved product in Arena's portfolio is obesity treatment drug, Belviq, which has delivered an unimpressive performance so far. We note that ramping up sales in the U.S. anti-obesity market is challenging due to several factors, including the tendency of health care providers to treat obesity symptoms instead of the disease itself, lesser focus on certain patient types for the treatment and historically, low third-party insurance coverage. The Zacks Consensus Estimate for Belviq is $1.9 million for the third quarter.
Arena has a few candidates in its pipeline on which, we expect an update in the third-quarter conference call. In July, the company announced that a phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension ('PAH'), met its primary endpoint. This positive data from the trial paves way for an expedited initiation of a phase III program on the candidate.
Other candidates include etrasimod (phase II for ulcerative colitis with data expected in the fourth quarter of 2017) and APD371 (phase II study for treatment of pain associated with Crohn's disease). Etrasimod has the potential to be developed for additional indications beyond inflammatory bowel disease.
What Our Model Indicates
Our proven model does not conclusively show that Arena will beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But this is not the case here, as you will see below.
Zacks ESP: Arena has an Earnings ESP of 0.00% because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 69 cents.You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Arena currently carries a Zacks Rank #3, which increases the predictive power of the ESP. However, an Earnings ESP of 0.00% makes surprise prediction difficult.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks worth considering as per our model, these have the right combination of elements to beat estimates this quarter:
Clovis Oncology, Inc. CLVS is scheduled to release results on Nov 1. The company has an Earnings ESP of +2.01% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Agenus Inc. AGEN is scheduled to release results on Nov 7. The company has an Earnings ESP of +8.11% and carries a Zacks Rank of 2 as well.
ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. The company has an Earnings ESP of +3.20% and carries a Zacks Rank of 3 as well.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report
Agenus Inc. (AGEN): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Click to get this free report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play The only approved product in Arena's portfolio is obesity treatment drug, Belviq, which has delivered an unimpressive performance so far. | Click to get this free report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Arena Pharmaceuticals, Inc. Price and EPS Surprise Arena Pharmaceuticals, Inc. Price and EPS Surprise | Arena Pharmaceuticals, Inc. Quote Last quarter, the company missed expectations with a negative earnings surprise of 13.24%. | Click to get this free report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Arena Pharmaceuticals, Inc. Price and EPS Surprise Arena Pharmaceuticals, Inc. Price and EPS Surprise | Arena Pharmaceuticals, Inc. Quote Last quarter, the company missed expectations with a negative earnings surprise of 13.24%. | ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Click to get this free report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Arena Pharmaceuticals, Inc.ARNA is scheduled to report third-quarter 2017 earnings on Nov 7, after the market closes . |
36061.0 | 2017-10-30 00:00:00 UTC | Ball Corporation (BLL) to Post Q3 Earnings: What to Expect? | ACAD | https://www.nasdaq.com/articles/ball-corporation-bll-to-post-q3-earnings%3A-what-to-expect-2017-10-30 | nan | nan | Ball CorporationBLL is set to release third-quarter 2017 results before the opening bell on Nov 2.
In the last reported quarter, the company had missed the Zacks Consensus Estimate. Ball Corporation delivered an average positive earnings surprise of 3.00% in the last four quarters.
Let's see how things are shaping up for this announcement.
Ball Corporation Price and EPS Surprise
Ball Corporation Price and EPS Surprise | Ball Corporation Quote
Factors to Consider
Ball Corporation anticipates its food and aerosol business to improve in the third quarter due to incremental progress in the Canton metal service center, improving manufacturing metrics, as well as the ramping-up of its new aluminum aerosol capacity in Europe and India. Further, the company's focus on expansion of highly sustainable and lightweight ReAl product line will likely drive growth.
Ball Corporation remains on track for transformational work in the second half of 2017. The company's debt came down by $300 million in the second quarter since the end of the first quarter on strong operational performance and working capital management despite normal seasonal working capital build. The company expects that debt will continue to come down in the quarter to be reported.
However, additional depreciation and non-steel related amortization expense will hurt its performance. Also, the company's third quarter is a seasonally slow quarter.
Moreover, shares of Ball Corporation have gained 11% over the past year, underperforming 12.2% growth recorded by the industry .
So what should investors expect from Ball Corporation's Q3 earnings announcement? By using our Zacks Consensus Estimates, as well as our exclusive non-financial metrics file, we've found three important things to note ahead of Ball Corporation's report:
Earnings
Based on the latest Zacks Consensus Estimate, we expect Ball Corporation to report earnings of 59 cents per share in the third quarter. This would mark growth of 23% from the 48 cents per share posted in the year-ago quarter.
Revenue
The Zacks Consensus Estimate for sales of Ball Corporation's Aerospace and Technologies segment is pegged at $238 million for the third quarter, reflecting 16.7% year over year improvement. We also expect that sales at the Beverage packaging, Europe segment will likely be $718 million, up 4.5% year over year.
Sales estimates for Beverage packaging in the North and Central America segment, and the South America segment are pegged at $1,116 million and $334 million, respectively, for the quarter to be reported. However, the Food and Aerosol Packaging segment is projected to report sales of $320 million, down 2.7% from $329 million reported in the prior-year quarter.
Currently, Ball Corporation carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are a few stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Apple Inc. AAPL is scheduled to report quarterly numbers on Nov 2. It has an Earnings ESP of +1.17% and carries a Zacks Rank of 3 (Hold). You can see t he complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
ACADIA Pharmaceuticals Inc. ACAD also has a Zacks Rank of 3 and its Earnings ESP is +3.20%. The company is slated to release third-quarter results on Nov 6.
Axcelis Technologies, Inc. ACLS has an Earnings ESP of +2.35% and carries a Zacks Rank of 3. It is scheduled to release earnings on Nov 2.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Axcelis Technologies, Inc. (ACLS): Free Stock Analysis Report
Apple Inc. (AAPL): Free Stock Analysis Report
Ball Corporation (BLL): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. ACAD also has a Zacks Rank of 3 and its Earnings ESP is +3.20%. Click to get this free report Axcelis Technologies, Inc. (ACLS): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Ball Corporation (BLL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Further, the company's focus on expansion of highly sustainable and lightweight ReAl product line will likely drive growth. | Click to get this free report Axcelis Technologies, Inc. (ACLS): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Ball Corporation (BLL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD also has a Zacks Rank of 3 and its Earnings ESP is +3.20%. Ball Corporation Price and EPS Surprise Ball Corporation Price and EPS Surprise | Ball Corporation Quote Factors to Consider Ball Corporation anticipates its food and aerosol business to improve in the third quarter due to incremental progress in the Canton metal service center, improving manufacturing metrics, as well as the ramping-up of its new aluminum aerosol capacity in Europe and India. | Click to get this free report Axcelis Technologies, Inc. (ACLS): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Ball Corporation (BLL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD also has a Zacks Rank of 3 and its Earnings ESP is +3.20%. Ball Corporation Price and EPS Surprise Ball Corporation Price and EPS Surprise | Ball Corporation Quote Factors to Consider Ball Corporation anticipates its food and aerosol business to improve in the third quarter due to incremental progress in the Canton metal service center, improving manufacturing metrics, as well as the ramping-up of its new aluminum aerosol capacity in Europe and India. | ACADIA Pharmaceuticals Inc. ACAD also has a Zacks Rank of 3 and its Earnings ESP is +3.20%. Click to get this free report Axcelis Technologies, Inc. (ACLS): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Ball Corporation (BLL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. So what should investors expect from Ball Corporation's Q3 earnings announcement? |
36062.0 | 2017-10-19 00:00:00 UTC | Implied FXH Analyst Target Price: $74 | ACAD | https://www.nasdaq.com/articles/implied-fxh-analyst-target-price-74-2017-10-19 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Health Care AlphaDEX Fund ETF (Symbol: FXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.48 per unit.
With FXH trading at a recent price near $67.85 per unit, that means that analysts see 9.77% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FXH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Neurocrine Biosciences, Inc. (Symbol: NBIX). Although ACAD has traded at a recent price of $36.73/share, the average analyst target is 31.36% higher at $48.25/share. Similarly, BMRN has 27.57% upside from the recent share price of $88.62 if the average analyst target price of $113.05/share is reached, and analysts on average are expecting NBIX to reach a target price of $74.18/share, which is 24.84% above the recent price of $59.42. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and NBIX:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ACAD has traded at a recent price of $36.73/share, the average analyst target is 31.36% higher at $48.25/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and NBIX: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FXH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Neurocrine Biosciences, Inc. (Symbol: NBIX). | Three of FXH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Neurocrine Biosciences, Inc. (Symbol: NBIX). Although ACAD has traded at a recent price of $36.73/share, the average analyst target is 31.36% higher at $48.25/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and NBIX: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and NBIX: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FXH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Neurocrine Biosciences, Inc. (Symbol: NBIX). Although ACAD has traded at a recent price of $36.73/share, the average analyst target is 31.36% higher at $48.25/share. | Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and NBIX: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FXH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Neurocrine Biosciences, Inc. (Symbol: NBIX). Although ACAD has traded at a recent price of $36.73/share, the average analyst target is 31.36% higher at $48.25/share. |
36063.0 | 2017-10-13 00:00:00 UTC | Lilly's Verzenio Gets Priority Review in First-Line Setting | ACAD | https://www.nasdaq.com/articles/lillys-verzenio-gets-priority-review-in-first-line-setting-2017-10-13 | nan | nan | Eli Lilly and CompanyLLY announced that the FDA has granted priority review to its new drug application (NDA) for Verzenio (abemaciclib). This drug is looking forward to get approved for the first-line treatment of advanced breast cancer.
Markedly, the NDA was based upon the positive interim results from MONARCH 3 study. The study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone as initial endocrine-based therapy in patients with HR+, HER2- advanced breast cancer. A decision from the FDA is expected by June 2018.
So far this year, Lilly's shares have underperformed the industry. While the stock has been up 17.5%, the industry gained 18.9%.
Generally, Priority Review designation from the FDA is granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Verzenio, a CDK 4/6 inhibitor, is one such drug that was approved by the FDA last week for two breast cancer indications. The drug got approved as a monotherapy for the treatment of hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, who had prior endocrine therapy and chemotherapy for metastatic disease and as a combination therapy with fulvestrant in HR+, HER2- advanced breast cancer patients, who had disease progression following endocrine therapy. While the monotherapy submission was based on data from the MONARCH 1 study, the combination application was based on data from the MONARCH 2 study.
We remind the investors that Novartis AG's NVS Kisqali, is already approved by the FDA. The drug is used in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer.
Also, AstraZeneca, plc's AZN breast cancer drug, Faslodex, received the FDA approval in August for a label extension in the first-line monotherapy setting for advanced breast cancer.
Eli Lilly and Company Price
Eli Lilly and Company Price | Eli Lilly and Company Quote
Zacks Rank & Stock to Consider
Lilly carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector includes ACADIA Pharmaceuticals Inc. ACAD carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. The company delivered positive earnings surprises in two of the trailing four quarters, with an average beat of 7.97%. The share price of the company increased 23% year to date.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor's Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the health care sector includes ACADIA Pharmaceuticals Inc. ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector includes ACADIA Pharmaceuticals Inc. ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector includes ACADIA Pharmaceuticals Inc. ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. | A better-ranked stock in the health care sector includes ACADIA Pharmaceuticals Inc. ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36064.0 | 2017-10-12 00:00:00 UTC | Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017 | ACAD | https://www.nasdaq.com/articles/heres-why-intercept-icpt-stock-lost-37-so-far-in-2017-2017-10-12 | nan | nan | Shares of Intercept Pharmaceuticals, Inc . ICPT declined 37.4% year to date against the industry 's gain of 15.4%. In particular, shares have plunged 40.4% over a month due to safety issues regarding approved drug Ocaliva.
Per a recent news article, prescriptions of the drug have fallen by 25%. The FDA issued a guideline regarding incorrect dosing of Ocaliva. The FDA reported 19 deaths due to Ocaliva, approved for primary biliary cholangitis (PBC) and stated that the drug may also affect the liver.
However, Intercept conducted an analysis and concluded that that these patients were prescribed once-daily doses of Ocaliva, which is seven times higher than the recommended weekly dose. The analysis was conducted in consultation with the FDA. The company concluded that deaths occurred due to overdosing.
Consequently, Intercept issued the Dear Healthcare Provider letter. Thereafter, the FDA issued their own safety communication to reinforce recommended label dosing. Intercept is also working in tandem with the FDA to develop Ocaliva's label for safety purposes.
We note that Ocaliva was approved in the United States in May 2016 (and subsequently in the European Union and Canada) for the treatment of PBC with an inadequate response to or intolerant to the standard of care, UDCA.
The dose recommended for earlier stage PBC patients with no or mild hepatic impairment was 5 mg once daily, which was increased after three months to 10 mg once daily based on tolerability and treatment response. On the other hand, in late stage patients with moderate or severe hepatic impairment (Child Pugh B or C cirrhosis), recommended dosing starts at 5 mg once weekly, with the possibility to gradually increase to a maximum of 10 mg twice weekly.
The warning comes a major setback for Intercept and we expect the company's sales to be hurt in the third quarter due to the same. The company expected the drug's sales to improve in 2017 as international demand was projected to pick up in the second half. Ocaliva is the company's only approved drug and such side-effects will limit the sales potential.
Zacks Rank & Key Picks
Intercept currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corporation CELG and Aduro Biotech, Inc. ADRO . All three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%.
Celgene's earnings estimates for both 2017 and 2018 have inched up 0.7% in the past 90 days. The stock has rallied 20% this year, outperforming the industry.
Aduro Biotech's loss per share estimates narrowed from $1.36 to $1.29 for 2017 over the last 30 days. The company delivered positive earnings surprises in two of the four trailing quarters with an average of 2.53%.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius. Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celgene Corporation (CELG): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corporation CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corporation CELG and Aduro Biotech, Inc. ADRO . Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corporation CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corporation CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. |
36065.0 | 2017-10-11 00:00:00 UTC | Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA | ACAD | https://www.nasdaq.com/articles/allergans-uterine-fibroids-candidates-nda-accepted-by-fda-2017-10-11 | nan | nan | Allergan plcAGN announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, ulipristal acetate. Allergan is looking to get ulipristal acetate approved for the treatment of abnormal uterine bleeding from fibroids in that organ. The company expects the FDA to give its decision in the first half of 2018. Once approved, ulipristal acetate will be the first once-daily non-surgical oral treatment option approved for the condition.
Allergan's shares have declined 1.2% compared with the industry 's decline of 20.4%.
There are other companies that have pipeline candidates being evaluated for uterine fibroids. In July 2017, Bayer Aktiengesellschaft BAYRY is evaluating vilaprisan in women suffering from uterine fibroids and in July initiated a phase III study ASTEROID for the same.
AbbVie Inc. ABBV along with Neurocrine Biosciences, Inc. is evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. In April this year, the companies announced positive results from a phase IIb study which showed that elagolix met its primary endpoint by significantly reducing the number of heavy bleeding days rapidly within the assessment period of six months from the baseline in comparison to a placebo, utilizing the alkaline hematin method.
Allergan PLC. Price
Allergan PLC. Price | Allergan PLC. Quote
Zacks Rank & Stock to Consider
Currently, Allergan carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is ACADIA Pharmaceuticals Inc ACAD carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. The company delivered positive earnings surprises in two of the trailing four quarters, with an average beat of 7.97%. Year to date, the share price of the company has climbed 27.9%.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan PLC. (AGN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Bayer AG (BAYRY): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the health care sector is ACADIA Pharmaceuticals Inc ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is ACADIA Pharmaceuticals Inc ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. | (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is ACADIA Pharmaceuticals Inc ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. | A better-ranked stock in the health care sector is ACADIA Pharmaceuticals Inc ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36066.0 | 2017-10-10 00:00:00 UTC | Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel | ACAD | https://www.nasdaq.com/articles/mallinckrodt-to-begin-sarcoidosis-study-on-acthar-gel-2017-10-10 | nan | nan | Mallinckrodt plcMNK announced that it will initiate a new phase IV study on H.P. Acthar Gel.
This multi-center, randomized, double blind, placebo-controlled study will further assess the efficacy of Acthar as a therapy option in patients with symptomatic sarcoidosis. The study will evaluate Acthar as a later-line treatment option for sarcoidosis patients with persistent disease.
The drug is already approved in the United States for this indication. The company is conducting the study to determine which class of patients will benefit the most from an alternative treatment like Acthar.
Acthar became part of the company's portfolio following the Questcor acquisition and is currently approved for 19 indications. Mallinckrodt is working on boosting Acthar sales in the approved indications including rheumatology and pulmonology as well as underserved patient populations. The company intends to invest in research and development activities for developing Acthar for indications like lupus, proteinuria in nephrotic syndrome, amyotrophic lateral sclerosis and diabetic nephropathy.
Performance of the drug has been impressive so far, propelled by solid demand for rheumatology, pulmonology, ophthalmology and nephrology, and expanded access in more recently promoted indications such as lupus and sarcoidosis, as well as mature indications such as infantile spasms and nephrotic syndrome.
Mallinckrodt's stock price has declined 28.0% year to date, compared with the industry 's fall of 20.7%.
We note that Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio and become a high-performing specialty pharmaceutical company. The company recently acquired privately-held InfaCare Pharmaceutical Corp. This specialty pharmaceutical company focuses on the development and commercialization of proprietary pharmaceuticals for neo-natal and pediatric patients.
The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both volumes and prices. The company expects double-digit declines in revenues from this segment. In addition, continued expected weakness in this segment will adversely impact gross profit margins also.
The company sold its Nuclear Imaging business due to persistent challenges. The company also sold its Intrathecal Therapy business to focus on key areas. While Acthar Gel sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments, sales of Therakos are expected to decline.
Zacks Rank & Stocks to Consider
Mallinckrodt currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corp. CELG and Aduro Biotech, Inc. ADRO . All three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%.
Celgene's earnings estimates for both 2017 and 2018 have inched up by 0.7% over the past 90 days. The stock has rallied 20.7% year to date, outperforming the industry.
Aduro Biotech's loss per share estimates narrowed from $1.36 to $1.29 for 2017 over the last 30 days. The company delivered positive earnings surprises in two of the four trailing quarters with an average of 2.53%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celgene Corporation (CELG): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Mallinckrodt PLC (MNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corp. CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corp. CELG and Aduro Biotech, Inc. ADRO . Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corp. CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corp. CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. |
36067.0 | 2017-10-09 00:00:00 UTC | AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation | ACAD | https://www.nasdaq.com/articles/astrazenecas-tagrisso-gets-breakthrough-therapy-designation-2017-10-09 | nan | nan | AstraZenecaAZN) announced that the FDA has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Tagrisso is currently approved in the United States, European Union, Japan and China, as second-line treatment for patients with advanced NSCLC who progress following treatment with an EGFR TKI due to the EGFR T790M resistance mutation.
AstraZeneca's shares have outperformed the industry year to date. The stock has surged 25.4% compared with the industry ''s gain of 18%.
The BTD is based on the phase III FLAURA study evaluating Tagrisso versus standard-of-care EGFR tyrosine kinase inhibitor (TKI) therapy in the first-line lung cancer setting. The data showed that treatment with Tagrisso reduced the risk of progression or death by more than half compared with other commonly-used EGFR inhibitors for the first-line treatment of patients with EGFR mutation-positive NSCLC. The median progression-free survival (PFS) was 18.9 months for patients on Tagrisso as compared with 10.2 months in the comparator arm. Tagrisso was well tolerated with a safety profile consistent with previous experience.
BTD from the FDA will expedite the development and review of drugs that are intended to treat serious diseases and should provide access of the drug to patients as soon as possible.
In a separate release the company also announced that European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Imfinzi (durvalumab) for the treatment of patients with locally-advanced (Stage III), unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy. The MAA submission was based on encouraging data from phase III PACIFIC study .
Imfinzi has already received accelerated approval in the United States for the treatment of patients with locally advanced or metastatic urothelial carcinoma, who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery.
A potential label expansion of the drugs will boost the sales of the company.
In June 2017, another pharmaceutical giant, Roche Holdings RHHBY announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment. Alecensa significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared with Pfizer's PFE Xalkori in patients suffering from anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Astrazeneca PLC Price
Astrazeneca PLC Price | Astrazeneca PLC Quote
Zacks Rank & Stocks to Consider
AstraZeneca carries a Zacks Rank #3 (Hold). Another better-ranked stocks in health care sector includes ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%. Share price of the company has climbed 33.6% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Pfizer, Inc. (PFE): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Astrazeneca PLC (AZN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another better-ranked stocks in health care sector includes ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Astrazeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Astrazeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. Another better-ranked stocks in health care sector includes ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Astrazeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. Another better-ranked stocks in health care sector includes ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. | Another better-ranked stocks in health care sector includes ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Astrazeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. |
36068.0 | 2017-10-09 00:00:00 UTC | Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit | ACAD | https://www.nasdaq.com/articles/emergent-biosolutions-acquires-sanofis-smallpox-vaccine-unit-2017-10-09 | nan | nan | Emergent BioSolutions Inc.EBS announced that it completed the acquisition of FDA-licensed smallpox vaccine's business of Sanofi SNY - ACAM2000. The company paid an upfront payment of $97.5 million and $20 million in milestone payments. The deal also includes a potential milestone payment of up to $7.5 million, tied to the achievement of remaining regulatory milestone event.
ACAM2000 includes ACAM2000 the only vaccine licensed by the FDA for active immunization against smallpox disease for people determined to be at high risk of smallpox infection. It also includes a cGMP live viral manufacturing facility and office as well as warehouse space, both in Canton, MA, and a cGMP viral fill/finish facility in Rockville, MD.
Emergent BioSolutions will also assume responsibility for Sanofi's existing 10-year Centers for Disease Control and Prevention or CDC contract with a remaining value of up to approximately $160 million for deliveries of ACAM2000 to the Strategic National Stockpile. The CDC contract was originally valued at up to $425 million which will expire and be up for renewal or extension in 2018. Pursuant to the acquisition, Emergent BioSolutions' anticipates completing the tech transfer of an upstream portion of ACAM2000 manufacturing to the Canton facility.
Emergent's shares have outperformed the industry year to date. The stock has surged 23.3% compared with the industry 's gain of 14.1%.
The acquisition of ACAM2000 is a strategic fit for Emergent BioSolutions which will enable the latter to expand existing smallpox countermeasure offering along with diversify its portfolio and enabling it to contribute to revenues meaningfully in 2018. Further, it will aid in achieving the goal of $1 billion in total revenues by 2020. The company also expects to generate more than 10% of total revenues from international markets from the deal.
Emergent Biosolutions, Inc. Price
Emergent Biosolutions, Inc. Price | Emergent Biosolutions, Inc. Quote
Zacks Rank & Stocks to Consider
Emergent carries a Zacks Rank #3 (Hold). Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%. Share price of the company has climbed 33.6% year to date.
Biogen's earnings per share estimates have moved up $21.38 to $21.48 for 2017 and from $23.12 to $23.29 for 2018 in the last 60 days. The company pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 6.41%. The share price of the company has increased 15.4% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB , each carrying a Zacks Rank #2 (Buy). Click to get this free report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36069.0 | 2017-10-09 00:00:00 UTC | Roche (RHHBY) Receives FDA Approval For Cobas Zika Test | ACAD | https://www.nasdaq.com/articles/roche-rhhby-receives-fda-approval-for-cobas-zika-test-2017-10-09 | nan | nan | Roche Holdings AGRHHBY announced that it has obtained the FDA's approval for the cobas Zika test for use on the cobas 6800/8800 Systems.
The approval makes it the first commercially available test for the detection of the Zika virus RNA in human plasma intended for use in screening blood donations.
This test can be now used alongside other routine tests for the screening of blood and plasma donations in the United States.
We expect a strong uptake in the use of Zika test given the need to prevent the spread of the virus.
The cobas Zika also expands Roche's industry-leading donor screening portfolio for blood-borne diseases
We note that the cobas Zika test has been used under the Investigational New Drug Application protocol to screen more than 4 million blood donations from the United States and Puerto Rico.
Roche's stock has rallied 14.2% year to date compared with industry 's gain of 21.1%.
Apart from providing therapeutic products and services for diverse medical needs, Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases. Immunodiagnostics is the key focus area for this segment. In 2016, Roche added nine instruments and tests to its comprehensive portfolio, further improving decision-making in healthcare, and supporting laboratories' efforts to increase efficiency. The launches including cobas e 801 immunoassay module, the CoaguChek INRange system to monitor vitamin K antagonist therapy, and the Accu-Chek Guide, a next-generation blood glucose monitoring system.
Meanwhile, Roche has a strong presence in the oncology market. The company dominates the breast cancer space with strong demand for its HER2 franchise drugs like Herceptin, Perjeta and Kadcyla. Apart from its strong breast cancer franchise, Roche's oncology portfolio also boasts drugs like Avastin and Tarceva for lung cancer.
However, sales of Avastin and Tarceva continue to decline. Generic competition for Xeloda continues to hurt sales. Competition from biosimilars looms large on Roche's key drugs like Herceptin, Avastin and Rituxan. The FDA accepted Novartis AG's NVS Biologics License Application for a proposed biosimilar version of Rituxan. Hence, approval of new drugs and label expansion of existing drugs will bode well for Roche.
Zacks Rank & Key Picks
Roche currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector are include ACADIA Pharmaceuticals Inc. ACAD and Aduro Biotech, Inc. ADRO . Both carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%.
Aduro Biotech's loss per share estimates narrowed from $1.36 to $1.29 for 2017 over the last 30 days. The company delivered positive earnings surprises in two of the four trailing quarters with an average of 2.53%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are include ACADIA Pharmaceuticals Inc. ACAD and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the health care sector are include ACADIA Pharmaceuticals Inc. ACAD and Aduro Biotech, Inc. ADRO . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are include ACADIA Pharmaceuticals Inc. ACAD and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some better-ranked stocks in the health care sector are include ACADIA Pharmaceuticals Inc. ACAD and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36070.0 | 2017-10-05 00:00:00 UTC | This Biotech Rockets — Then Dips — After FDA Breakthrough Win | ACAD | https://www.nasdaq.com/articles/biotech-rockets-then-dips-after-fda-breakthrough-win-2017-10-05 | nan | nan | Acadia Pharmaceuticals ( ACAD ) briefly rallied, then dipped nearly 1% early Thursday, in the wake of its announcement that its dementia drug had gotten breakthrough designation just ahead of enrolling a Phase 3 trial.
[ibd-display-video id=2326965 width=50 float=left autostart=true]Acadia popped as much as 5.3%, touching a high last seen in June 2016, before falling 2.2% to close at 38.30 on the stock market today . Shares broke out of a cup-with-handle at a 37.78 buy point in September.
At least three analysts increased their price targets on Acadia on Thursday, including JMP Securities analyst Jason Butler who bumped his target on Acadia to 50 from 47. Butler kept his market outperform rating on the stock.
The FDA designation reflects "compelling clinical evidence of benefit," Butler said. He sees a 65% chance of success in using Nuplazid to treat psychosis in a wide array of dementias. Nuplazid is already approved to treat dementia-related psychosis in Parkinson's disease.
Acadia plans to see whether Nuplazid has a benefit in reducing hallucinations and delusions in patients with various forms of dementia, including Alzheimer's disease, Parkinson's disease, dementia related to blocked or reduced blood flow to the brain and frontotemporal dementia.
"Relapse prevention design (in the trial) is capital and time efficient and should optimize potential for success by initially selecting (Nuplazid) responders, in our view," Butler wrote in a note to clients.
IBD'S TAKE:Biotech news has sent the industry group flying this month. It's now ranked second out of 197 groups tracked by IBD. Head to IBD Industry Themes for a deep dive on what's helped spike the stocks.
The firm plans to enroll 360 patients in the trial, Needham analyst Alan Carr wrote in a note to clients. All will be treated with Nuplazid for 12 weeks after which those who respond to the drug will then receive either Nuplazid or a placebo for 26 weeks.
Acadia's key goal is to measure time to relapse of psychosis. The dose of Nuplazid could be lowered in some patients during the four-week open-label period, Carr said. Enrolling patients could take more than two years, Acadia has said.
Carr kept his buy rating and 49 price target on Acadia, noting, "We have a favorable bias toward Nuplazid in dementia given encouraging results from a Phase 2 trial last year."
Meanwhile, Acadia will discontinue enrolling a Phase 2 trial of Nuplazid in treating agitation in Alzheimer's due to overlap with the just-announced Phase 3 trial in dementia-related psychosis. A Phase 2 trial of Nuplazid in psychosis of Alzheimer's patients is set to read out next month.
RELATED:
Acadia Pharma Stock Rockets On Drug Breakthrough Nod
Why These Biotechs Are Leading The Group Near A 21-Month High
CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals ( ACAD ) briefly rallied, then dipped nearly 1% early Thursday, in the wake of its announcement that its dementia drug had gotten breakthrough designation just ahead of enrolling a Phase 3 trial. Carr kept his buy rating and 49 price target on Acadia, noting, "We have a favorable bias toward Nuplazid in dementia given encouraging results from a Phase 2 trial last year." [ibd-display-video id=2326965 width=50 float=left autostart=true]Acadia popped as much as 5.3%, touching a high last seen in June 2016, before falling 2.2% to close at 38.30 on the stock market today . | At least three analysts increased their price targets on Acadia on Thursday, including JMP Securities analyst Jason Butler who bumped his target on Acadia to 50 from 47. Acadia plans to see whether Nuplazid has a benefit in reducing hallucinations and delusions in patients with various forms of dementia, including Alzheimer's disease, Parkinson's disease, dementia related to blocked or reduced blood flow to the brain and frontotemporal dementia. Acadia Pharmaceuticals ( ACAD ) briefly rallied, then dipped nearly 1% early Thursday, in the wake of its announcement that its dementia drug had gotten breakthrough designation just ahead of enrolling a Phase 3 trial. | Acadia plans to see whether Nuplazid has a benefit in reducing hallucinations and delusions in patients with various forms of dementia, including Alzheimer's disease, Parkinson's disease, dementia related to blocked or reduced blood flow to the brain and frontotemporal dementia. Meanwhile, Acadia will discontinue enrolling a Phase 2 trial of Nuplazid in treating agitation in Alzheimer's due to overlap with the just-announced Phase 3 trial in dementia-related psychosis. Acadia Pharma Stock Rockets On Drug Breakthrough Nod Why These Biotechs Are Leading The Group Near A 21-Month High CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Carr kept his buy rating and 49 price target on Acadia, noting, "We have a favorable bias toward Nuplazid in dementia given encouraging results from a Phase 2 trial last year." Acadia Pharmaceuticals ( ACAD ) briefly rallied, then dipped nearly 1% early Thursday, in the wake of its announcement that its dementia drug had gotten breakthrough designation just ahead of enrolling a Phase 3 trial. [ibd-display-video id=2326965 width=50 float=left autostart=true]Acadia popped as much as 5.3%, touching a high last seen in June 2016, before falling 2.2% to close at 38.30 on the stock market today . |
36071.0 | 2017-10-05 00:00:00 UTC | ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status | ACAD | https://www.nasdaq.com/articles/acadias-antipsychotic-drug-gets-breakthrough-therapy-status-2017-10-05 | nan | nan | ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase III study - HARMONY - for evaluating its antipsychotic drug, Nuplazid, for the treatment of hallucinations and delusions associated with dementia-related psychosis. The FDA also granted Breakthrough Therapy Designation to the drug for this indication.
The Breakthrough Therapy designation was granted to speed up the development and review of drugs that target serious or life-threatening conditions.
Nuplazid is currently approved as the only treatment for hallucinations and delusions associated with Parkinson's disease psychosis in the United States.
ACADIA's stock was up 7.2% in aftermarket hours on Wednesday following the news. In fact, shares of the company are up 35.7% so far this year, outperforming the industry 's rise of 14.5%.
The HARMONY study will evaluate the ability of the drug in preventing relapse of psychotic symptoms inAlzheimer's disease, dementia with Lewy bodies, Parkinson's disease dementia, vascular dementia and frontotemporal dementia. The above indications are the most common subtypes of dementia. The study will observe the patients over 12 weeks for dose stabilization followed by another 26 weeks for relapse of psychosis.
The phase III study is designed based on clinically meaningful and statistically significant outcomes in Phase II -019 study of the drug evaluated in patients with Alzheimer's disease psychosis. The study administered 34mg of the drug over a period of 6 weeks.
Moreover, the Breakthrough Therapy designation was granted based on phase II -019 study as well as phase II -020 study investigating the drug in Parkinson's disease psychosis.
Dementia-related psychosis is a serious medical condition with no approved therapy available currently. Per the press release, there are almost 8 million people suffering from dementia with 30% among them having psychosis.
The sale of Nuplazid generated $45.8 million in the first half of 2017. The broadening of the indication upon successful completion of the phase III study and a potential approval will boost sales of the drug driving the company's revenues.
ACADIA Pharmaceuticals Inc. Price and Consensus
ACADIA Pharmaceuticals Inc. Price and Consensus | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank & Other Stocks to Consider
ACADIA carries a Zacks Rank #2 (Buy). Other stocks worth considering in the health care sector include Adaptimmune Therapeutics PLC ADAP , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . All the stocks carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Adaptimmune's loss per share estimates have narrowed from $1.03 to 95 cents for 2017 and from 95 cents to 90 cents for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 2.56%. The share price of the company has increased 115.8% year to date.
Biogen's earnings per share estimates have moved up from $21.37 to $21.42 for 2017 and from $23.11 to $23.23 for 2018 over the last 30 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 6.41%. The share price of the company has increased 11% year to date.
Aduro's loss estimates per share have narrowed from $1.36 to $1.29 for 2017 over last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 2.53%.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor's Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB): Free Stock Analysis Report
Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase III study - HARMONY - for evaluating its antipsychotic drug, Nuplazid, for the treatment of hallucinations and delusions associated with dementia-related psychosis. ACADIA's stock was up 7.2% in aftermarket hours on Wednesday following the news. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. Price and Consensus | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider ACADIA carries a Zacks Rank #2 (Buy). | ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. Price and Consensus | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider ACADIA carries a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase III study - HARMONY - for evaluating its antipsychotic drug, Nuplazid, for the treatment of hallucinations and delusions associated with dementia-related psychosis. | ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. Price and Consensus | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider ACADIA carries a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase III study - HARMONY - for evaluating its antipsychotic drug, Nuplazid, for the treatment of hallucinations and delusions associated with dementia-related psychosis. | ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase III study - HARMONY - for evaluating its antipsychotic drug, Nuplazid, for the treatment of hallucinations and delusions associated with dementia-related psychosis. ACADIA's stock was up 7.2% in aftermarket hours on Wednesday following the news. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. Price and Consensus | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider ACADIA carries a Zacks Rank #2 (Buy). |
36072.0 | 2017-10-05 00:00:00 UTC | Ligand (LGND) Signs Deal to Acquire Crystal Bioscience | ACAD | https://www.nasdaq.com/articles/ligand-lgnd-signs-deal-to-acquire-crystal-bioscience-2017-10-05 | nan | nan | Ligand Pharmaceuticals IncorporatedLGND inked a deal to acquire Crystal Bioscience, Inc. for $25 million in cash. The company will also pay an additional $10.5 million to the shareholders of Crystal Bioscience on success-based milestones.
Additionally, Crystal Bioscience will share revenues from existing licensees for a defined period. Crystal Bioscience's core technology, HuMab, is a chicken-based antibody platform used to generate human antibodies.
Consequently, Ligands shares have outperformed the industry year to date.
The stock has surged 36.4% compared with the industry 's gain of 14.6% in the same time frame.
Pursuant to the acquisition, the HuMab technology will become a a part of Ligand's OmniAb brand and will be called OmniChicken. Notably, OmniAb is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The technology was added to Ligand's portfolio in January 2016, when the company acquired OMT, Inc., (Open Monoclonal Technology) for about $178 million.
OmniAb has three distinct transgenic rodent systems for generating antibodies, OmniRat, OmniMouse and OmniFlic. While OmniRat is the industry's first human monoclonal antibody technology based on rats, OmniFlic is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. OmniMouse is a transgenic mouse.
Hence, the addition of OmniChicken platform to Ligand's OmniAb technology adds a third species for fully-humanized antibody discovery.
Going forward, it is expected that OmniChicken technology will be utilized by some of Ligand's existing OmniAb partners and potential new partners. The deal will add four fully-funded partnerships to Ligand's business (Boehringer Ingelheim, Alexo Therapeutics, Achaogen and an undisclosed large pharmaceutical company).
Ligand anticipates Crystal Bioscience's acquisition to contribute up to $1 million of revenue during the fourth quarter of 2017. Also, it expects total revenues for 2017 to be at least $134 million compared with the previous guidance of $133 million.
However, the company reiterated its guidance to receive additional contract revenues of approximately $9 millionfor 2017. With revenues of $134 million, Ligand's outlook for the adjusted earnings per share remained unchanged at $2.93 for the current year.
For 2018, Ligand expects this latest buyout to contribute at least $5 million and incremental earnings of at least 9 cents.
Ligand Pharmaceuticals Incorporated Price
Ligand Pharmaceuticals Incorporated Price | Ligand Pharmaceuticals Incorporated Quote
Zacks Rank & Stocks to Consider
Ligand carries a Zacks Rank #3 (Hold). Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO , each holding a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates have narrowed from $2.82 to $2.53 for 2017 and from $2.07 to $1.87 for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%. Share price of the company has climbed 35.7% year to date.
Biogen's earnings per share estimates have moved up $21.37 to $21.42 for 2017 and from $23.11 to $23.23 for 2018 over the last 60 days. The company pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 6.41%. The share price of the company has increased 11% year to date.
Aduro's loss estimates per share have narrowed from $1.36 to $1.29 for 2017 over last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 2.53%.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor's Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB): Free Stock Analysis Report
Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO , each holding a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.82 to $2.53 for 2017 and from $2.07 to $1.87 for 2018 over the last 60 days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO , each holding a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates have narrowed from $2.82 to $2.53 for 2017 and from $2.07 to $1.87 for 2018 over the last 60 days. | Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO , each holding a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.82 to $2.53 for 2017 and from $2.07 to $1.87 for 2018 over the last 60 days. | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO , each holding a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.82 to $2.53 for 2017 and from $2.07 to $1.87 for 2018 over the last 60 days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36073.0 | 2017-10-04 00:00:00 UTC | Emergent Completes Acquisition of Anthrax Drug Raxibacumab | ACAD | https://www.nasdaq.com/articles/emergent-completes-acquisition-of-anthrax-drug-raxibacumab-2017-10-04 | nan | nan | Emergent BioSolutions Inc.EBS announced that it has closed the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline plc GSK . In December 2012, raxibacumab was approved of by the FDA for the treatment and prophylaxis of inhalational anthrax.
Going forward, the company plans to assume responsibility of supplying the product to the U.S. Strategic National Stockpile (SNS) under a multi-year contract with the Biomedical Advanced Research and Development Authority ("BARDA").
The contract is valued at approximately $130 million. Notably, Emergent plans to transfer manufacturing of raxibacumab to its existing facilities in Baltimore in 2020. Also, the company expects to purchase product from GlaxoSmithkline to enable completion of deliveries to SNS under existing BARDA procurement contract.
Emergent's shares have outperformed the industry year to date. The stock has rallied 24.7% compared with the industry 's gain of 15.2% in the same time frame.
In fact, with the acquisition of raxibacumab, the company expects the revenues to increase by about $9 million for full-year 2017. Additionally, Emergent expects the GAAP net income to remain neutral reflecting the impact of initial costs to begin the process of transferring raxibacumab manufacturing from GSK to Emergent, which is expected to be completed in 2020.
Emergent Biosolutions, Inc. Price
Emergent Biosolutions, Inc. Price | Emergent Biosolutions, Inc. Quote
Zacks Rank & Stocks to Consider
Emergent carries a Zacks Rank #3 (Hold). Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD and Biogen Inc. BIIB . Both ACADIA and , Biogen carry Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%. Share price of the company has climbed 34.7% year to date.
Biogen's earnings per share estimates have moved up $21.37 to $21.42 for 2017 and from $23.11 to $23.23 for 2018 over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 6.41%. The share price of the company has increased 11.9% year to date.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD and Biogen Inc. BIIB . Both ACADIA and , Biogen carry Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD and Biogen Inc. BIIB . Both ACADIA and , Biogen carry Zacks Rank #2 (Buy). | Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD and Biogen Inc. BIIB . Both ACADIA and , Biogen carry Zacks Rank #2 (Buy). | Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD and Biogen Inc. BIIB . Both ACADIA and , Biogen carry Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. |
36074.0 | 2017-10-04 00:00:00 UTC | Celsion's Immunotherapy Candidate Impresses, Stock Surges | ACAD | https://www.nasdaq.com/articles/celsions-immunotherapy-candidate-impresses-stock-surges-2017-10-04 | nan | nan | Celsion CorporationCLSN announced results from phase Ib study - OVATION - evidently showing biological activity of its immunotherapy candidate, GEN1, in advanced ovarian cancer patients. Celsion is developing the candidate for newly diagnosed patients, who will be administered in combination with neoadjuvant chemotherapy.
Investors cheered the news as the stock skyrocketed over 300% on Tuesday. In fact, shares of the company have surged 42.4% so far this year, outperforming the industry 's rally of 15.2% during the period.
Of the 14 patients treated to date, two have demonstrated a complete response (CR), 10, a partial response (PR) and another two, a stable response. This reflected a 100% disease control rate (DCR) and an 86% objective response rate (ORR). Of the five patients treated in the highest dose cohort, there was 100% objective response rate with one patient achieving complete response and four, affirming partial responses.
The company also announced improvement in median progression free survival (PFS), which increased from 12 months to 18 months with longest PFS of 24 months. Plus, GEN1 brought favorable immunological changes that are likely to get translated into clinical benefit.
The company met with advisory board last month and based on their recommendation is planning to file the phase II design with the FDA by this year-end.
Celsion is also developing the candidate in combination with PEGylated doxorubicin for patients with platinum-resistant ovarian cancer.
Apart from GEN-1 immunotherapy, another cancer program in Celsion's portfolio is ThermoDox, currently being investigated in a phase III evaluation for primary liver cancer.
Spectrum Pharmaceuticals, Inc. Price and Consensus
Spectrum Pharmaceuticals, Inc. Price and Consensus | Spectrum Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Celsion carries a Zacks Rank #2 (Buy). Some other bullish-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . All the stocks carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7.97%. Share price of the company has climbed 34.7% year to date.
Biogen's earnings per share estimates have moved up from $21.37 to $21.42 for 2017 and from $23.11 to $23.23 for 2018 over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters with an average beat of 6.41%. Share price of the company has rallied 11.9% year to date.
Aduro's loss estimates per share have narrowed from $1.36 to $1.29 for 2017 over the last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters with an average beat of 2.53%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
Celsion Corporation (CLSN): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other bullish-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Celsion Corporation (CLSN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some other bullish-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Celsion Corporation (CLSN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Celsion Corporation (CLSN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some other bullish-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some other bullish-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Celsion Corporation (CLSN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36075.0 | 2017-10-04 00:00:00 UTC | Acadia Pharma Stock Rockets On Drug Breakthrough Nod | ACAD | https://www.nasdaq.com/articles/acadia-pharma-stock-rockets-drug-breakthrough-nod-2017-10-04 | nan | nan | Acadia Pharmaceuticals ( ACAD ) rallied after the Food and Drug Administration late Wednesday granted its dementia drug breakthrough designation just as the drug begins a Phase 3 trial.
[ibd-display-video id=2326965 width=50 float=left autostart=true]In premarket trading on the stock market today , Acadia jumped 5.3% to 41.20. Shares finished the regular trading session up 0.7%, at 39.14, on Wednesday.
The drug, dubbed pimavanserin, is being investigated as a treatment for hallucinations and delusions associated with dementia-related psychosis. There is no treatment approved by the FDA for the condition, Acadia said in a news release.
Dementia-related psychosis includes psychosis in patients with Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease dementia, dementia related to reduced or blocked blood flow to the brain and frontotemporal dementia, a rare disorder related to Alzheimer's.
Pimavanserin is already approved to treat hallucinations and delusions associated with Parkinson's disease psychosis. It's marketed under the trade name Nuplazid. If the program is successful, this would significantly expand the approved use of the drug, Acadia said.
"With receipt of the FDA's Breakthrough Therapy Designation for pimavanserin, we are able to accelerate this important program," Acadia Chief Executive Steve Davis said in a statement.
RELATED:
Why These Biotechs Are Leading The Group Near A 21-Month High
How Mylan's MS-Generic Approval Caused Teva, Momenta To Plunge
CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | "With receipt of the FDA's Breakthrough Therapy Designation for pimavanserin, we are able to accelerate this important program," Acadia Chief Executive Steve Davis said in a statement. Acadia Pharmaceuticals ( ACAD ) rallied after the Food and Drug Administration late Wednesday granted its dementia drug breakthrough designation just as the drug begins a Phase 3 trial. [ibd-display-video id=2326965 width=50 float=left autostart=true]In premarket trading on the stock market today , Acadia jumped 5.3% to 41.20. | Acadia Pharmaceuticals ( ACAD ) rallied after the Food and Drug Administration late Wednesday granted its dementia drug breakthrough designation just as the drug begins a Phase 3 trial. [ibd-display-video id=2326965 width=50 float=left autostart=true]In premarket trading on the stock market today , Acadia jumped 5.3% to 41.20. There is no treatment approved by the FDA for the condition, Acadia said in a news release. | Acadia Pharmaceuticals ( ACAD ) rallied after the Food and Drug Administration late Wednesday granted its dementia drug breakthrough designation just as the drug begins a Phase 3 trial. [ibd-display-video id=2326965 width=50 float=left autostart=true]In premarket trading on the stock market today , Acadia jumped 5.3% to 41.20. There is no treatment approved by the FDA for the condition, Acadia said in a news release. | Acadia Pharmaceuticals ( ACAD ) rallied after the Food and Drug Administration late Wednesday granted its dementia drug breakthrough designation just as the drug begins a Phase 3 trial. [ibd-display-video id=2326965 width=50 float=left autostart=true]In premarket trading on the stock market today , Acadia jumped 5.3% to 41.20. There is no treatment approved by the FDA for the condition, Acadia said in a news release. |
36076.0 | 2017-10-04 00:00:00 UTC | 2 Stocks Move in After-Hours Trading | ACAD | https://www.nasdaq.com/articles/2-stocks-move-after-hours-trading-2017-10-04 | nan | nan | On Wednesday, U.S. stock market indexes closed in the green after opening lower. The S&P 500 and the Dow Jones Industrial Average recorded highs. The S&P 500 rose 0.12% points to close at 2,537.74, the Nasdaq Composite gained 0.04% to 6,534.63 and the Dow Jones increased 0.09% to 22,661.64.
Shares of ImmunoGen Inc. ( IMGN ) closed 2.35% higher on Wednesday, but fell more than 8% in after-hours trading after announcing a secondary offering of 13 million shares. The biotech company plans to use the proceeds to finance research and development, clinical trials and other expenses like commercialization preparation, acquisitions of new technologies, capital expenditures and working capital. Jefferies, Leerink Partners and RBC Capital Markets will be the underwriters.
On the other hand, AcadiaPharmaceuticalsInc. ( ACAD ) gained 0.72% and is also trading higher after market close. The pharmaceutical company announced the U.S. Food and Drug Administration granted pimavanserin, which treats dementia-related psychosis, breakthrough therapy designation.
Serge Stankovic, executive vice president and head of research and development, was pleased with the FDA's decision as it "has agreed to an efficient development path for pimavanserin in this broad indication and granted Breakthrough Therapy Designation in recognition of this serious unmet need."
"Initiation of our Phase III study is supported by clinical and preclinical evidence of pimavanserin's antipsychotic activity without detrimental effects on cognitive function or other side effects associated with antipsychotics currently used off-label for this indication," he added.
Disclosure : The author holds no positions in any stocks mentioned.
Premium Members
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On the other hand, AcadiaPharmaceuticalsInc. ( ACAD ) gained 0.72% and is also trading higher after market close. The S&P 500 rose 0.12% points to close at 2,537.74, the Nasdaq Composite gained 0.04% to 6,534.63 and the Dow Jones increased 0.09% to 22,661.64. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. On the other hand, AcadiaPharmaceuticalsInc. ( ACAD ) gained 0.72% and is also trading higher after market close. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. On the other hand, AcadiaPharmaceuticalsInc. ( ACAD ) gained 0.72% and is also trading higher after market close. | ( ACAD ) gained 0.72% and is also trading higher after market close. On the other hand, AcadiaPharmaceuticalsInc. On Wednesday, U.S. stock market indexes closed in the green after opening lower. |
36077.0 | 2017-09-29 00:00:00 UTC | Noteworthy Friday Option Activity: GRA, DDD, ACAD | ACAD | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-gra-ddd-acad-2017-09-29 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Grace & Co (Symbol: GRA), where a total volume of 4,912 contracts has been traded thus far today, a contract volume which is representative of approximately 491,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 91.2% of GRA's average daily trading volume over the past month, of 538,575 shares. Particularly high volume was seen for the $70 strike call option expiring October 20, 2017 , with 2,935 contracts trading so far today, representing approximately 293,500 underlying shares of GRA. Below is a chart showing GRA's trailing twelve month trading history, with the $70 strike highlighted in orange:
3D Systems Corp. (Symbol: DDD) options are showing a volume of 10,368 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 60.8% of DDD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $15 strike put option expiring November 17, 2017 , with 10,000 contracts trading so far today, representing approximately 1.0 million underlying shares of DDD. Below is a chart showing DDD's trailing twelve month trading history, with the $15 strike highlighted in orange:
And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,894 contracts thus far today. That number of contracts represents approximately 689,400 underlying shares, working out to a sizeable 55.4% of ACAD's average daily trading volume over the past month, of 1.2 million shares. Especially high volume was seen for the $30 strike put option expiring December 15, 2017 , with 5,076 contracts trading so far today, representing approximately 507,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange:
For the various different available expirations for GRA options , DDD options , or ACAD options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $30 strike put option expiring December 15, 2017 , with 5,076 contracts trading so far today, representing approximately 507,600 underlying shares of ACAD. Below is a chart showing DDD's trailing twelve month trading history, with the $15 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,894 contracts thus far today. That number of contracts represents approximately 689,400 underlying shares, working out to a sizeable 55.4% of ACAD's average daily trading volume over the past month, of 1.2 million shares. | That number of contracts represents approximately 689,400 underlying shares, working out to a sizeable 55.4% of ACAD's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing DDD's trailing twelve month trading history, with the $15 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,894 contracts thus far today. Especially high volume was seen for the $30 strike put option expiring December 15, 2017 , with 5,076 contracts trading so far today, representing approximately 507,600 underlying shares of ACAD. | Below is a chart showing DDD's trailing twelve month trading history, with the $15 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,894 contracts thus far today. That number of contracts represents approximately 689,400 underlying shares, working out to a sizeable 55.4% of ACAD's average daily trading volume over the past month, of 1.2 million shares. Especially high volume was seen for the $30 strike put option expiring December 15, 2017 , with 5,076 contracts trading so far today, representing approximately 507,600 underlying shares of ACAD. | That number of contracts represents approximately 689,400 underlying shares, working out to a sizeable 55.4% of ACAD's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for GRA options , DDD options , or ACAD options , visit StockOptionsChannel.com. Below is a chart showing DDD's trailing twelve month trading history, with the $15 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,894 contracts thus far today. |
36078.0 | 2017-09-26 00:00:00 UTC | Allergan Authorizes New $2B Share Buyback Plan, Stock Up | ACAD | https://www.nasdaq.com/articles/allergan-authorizes-new-%242b-share-buyback-plan-stock-up-2017-09-26 | nan | nan | In an effort to reward shareholders, the board of directors of AllerganplcAZN has sanctioned a new stock repurchase program, thereby allowing the company to buy back shares worth up to $2 billion.
The company also reiterated its commitment to increase quarterly cash dividend annually.
The company retained its previous target to pay down $3.75 billion of debt in 2018. These announcements reflect the company's strategy to develop a strong future cash flow position and investment grade ratings by reducing its debt burden. Notably, Allergan has been prudent in paying down debt. The company repaid debt of almost $10 billion in 2016 and $2.6 billion in the first half of 2017.
The company has also reaffirmed financial guidance for third-quarter 2017 and FY17 which it previously issued in August earlier. Allergan expects total revenue in the range of $15.85-$16.05 billion for 2017. Adjusted earnings per share are expected in the range of $16.05-$16.45 during the same period.
Allergan's shares were up almost 4% after the company announced the buyback of shares along with the reaffirmation of financial guidance and a hike in quarterly cash dividend. Also, shares have nudged up 0.8% so far this year against the 20.9% decrease of the industry during the period.
We remind investors that the company has recently completed a share buyback of $15 billion including a $10 billion accelerated share repurchase. It bought back shares from a portion of the net proceeds it generated from divestiture of its generics business to Teva Pharmaceutical TEVA , last August.
In a separate press release, Allergan announced retirement of Executive Vice President (EVP) and Chief Financial Officer (CFO), Tessa Hilado. However, the company stressed that Hilado will continue in her current role until a replacement is found. The organization has already initiated a search for a new CFO.
Allergan PLC. Price
Allergan PLC. Price | Allergan PLC. Quote
Zacks Rank & Stocks to Consider
Allergan currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.29 for 2017 and from $1.41 to $1.26 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36079.0 | 2017-09-21 00:00:00 UTC | Commit To Buy Acadia Pharmaceuticals At $25, Earn 8.2% Using Options | ACAD | https://www.nasdaq.com/articles/commit-buy-acadia-pharmaceuticals-25-earn-82-using-options-2017-09-21 | nan | nan | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but cautious about paying the going market price of $37.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $25 strike, which has a bid at the time of this writing of $2.05. Collecting that bid as the premium represents a 8.2% return against the $25 commitment, or a 6.2% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $25 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Acadia Pharmaceuticals Inc sees its shares decline 32.5% and the contract is exercised (resulting in a cost basis of $22.95 per share before broker commissions, subtracting the $2.05 from $25), the only upside to the put seller is from collecting that premium for the 6.2% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $25 strike for the 6.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $37.17) to be 51%. For other put options contract ideas at the various different available expirations, visit the ACAD Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Thursday, the put volume among S&P 500 components was 696,190 contracts, with call volume at 696,190, for a put:call ratio of 0.73 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today .
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but cautious about paying the going market price of $37.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $25 strike for the 6.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $37.17) to be 51%. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $25 strike for the 6.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Acadia Pharmaceuticals Inc (considering the last 252 trading day closing values as well as today's price of $37.17) to be 51%. Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but cautious about paying the going market price of $37.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $25 strike for the 6.2% annualized rate of return represents good reward for the risks. Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but cautious about paying the going market price of $37.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. | Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but cautious about paying the going market price of $37.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $25 strike for the 6.2% annualized rate of return represents good reward for the risks. Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. |
36080.0 | 2017-09-21 00:00:00 UTC | Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You? | ACAD | https://www.nasdaq.com/articles/billionaires-are-gobbling-beaten-down-biotech-stock-should-you-2017-09-21 | nan | nan | Julian and Felix Baker of the $15.6 billion hedge fund Baker Bros. Advisors are well-known for their uncanny ability to unearth hidden gems in biotech and biopharma. So when I noticed that the dynamic duo purchased a noteworthy 2 million shares of the beaten-down vaccine maker Novavax (NASDAQ: NVAX) in the second quarter of 2017, it piqued my interest to say the least.
The Baker Bros., after all, have repeatedly picked some of the top-performing biotech stocks over the past six years, and they've also successfully mined the ultra-risky landscape of clinical setbacks to produce some truly astounding gains.
Acadia Pharmaceuticals (NASDAQ: ACAD) , for example, has proven to be an outstanding growth vehicle since the fund first bought it in 2010 (up over 9,600%), even though Acadia's Parkinson's disease psychosis drug, Nuplazid, initially missed the mark in late-stage testing.
Novavax, for its part, has seen its shares lose over 90% of their value since August 2015 due to an extremely poor showing of its experimental respiratory syncytial virus (RSV) vaccine in elderly adults in a late-stage trial last year. The vaccine, if approved, is widely believed by industry insiders to be capable of producing several billion in sales. But this pivotal-stage failure suggests that it may not have the efficacy profile to ever garner a regulatory approval for this key indication.
Even so, the Acadia Pharmaceuticals example clearly shows that even drugs with a problematic clinical history can make remarkable comebacks when the appropriate changes are made in future trials. So, based on this insight, let's consider if average investors should take a cue from the Baker Bros. when it comes to Novavax and its experimental RSV vaccine.
RSV is a monstrous commercial opportunity
Novavax's experimental RSV vaccine is targeting approximately 4 million infants and 65 million elderly adults in just the United States. So if the company decided to price its RSV vaccine along the lines of, say, a typical flu shot (roughly $50 per dose) -- which is well below the price point of most other vaccines like Pfizer 's Prevnar 13 or GlaxoSmithKline 's Engerix-B -- this product could achieve blockbuster status with only a 30% penetration rate, thanks to the enormous size of its target markets.
Both Novavax and industry insiders, however, think this particular vaccine could far exceed even $1 billion in annual sales. Using a more likely price point that mimics other more specialized vaccines such as Prevnar 13 and Engerix-B, for instance, the numbers easily suggest that even $6 billion isn't an unrealistic peak sales estimate across both of its proposed indications (infants and older adults). That's a truly astounding figure, especially for a company with a market cap of around $324 million at the moment.
Can Novavax cross the finish line?
Whether Novavax can push its RSV vaccines across the goal line for either of these high-value indications, though, is another matter altogether. The vaccine's mid-stage data in pregnant women and elderly adults, after all, wasn't exactly awe-inspiring. The p-values of these trials were both only marginally significant, and those data were the basis for its late-stage program that now hangs in the balance.
Worse still, the vaccine's first pivotal-stage trial in older adults was an utter disaster, with a p-value of 0.78 . Point blank: The clinical data so far doesn't paint a compelling picture of the vaccine's ability to reduce symptoms associated with RSV, even though the company has repeatedly suggested otherwise during investor presentations and press releases.
Equally as important, the company's operating cash flows (negative $193 million over the past 12 months) and last stated cash position ($187 million) suggest that it may need to raise capital in a big way within a year's time. In fact, there's no clear financial path for the company to actually execute the necessary changes to the vaccine's elderly adult program at this time without either a partner or a value-destroying secondary offering.
Unfortunately, a sizable secondary offering would also put the company's stock at risk of being delisted on the Nasdaq due to the exchange's minimum bid requirements (> $1 per share), implying that a secondary may not be a realistic option.
Novavax: Buy or avoid?
There's no question that if Novavax can somehow change the trajectory of its RSV program, its stock could mimic even the jaw-dropping gains of Acadia Pharmaceuticals. But the fact of the matter is that no deep-pocketed partner has yet to step forward to offer Novavax a much-needed lifeline, which seems to reflect the industry's dire view of the vaccine's prospects moving forward.
So while the Baker Bros. may have indeed picked another diamond in the rough, there's no compelling reason -- at least to outsiders like myself -- to think that a comeback is likely at this stage. Put simply, Novavax's stock shouldn't be viewed as an investment, but rather a flat-out gamble based on all available evidence regarding its core RSV program. And that's not a particularly Foolish way to put your capital to work.
Thus, I think this penny biotech stock just isn't worth buying right now -- but its tremendous value proposition perhaps does merit making it a watchlist candidate.
10 stocks we like better than Novavax
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
George Budwell owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Acadia Pharmaceuticals (NASDAQ: ACAD) , for example, has proven to be an outstanding growth vehicle since the fund first bought it in 2010 (up over 9,600%), even though Acadia's Parkinson's disease psychosis drug, Nuplazid, initially missed the mark in late-stage testing. Even so, the Acadia Pharmaceuticals example clearly shows that even drugs with a problematic clinical history can make remarkable comebacks when the appropriate changes are made in future trials. There's no question that if Novavax can somehow change the trajectory of its RSV program, its stock could mimic even the jaw-dropping gains of Acadia Pharmaceuticals. | Acadia Pharmaceuticals (NASDAQ: ACAD) , for example, has proven to be an outstanding growth vehicle since the fund first bought it in 2010 (up over 9,600%), even though Acadia's Parkinson's disease psychosis drug, Nuplazid, initially missed the mark in late-stage testing. Even so, the Acadia Pharmaceuticals example clearly shows that even drugs with a problematic clinical history can make remarkable comebacks when the appropriate changes are made in future trials. There's no question that if Novavax can somehow change the trajectory of its RSV program, its stock could mimic even the jaw-dropping gains of Acadia Pharmaceuticals. | Acadia Pharmaceuticals (NASDAQ: ACAD) , for example, has proven to be an outstanding growth vehicle since the fund first bought it in 2010 (up over 9,600%), even though Acadia's Parkinson's disease psychosis drug, Nuplazid, initially missed the mark in late-stage testing. Even so, the Acadia Pharmaceuticals example clearly shows that even drugs with a problematic clinical history can make remarkable comebacks when the appropriate changes are made in future trials. There's no question that if Novavax can somehow change the trajectory of its RSV program, its stock could mimic even the jaw-dropping gains of Acadia Pharmaceuticals. | Acadia Pharmaceuticals (NASDAQ: ACAD) , for example, has proven to be an outstanding growth vehicle since the fund first bought it in 2010 (up over 9,600%), even though Acadia's Parkinson's disease psychosis drug, Nuplazid, initially missed the mark in late-stage testing. Even so, the Acadia Pharmaceuticals example clearly shows that even drugs with a problematic clinical history can make remarkable comebacks when the appropriate changes are made in future trials. There's no question that if Novavax can somehow change the trajectory of its RSV program, its stock could mimic even the jaw-dropping gains of Acadia Pharmaceuticals. |
36081.0 | 2017-09-19 00:00:00 UTC | Supernus Drops SPN-810's Lower Dose Test in Phase III Trials | ACAD | https://www.nasdaq.com/articles/supernus-drops-spn-810s-lower-dose-test-in-phase-iii-trials-2017-09-19 | nan | nan | Supernus Pharmaceuticals, Inc. 's SUPN shares have dropped almost 10% after the company announced decision to stop evaluating the lower dose option (18 mg) of its pipeline candidate, SPN-810, in two phase III clinical trials. However, the company will carry on with its 36 mg dose of SPN-810 or placebo of similar proportion in both the studies.
Significantly, SPN-810 is being developed as a novel treatment option for impulsive aggression (IA) in patients aged 6-12 years with attention deficit hyperactivity disorder (ADHD).
Supernus' shares have significantly soared 79.8% so far this year in contrast to the 18.2% decrease of the industry during the period.
The two phase III studies were designed under a Special Protocol Assessment (SPA) by the FDA. The decision taken by the company to terminate the lower dose regime is an outcome of the planned interim analysis from the first phase III clinical trial on SPN-810. The interim analysis was planned when 50% of the patients (n=146) reached randomization in the first trial.
The program was conducted by an independent third-party statistician to evaluate both the doses and provide optimization of the study design. The company believes that chances of achieving a statistically substantial result with the 36 mg dose will be high. Implementation of the suggested changes will be executed immediately.
Notably, enrollment in the first and second trial has already completed 64% and 56%, respectively. The company expects enrollment to continue through mid-2018.
We remind investors that SPN-810 is a key candidate in Supernus' pipeline, already granted with a fast-track designation from the FDA.
Additionally, Supernus is developing SPN-812 for ADHD treatment.
However, the ADHD market is currently dominated by companies like Shire plc SHPG . Some drugs approved for this indication are Vyvanse, Adderall XR, Intuniv and Equasym XL.
Supernus Pharmaceuticals, Inc. Price
Supernus Pharmaceuticals, Inc. Price | Supernus Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Supernuscurrently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
4 Promising Stock Picks to Keep an Eye On
With news stories about computer hacking and identity theft becoming increasingly commonplace, the cybersecurity industry looks like a promising investment opportunity. But which stocks should you buy? Zacks just released Cybersecurity: An Investor's Guide to Locking Down Profits to help answer this question.
This new Special Report gives you the information you need to make well-informed investment choices in this space. More importantly, it also highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Shire PLC (SHPG): Free Stock Analysis Report
Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. |
36082.0 | 2017-09-19 00:00:00 UTC | Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD | ACAD | https://www.nasdaq.com/articles/glaxo-innovivas-triple-combo-therapy-gets-fda-nod-for-copd-2017-09-19 | nan | nan | GlaxoSmithKline plcGSK and partner Innoviva, Inc. INVA announced that the FDA has approved a once-daily, single inhaler triple combination therapy - FF/UMEC/VI (fluticasone furoate/umeclidinium/vilanterol) - as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The drug is approved under the brand name, Trelegy Ellipta. The company said that the medicine will be available in the United States shortly.
While fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2-adrenergic agonist (LABA). This combination medicine will be delivered once daily in the Ellipta dry powder inhaler. Typically, the ICS/LAMA/LABA amalgamation for advanced COPD is delivered via two or more inhalers with potentially differing dose regime. However, GlaxoSmithKline's triple therapy combination offers a daily treatment in a single Ellipta inhaler.
Notably, closed triple combination therapy is not licensed as a single inhaler triple therapy anywhere outside the United States.
GlaxoSmithKline's shares are up 4% so far this year, comparing unfavorably with the 16.4% rally of the industry during the period.
We remind investors that in November last year, GlaxoSmithKline and Innoviva announced filing of a regulatory submission for the triple combination therapy in the United States for the given indication. Good news is that the regulatory application was submitted around 18 months earlier than expectations.
Additionally, last December, GlaxoSmithKline and Innoviva had filed regulatory applications for the combination therapy in the EU.
The filing was based on data from the closed triple combination therapy development program as well as results of the phase III FULFIL study on FF, UMEC and VI, either alone or in combination. The study revealed superiority of the closed triple combination over Symbicort Turbohaler in improving lung function and health-related quality of life in COPD patients.
Good news is that this month, European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the combination treatment.
Notably, the combination therapy is also under assessment across a number of other countries, including Australia and Canada.
Per the company's press release, COPD is a progressive serious lung disease, commonly found to affect approximately 384 million people worldwide, representing a significant need for such therapies.
GlaxoSmithKline PLC Price
GlaxoSmithKline PLC Price | GlaxoSmithKline PLC Quote
Zacks Rank & Stocks to Consider
GlaxoSmithKline currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
4 Promising Stock Picks to Keep an Eye On
With news stories about computer hacking and identity theft becoming increasingly commonplace, the cybersecurity industry looks like a promising investment opportunity. But which stocks should you buy? Zacks just released Cybersecurity: An Investor's Guide to Locking Down Profits to help answer this question.
This new Special Report gives you the information you need to make well-informed investment choices in this space. More importantly, it also highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline PLC (GSK): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Innoviva, Inc. (INVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Innoviva, Inc. (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Innoviva, Inc. (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Innoviva, Inc. (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Innoviva, Inc. (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36083.0 | 2017-09-18 00:00:00 UTC | BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA | ACAD | https://www.nasdaq.com/articles/biomarin-says-fda-not-planning-an-adcom-for-pegvaliase-bla-2017-09-18 | nan | nan | BioMarin Pharmaceutical Inc.BMRN announced that the FDA is currently not planning to hold an advisory committee meeting (AdCom) to discuss the Biologics License Application (BLA) for pipeline candidate, pegvaliase.
The company is looking to get pegvaliase approved for lowering blood phenylalanine (Phe) levels in adult patients with phenylketonuria (PKU), a rare genetic enzyme deficiency disorder, having uncontrolled blood Phe levels with existing treatment options.
Notably, the FDA responded to the company's BLA through a Day-74 filing letter, communicating potential review issues. However, we are positive on the FDA's current decision as it indicates the agency's comfort with the safety and efficacy data of pegvaliase submitted from completed clinical studies. Also, the preliminary evaluation of the FDA is in line with the company's expectations.
Additionally, an application in the EU for pegvaliase is expected to be filed by the end of this year.
BioMarin's shares are up 11% so far this year, comparing unfavorably with the 15.5% rally of the industry during the period.
We remind investors that in August, the FDA accepted the BLA for pegvaliase under priority review. However, the regulatory body requested additional information on chemistry, manufacturing and controls related to pegvaliase. The company expects submission of this information to the FDA to be classified as a major amendment that will extend the review process by three months. As of now, a decision is expected on Feb 28, 2018.
BioMarin is hoping that pegvaliase, if approved, will supplement the company's phenylketonuria portfolio, also including Kuvan. A potential approval will strengthen the company's commercial leadership in the treatment of PKU with potential to drive the company's revenues, going forward.
However, Kuvan is set to face generic competition from 2020 onward. The approval of pegvaliase will help BioMarin offset any loss of revenues from Kuvan in the long term.
Per the company provided information, approximately 50,000 individuals in the developed countries are diagnosed with PKU, representing a significant need for such therapies.
We remind investors that in January last year, BioMarin acquired all global rights to Kuvan and pegvaliase from Merck Serono. Previously, the company had exclusive rights to Kuvan in the United States as well as Canada and to pegvaliase in the United States plus Japan.
With this transaction, BioMarin has gained exclusive worldwide rights to Kuvan and pegvaliase with the exception of Kuvan in Japan. The acquisition of PKU rights in these markets represents a significant opportunity for BioMarin to establish commercial leadership for treatment of PKU, first with Kuvan and then with pegvaliase, upon regulatory developments.
BioMarin Pharmaceutical Inc. Price
BioMarin Pharmaceutical Inc. Price | BioMarin Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
BioMarin currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Akebia's loss per share estimates narrowed from $4.14 to $3.85 for 2017 and from $1.98 to $1.88 for 2018 over the last 60 days. Its share price soared 66.2% so far this year.
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
New Report: An Investor's Guide to Cybersecurity
Cyberattacks have become more frequent and destructive than ever. In fact, they're expected to cause $6 trillion per year in damage by 2020.
The cybersecurity industry is expanding quickly in response to these threats. In fact, a projected $170 billion per year will be spent to protect consumer and corporate assets. Zacks has just released Cybersecurity: An Investor's Guide to Locking Down Profits which reveals 4 promising investment candidates.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36084.0 | 2017-09-15 00:00:00 UTC | The Math Shows FBT Can Go To $140 | ACAD | https://www.nasdaq.com/articles/math-shows-fbt-can-go-140-2017-09-15 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $140.11 per unit.
With FBT trading at a recent price near $123.28 per unit, that means that analysts see 13.65% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FBT's underlying holdings with notable upside to their analyst target prices are Intrexon Corp (Symbol: XON), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Although XON has traded at a recent price of $18.89/share, the average analyst target is 100.11% higher at $37.80/share. Similarly, BMRN has 24.89% upside from the recent share price of $91.23 if the average analyst target price of $113.94/share is reached, and analysts on average are expecting ACAD to reach a target price of $44.60/share, which is 22.70% above the recent price of $36.35. Below is a twelve month price history chart comparing the stock performance of XON, BMRN, and ACAD:
Combined, XON, BMRN, and ACAD represent 9.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of XON, BMRN, and ACAD: Combined, XON, BMRN, and ACAD represent 9.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Three of FBT's underlying holdings with notable upside to their analyst target prices are Intrexon Corp (Symbol: XON), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BMRN has 24.89% upside from the recent share price of $91.23 if the average analyst target price of $113.94/share is reached, and analysts on average are expecting ACAD to reach a target price of $44.60/share, which is 22.70% above the recent price of $36.35. | Three of FBT's underlying holdings with notable upside to their analyst target prices are Intrexon Corp (Symbol: XON), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BMRN has 24.89% upside from the recent share price of $91.23 if the average analyst target price of $113.94/share is reached, and analysts on average are expecting ACAD to reach a target price of $44.60/share, which is 22.70% above the recent price of $36.35. Below is a twelve month price history chart comparing the stock performance of XON, BMRN, and ACAD: Combined, XON, BMRN, and ACAD represent 9.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Similarly, BMRN has 24.89% upside from the recent share price of $91.23 if the average analyst target price of $113.94/share is reached, and analysts on average are expecting ACAD to reach a target price of $44.60/share, which is 22.70% above the recent price of $36.35. Three of FBT's underlying holdings with notable upside to their analyst target prices are Intrexon Corp (Symbol: XON), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of XON, BMRN, and ACAD: Combined, XON, BMRN, and ACAD represent 9.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | Below is a twelve month price history chart comparing the stock performance of XON, BMRN, and ACAD: Combined, XON, BMRN, and ACAD represent 9.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF. Three of FBT's underlying holdings with notable upside to their analyst target prices are Intrexon Corp (Symbol: XON), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Similarly, BMRN has 24.89% upside from the recent share price of $91.23 if the average analyst target price of $113.94/share is reached, and analysts on average are expecting ACAD to reach a target price of $44.60/share, which is 22.70% above the recent price of $36.35. |
36085.0 | 2017-09-14 00:00:00 UTC | Alexion (ALXN) Reports Interim Results for Soliris Study | ACAD | https://www.nasdaq.com/articles/alexion-alxn-reports-interim-results-for-soliris-study-2017-09-14 | nan | nan | Alexion Pharmaceuticals, Inc.ALXN announced results from an interim analysis of an ongoing phase III REGAIN study of lead drug Soliris for the treatment of patients with refractory generalized myasthenia gravis (gMG), who are anti-acetylcholine receptor (AChR) antibody-positive.
We note that, Soliris is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system, paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Alexion's shares have outperformed the industry year to date. The stock has been up 19.6% compared with the industry 's gain of 16% in the same time frame.
Furthermore, the evaluation showed that the benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in the extension study across all four assessment scales for an additional 52 weeks (78 weeks in total). In fact, the patients who received placebo in REGAIN and then were treated with Soliris in the extension study, demonstrated significant treatment benefits within 1 to 4 weeks and were sustained through 52 weeks across all four assessment scales.
Meanwhile, Alexion has filed regulatory applications with the FDA as well as the European Medicines Agency (EMA) for Soliris for the treatment of refractory gMG in patients who are anti-acetylcholine receptor antibody-positive. The FDA accepted the supplemental Biologics License Application (sBLA) and set a Prescription Drug User Fee Act date of Oct 23.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has also adopted a positive opinion for the same and the final decision from the European Commission (EC) is anticipated in the third quarter of 2017.
Additionally, a phase III study (PREVENT) on Soliris in patients with relapsing neuromyelitis optica spectrum disorder is ongoing with enrollment being expected to be completed in 2017 and data expected in 2018. Label expansion into additional indications would give Soliris access to a higher patient population and increase the commercial potential of the drug significantly.
Alexion Pharmaceuticals, Inc. Price
Alexion Pharmaceuticals, Inc. Price | Alexion Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Alexion currently sports a Zacks Rank #1 (Strong Buy). Some other top-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , ACADIA Pharmaceuticals Inc. ACAD and Aduro BioTech, Inc. ADRO . While Regeneron carries the same bullish rank as Alexion, ACADIA and Aduro hold a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
ACADIA Pharmaceuticals loss estimates per share have narrowed from $2.59 to $2.57 for 2017 and from $1.92 to $1.90 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 7.97%. The share price of the company has increased 25.7% year to date.
Regeneron's earnings per share estimates have increased from $12.83 to $14.99 for 2017 and from $15.38 to $16.64 for 2018 over the last 30 days. The company delivered positive earnings surprises in two of the trailing four quarters, with an average beat of 10.11%. The share price of the company has increased 17.6% year to date.
Aduro's loss estimates per share have narrowed from $1.46 to $1.32 for 2017 and from $1.55 to $1.24 for 2018 over last 30 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 2.53%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , ACADIA Pharmaceuticals Inc. ACAD and Aduro BioTech, Inc. ADRO . While Regeneron carries the same bullish rank as Alexion, ACADIA and Aduro hold a Zacks Rank #2 (Buy). ACADIA Pharmaceuticals loss estimates per share have narrowed from $2.59 to $2.57 for 2017 and from $1.92 to $1.90 for 2018 over the last 30 days. | Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , ACADIA Pharmaceuticals Inc. ACAD and Aduro BioTech, Inc. ADRO . While Regeneron carries the same bullish rank as Alexion, ACADIA and Aduro hold a Zacks Rank #2 (Buy). | Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , ACADIA Pharmaceuticals Inc. ACAD and Aduro BioTech, Inc. ADRO . While Regeneron carries the same bullish rank as Alexion, ACADIA and Aduro hold a Zacks Rank #2 (Buy). | Some other top-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , ACADIA Pharmaceuticals Inc. ACAD and Aduro BioTech, Inc. ADRO . While Regeneron carries the same bullish rank as Alexion, ACADIA and Aduro hold a Zacks Rank #2 (Buy). ACADIA Pharmaceuticals loss estimates per share have narrowed from $2.59 to $2.57 for 2017 and from $1.92 to $1.90 for 2018 over the last 30 days. |
36086.0 | 2017-09-14 00:00:00 UTC | GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down | ACAD | https://www.nasdaq.com/articles/gtxs-gtxi-enobosarm-positive-in-phase-ii-shares-down-2017-09-14 | nan | nan | GTx, Inc.GTXI announced positive top-line data from a phase II study, evaluating lead pipeline candidate, enobosarm 3 mg (GTx-024), for treating postmenopausal women with stress urinary incontinence (SUI). Data from the study was presented at International Continence Society (ICS) Annual Meeting.
Shares of GTx have decreased almost 9% despite the good news as the data announced was probably below market expectations. However, shares of the company have outperformed the industry so far this year. The stock has surged 42.4% compared with the broader industry's increase of 16%.
The open-label, non-placebo controlled, proof-of-concept phase II study was conducted on 17 postmenopausal women with SUI. The trial met primary endpoints and revealed that women treated with enobosarm experienced significant reduction (50% or greater) in incontinence episodes per day compared with baseline, which sustained for up to seven months following completion of treatment. Mean stress leaks declined by 83% from baseline over a period of 12 weeks. Adverse events reported in the study were minimal.
Based on results from the study, GTx started a randomized, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of enobosarm across two doses (1 mg and 3 mg) compared with placebo in postmenopausal women with SUI.
Investors are reminded that presently, the company is conducting another phase II study, evaluating enobosarm in patients whose advanced breast cancer is both estrogen receptor (ER) positive and androgen receptor (AR) positive. Top-line data from the program is expected later in 2017.
Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg.
GTx, Inc. Price
GTx, Inc. Price | GTx, Inc. Quote
Stocks to Consider
Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Akebia's loss per share estimates narrowed from $4.14 to $3.85 for 2017 and from $1.98 to $1.88 for 2018 over the last 60 days. Its share price soared 69% so far this year.
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.55 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg. GTx, Inc. Price GTx, Inc. Price | GTx, Inc. Quote Stocks to Consider Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. | Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg. GTx, Inc. Price GTx, Inc. Price | GTx, Inc. Quote Stocks to Consider Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg. GTx, Inc. Price GTx, Inc. Price | GTx, Inc. Quote Stocks to Consider Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg. GTx, Inc. Price GTx, Inc. Price | GTx, Inc. Quote Stocks to Consider Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36087.0 | 2017-09-12 00:00:00 UTC | Marinus Stock Surges on Successful Phase II Epilepsy Study | ACAD | https://www.nasdaq.com/articles/marinus-stock-surges-on-successful-phase-ii-epilepsy-study-2017-09-12 | nan | nan | Marinus Pharmaceuticals, Inc.MRNS announced successful completion of a phase II study assessing pipeline candidate, ganaxolone, for the treatment of patients with CDKL5 disorder. The data supports the advancing of the candidate in a late stage study.
Shares rallied 33% on Monday after the announcement of the news. Marinus' share price has risen 310.9% so far this year, significantly outperforming the industry 's gain of 4.6% in the same time frame.
The study met its primary endpoint by achieving a median decrease of 43% in 28-day seizure frequency from baseline in the intent-to-treat (ITT) patient population. The data also demonstrated an increase of 73% in seizure-free days compared to baseline in ITT patient population.
We remind investors that ganaxolone was granted orphan drug designation by the FDA in June 2017 for the treatment of adult and pediatric patients with CDKL5 disorder. We note that the company is focused on developing treatments for patients suffering from epilepsy and neuropsychiatric disorders.
CDKL5 is a rare genetic disorder, which predominantly affects girls and is characterized by seizures and severe neuro-developmental impairment that impacts the ability to walk and talk.
Currently, there is no approved treatment for this indication. The promising data for ganaxolone in the study and a potential late stage study bode well for the company..
Stocks worth considering in the healthcare sector include Adverum Biotechnologies, Inc. ADVM , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro's loss estimates narrowed 9.6% to $1.32 for 2017 and 20% to $1.24 for 2018 over the last 60 days. The company delivered an average earnings beat of 2.53% for the four trailing quarters.
ACADIA Pharma's loss estimates have narrowed 8.9% to $2.59 for 2017 and 8.2% to $1.92 for 2018 over the last 60 days. The company delivered an average earnings beat of 7.97% in the four trailing quarters. The stock is up 28.5% so far this year.
Adverum's loss estimates narrowed 33% to $1.26 for 2017 and 37.7% to $1.27 for 2018, over the last 30 days. The company's shares are up 3.5% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The promising data for ganaxolone in the study and a potential late stage study bode well for the company.. Stocks worth considering in the healthcare sector include Adverum Biotechnologies, Inc. ADVM , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD . ACADIA Pharma's loss estimates have narrowed 8.9% to $2.59 for 2017 and 8.2% to $1.92 for 2018 over the last 60 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. | The promising data for ganaxolone in the study and a potential late stage study bode well for the company.. Stocks worth considering in the healthcare sector include Adverum Biotechnologies, Inc. ADVM , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD . Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharma's loss estimates have narrowed 8.9% to $2.59 for 2017 and 8.2% to $1.92 for 2018 over the last 60 days. | The promising data for ganaxolone in the study and a potential late stage study bode well for the company.. Stocks worth considering in the healthcare sector include Adverum Biotechnologies, Inc. ADVM , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD . Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharma's loss estimates have narrowed 8.9% to $2.59 for 2017 and 8.2% to $1.92 for 2018 over the last 60 days. | The promising data for ganaxolone in the study and a potential late stage study bode well for the company.. Stocks worth considering in the healthcare sector include Adverum Biotechnologies, Inc. ADVM , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD . ACADIA Pharma's loss estimates have narrowed 8.9% to $2.59 for 2017 and 8.2% to $1.92 for 2018 over the last 60 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. |
36088.0 | 2017-09-12 00:00:00 UTC | Ultragenyx's Burosumab Positive in Phase II for XLH and TIO | ACAD | https://www.nasdaq.com/articles/ultragenyxs-burosumab-positive-in-phase-ii-for-xlh-and-tio-2017-09-12 | nan | nan | Ultragenyx Pharmaceutical Inc.RARE announced positive data from two phase II studies, evaluating pipeline candidate burosumab (KRN23) in children with X-linked hypophosphatemia (XLH) and adult with tumor-induced osteomalacia (TIO). Data from the studies were presented at the American Society for Bone and Mineral Research (ASBMR).
Notably, in August, Ultragenyx announced filing of a biologics license application (BLA) to the FDA for burosumab for treatment of XLH. The FDA informed that a decision on acceptance of the same will be made within 60 days.
In January, European Medicines Agency (EMA) had accepted the company's marketing application for burosumab for review. The company now expects an opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) later in 2017.
Shares of the company have inched up more than 1% following this news. However, Ultragenyx's share price movement shows that the stock has significantly underperformed the industry so far this year. Specifically, the stock has plunged 28.1% as against the industry's 16% gain.
The 64-week pediatric phase II study was designed to assess the safety, pharmacodynamics and efficacy of burosumab, administered every two weeks. The study was conducted on 13 children with the given indication, having completed 40 weeks of treatment.
Data from the study demonstrated better results in serum phosphorus levels, rickets, growth rates and other functional outcomes with use of burosumab, sustained through a prolonged treatment period. The study showed 77% of children achieved normal serum phosphorus levels at week 40.
On the other hand, the 48-week phase II study on adult patients with TIO was also designed to assess the safety and efficacy of burosumab. The trial was conducted on a total of 17 patients. The co-primary endpoints in this study are change in serum phosphorus and key biopsy parameters of osteomalacia. Data from the study confirmed improvement in mean serum phosphorus, renal phosphate reabsorption and serum 1,25 dihydroxy vitamin D levels over 24 weeks' treatment of 16 patients. However, adverse events were noticed in 44% of patients.
It is important to note that Ultragenyx is conducting the studies under a collaboration and license agreement with Kyowa Hakko Kirin, a Japanese company, to develop and commercialize burosumab.
We remind investors that in June 2016, the FDA had granted a therapy designation to burosumab for treatment of XLH in pediatric patients.
Ultragenyx is making a significant progress with other pipeline candidates as well. Another candidate rhGUS (UX003) is under review in both the United States and the EU for treatment of mucopolysaccharidosis 7 (MPS 7). The company expects a response from the FDA by this year-end and the EU's feedback is awaited in the first half of 2018.
In the near term, we expect investors' focus to revolve around the opinion of Committee for Medicinal Products for Human Use (CHMP) on burosumab and for regulatory responses to rhGUS.
Ultragenyx Pharmaceutical Inc. Price
Ultragenyx Pharmaceutical Inc. Price | Ultragenyx Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
Ultragenyx currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Akebia's loss per share estimates narrowed from $4.14 to $3.85 for 2017 and from $1.98 to $1.88 for 2018 over the last 60 days. Its share price soared 65% so far this year.
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.55 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36089.0 | 2017-09-07 00:00:00 UTC | Merck (MRK) Opts for Buying German Immuno-Oncology Biotech | ACAD | https://www.nasdaq.com/articles/merck-mrk-opts-for-buying-german-immuno-oncology-biotech-2017-09-07 | nan | nan | MerckMRK announced that it will acquire Germany-based Rigontec, a privately held immuno-oncology focused biotech for an upfront cash payment of almost $137 million (115 million euros).
Rigontec is a leader in retinoic acid-inducible gene I (RIG-I), targeting therapeutics. It is a novel immuno-oncology treatment approach.The deal's completion date is not yet disclosed, subject to certain closing conditions.
Apart from the upfront payment, based upon achievement of certain milestones, Merck may also make additional contingent payments worth approximately 349 million euros.
Shares of Merck have underperformed the industry year to date. The stock has gained 8.7% compared with the industry's 12.6% rally during the period.
The acquisition complements Merck's current immuno-oncology pipeline of Keytruda label expansion studies. With the winding up of this buyout, Merck will add Rigontec's lead candidate, RGT100, in its portfolio. Notably, RGT100 is currently under evaluation in a phase I study for treatment of patients with various tumors.
Significantly, Merck is actively pursuing deals in order to build a long-term portfolio. The company entered into several licensing deals in the past few of years and targets to achieve more in the future.
We remind investors that in July, Merck announced an oncology collaboration with AstraZeneca AZN to jointly commercialize and develop the latter's PARP Inhibitor, Lynparza and MEK 1/2 inhibitor, selumetinib (another oncology candidate of AstraZeneca), both as monotherapy and in combination studies, for multiple cancer types.
Merck will make an upfront payment of $1.6 billion to AstraZeneca. Presently marketed for advanced ovarian cancer, Lynparza is in different studies for a range of tumor types including breast, prostate and pancreatic cancers.
Merck and AstraZeneca will independently develop combination medicines with Lynpraza or selumetinib with their respective PD-L1/PD-1 inhibitors, Imfinzi and Keytruda.
Merck & Company, Inc. Price
Merck & Company, Inc. Price | Merck & Company, Inc. Quote
Zacks Rank & Stocks to Consider
Merck currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.26 to $1.24 for 2018 over the last 30 days. The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. The company posted positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN): Free Stock Analysis Report
Merck & Company, Inc. (MRK): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. | Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36090.0 | 2017-09-07 00:00:00 UTC | BioMarin Presents Interim Data on BMN 250 from Phase I/II | ACAD | https://www.nasdaq.com/articles/biomarin-presents-interim-data-on-bmn-250-from-phase-i-ii-2017-09-07 | nan | nan | BioMarin Pharmaceutical Inc.BMRN announced interim data from part 2 portion of an ongoing dose escalation phase I/II study on investigational enzyme replacement therapy, BMN 250, currently developed for treatment of patients with Sanfilippo B syndrome or mucopolysaccharidosis IIIB (MPS IIIB).
This data was presented at the International Congress of Inborn Errors of Metabolism (ICIEM).
Notably, Sanfilippo B is a disease caused by deficiency in enzyme alpha-N-acetyglucosaminidase (NAGLU), one of the four enzymes required for heparan sulfate (HS) degradation.
Shares of BioMarin have underperformed the industry year to date. The stock has increased 8.5% compared with the industry's 15.7% rally during the period.
Data from the trial demonstrated improvement in cognitive Development Quotient (DQ), a measure of cognitive function normalized to age, in two of the three patients compared with their pre-dose baselines. Additionally, data also showed rapid decreases in liver size to normal range from baseline in the same patients. Notably, patients with untreated Sanfilippo B usually show progressive decline in DQ.
We remind investors that in January, the company presented positive, preliminary results from the part I portion of the phaseI/II study. Data from the research demonstrated that BMN 250 reduced heparan sulfate levels to normal range in cerebral spinal fluid of MPS IIIB patients.
Significantly, BMN 250 enjoys an orphan drug status in both the U.S. and the EU for the given indication.
Per the company's press release, approximately 2,000-3,000 patients are living with Sanfilippo B syndrome in territories where Biomarin operates. Hence, approval of the candidate will provide the company an access to the market, holding huge potential.
Apart from BMN 250, other interesting candidates include pegvaliase and BMN 270. While pegvaliase is under review in the United States for treatment of phenylketonuria (PKU), BMN 270 is being evaluated in phase I/II study for curing hemophilia A. Successful development and commercialization of these candidates will help drive long-term growth at BioMarin.
BioMarin Pharmaceutical Inc. Price
BioMarin Pharmaceutical Inc. Price | BioMarin Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
BioMarin currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Akebia's loss per share estimates narrowed from $4.14 to $3.85 for 2017 and from $1.98 to $1.88 for 2018 over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 25.93%. Its share price soared 58.4% so far this year.
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.26 to $1.24 for 2018 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. | Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36091.0 | 2017-09-06 00:00:00 UTC | Notable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD | ACAD | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-juno-exel-acad-2017-09-06 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $121.7 million dollar inflow -- that's a 3.0% increase week over week in outstanding units (from 49,000,000 to 50,450,000). Among the largest underlying components of XBI, in trading today Juno Therapeutics Inc (Symbol: JUNO) is off about 2.5%, Exelixis Inc (Symbol: EXEL) is up about 0.8%, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is lower by about 1.7%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $53.15 per share, with $84.90 as the 52 week high point - that compares with a last trade of $83.68. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Juno Therapeutics Inc (Symbol: JUNO) is off about 2.5%, Exelixis Inc (Symbol: EXEL) is up about 0.8%, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is lower by about 1.7%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $53.15 per share, with $84.90 as the 52 week high point - that compares with a last trade of $83.68. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XBI, in trading today Juno Therapeutics Inc (Symbol: JUNO) is off about 2.5%, Exelixis Inc (Symbol: EXEL) is up about 0.8%, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is lower by about 1.7%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $53.15 per share, with $84.90 as the 52 week high point - that compares with a last trade of $83.68. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XBI, in trading today Juno Therapeutics Inc (Symbol: JUNO) is off about 2.5%, Exelixis Inc (Symbol: EXEL) is up about 0.8%, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $121.7 million dollar inflow -- that's a 3.0% increase week over week in outstanding units (from 49,000,000 to 50,450,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $53.15 per share, with $84.90 as the 52 week high point - that compares with a last trade of $83.68. | Among the largest underlying components of XBI, in trading today Juno Therapeutics Inc (Symbol: JUNO) is off about 2.5%, Exelixis Inc (Symbol: EXEL) is up about 0.8%, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $121.7 million dollar inflow -- that's a 3.0% increase week over week in outstanding units (from 49,000,000 to 50,450,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $53.15 per share, with $84.90 as the 52 week high point - that compares with a last trade of $83.68. |
36092.0 | 2017-08-31 00:00:00 UTC | The Medicines Company's Infection Drug Vabomere Gets FDA Nod | ACAD | https://www.nasdaq.com/articles/the-medicines-companys-infection-drug-vabomere-gets-fda-nod-2017-08-31 | nan | nan | The Medicines CompanyMDCO announced that the FDA has granted accelerated approval to its experimental antibiotic, Vabomere, a combination of meropenem and vaborbactam, for treating complicated urinary tract infections (cUTI), including the pyelonephritis.
The company expects to make Vabomere available in the market in fourth-quarter 2017. It filed a new drug application (NDA) for the antibiotic in February, currently under review in the EU.
Shares of The Medicines Company have outperformed the industry year to date. The stock has rallied 14.2% compared with the industry's 9.7% gain during the period.
The NDA was supported by positive data from a phase III (TANGO-1) multi-center, randomized, double-blind, double-dummy study. The study (n=550) was designed to evaluate the efficacy, safety and tolerability of Vabomere in patients with cUTIs or acute pyelonephritis compared with Pfizer Inc.'s PFE Zosyn (piperacillin/tazobactam).
Data from this trial showed that Vabomere achieved statistical superiority over Zosyn with successful results obtained from 98.4% of patients treated with Vabomere compared with 94.3% administered with Zosyn.
We remind investors that in July, an independent data safety and monitoring board stopped the phase III TANGO-2 study on Vabomere based on an interim analysis. Interim results from the study showed that Vabomere improved clinical cure rates across all infection types and reduced rate of renal adverse events in comparison to the best available therapy.
Vabomere has been designated as a Qualified Infectious Disease Product by the FDA. Antibiotic resistance, especially to carbapenems, is a rapidly growing problem in the medicine sector. In fact, carbapenem-resistant enterobacteriaceae (CRE) infections are one of the deadliest diseases, given its 40% mortality rate. As a result, there is an urgent need for antimicrobials like Vabomere to effectively treat CRE and other resistant organisms.
Successful commercialization of Vabomere is expected to boost the company's top line, considering the lucrative market that it targets.
The Medicines Company Price
The Medicines Company Price | The Medicines Company Quote
Zacks Rank & Stocks to Consider
The Medicines Company currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer, Inc. (PFE): Free Stock Analysis Report
The Medicines Company (MDCO): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report The Medicines Company (MDCO): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report The Medicines Company (MDCO): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report The Medicines Company (MDCO): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report The Medicines Company (MDCO): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36093.0 | 2017-08-30 00:00:00 UTC | FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down | ACAD | https://www.nasdaq.com/articles/fdas-refusal-to-file-letter-for-inbrija-pushes-acorda-down-2017-08-30 | nan | nan | Shares of Acorda Therapeutics, Inc.ACOR have plunged almost 25% after the company announced that it has received a refusal to file (RTF) letter from the FDA in connection with the new drug application (NDA) for pipeline candidate, Inbrija.
Notably, Acorda is seeking approval for Inbrija (CVT-301, levodopa inhalation powder) in the United States as a treatment option for symptoms of OFF periods in people with Parkinson's taking a carbidopa / levodopa regimen.
Shares of Acorda have underperformed the industry year to date. The stock has increased 3.7% as against the industry's 9.7% gain during the period.
However, the FDA has deemed the application incomplete after a preliminary review and as a result, the regulatory body now requires additional supporting information to review the application.
The FDA stated two main reasons for the RTF: date specification as to when the manufacturing site can be ready for inspection and questions related to drug master production record. Additionally, the FDA has also asked for some extra data, unrelated to the main issues of the RTF.
Notably, Acorda mentioned that it will request the FDA for a Type A meeting in a bid to resolve the issues.
The FDA's refusal for Inbrija's NDA is a major setback for the company as this would delay its commercial launch, previously expected in the first half of 2018. However, good news is that the FDA has not recommended any additional efficacy/safety study to be conducted to resubmit the filing.
It is important to note that the NDA application was based on positive data from one phase III safety and efficacy study (SPAN-PD) and from two ongoing long-term safety studies (CVT-301-005 and CVT-301-004E) on people with Parkinson's.
Significantly, Acorda is planning to submit regulatory applications for Inbrija in the EU by the end of 2017 for the given indication.
Going forward, we expect investors to remain focused on further updates on this development around Inbrija.
Acorda Therapeutics, Inc. Price
Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Acorda currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Akebia's loss per share estimates narrowed from $4.14 to $3.85 for 2017 and from $1.98 to $1.88 for 2018 over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 25.93%. Its share price soared 60.5% so far this year.
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really take off.
See Stocks Now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. |
36094.0 | 2017-08-29 00:00:00 UTC | The Medicines Co's Inclisiran Positive in Extension Study | ACAD | https://www.nasdaq.com/articles/the-medicines-cos-inclisiran-positive-in-extension-study-2017-08-29 | nan | nan | The Medicines CompanyMDCO along with partner Alnylam Pharmaceuticals, Inc. ALNY announced new one-year safety and efficacy data from the ongoing ORION-1 phase II study, evaluating pipeline candidate, Inclisiran (PCSK9 Inhibitor), for the treatment of hypercholesterolemia.
This new data reaffirmed the earlier results from the ORION-1 study, demonstrating significant reductions of LDL-C (low-density lipoprotein) or "bad" cholesterol at six months and one year.
Notably, ORION-1 is a placebo-controlled, double-blinded, randomized, dose-finding phase II study. It compares and evaluates the effect of various doses of single or multiple subcutaneous injections of Inclisiran. The trial compares the effect of different doses of Inclisiran and evaluates the potential of an infrequent dosing regimen.
So far this year, The Medicines Company's shares have outperformed the industry . The company's shares have rallied 11.6% compared with the industry's 9.4% increase.
Data from the study was presented at the European Society of Cardiology (ESC) Congress 2017. These robust findings underscore the selection of a six-monthly maintenance dose of 300 mg in Phase III trials, presently in advanced stages of preparation.
We remind investors that the FDA approved of a phase III study design for Inclisiran in April this year. The study will be conducted on patients with atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH). The company anticipates data readouts from the study during the second half of 2019.
The phase III study is designed to support the submission of a new drug application (NDA) to the FDA and a marketing application in the EU for the given indication.
Apart from Inclisiran, another key candidate in the company's portfolio is Vabomere (formerly Carbavance), a fixed dose combination of meropenem-vaborbactam. It is currently under review in both the United States and the EU.
Going forward, we expect the investors' focus to rest on further regulatory updates on Inclisiran and Vabomere.
The Medicines Company Price
The Medicines Company Price | The Medicines Company Quote
Zacks Rank & Stocks to Consider
The Medicines Companycurrently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Medicines Company (MDCO): Free Stock Analysis Report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36095.0 | 2017-08-28 00:00:00 UTC | J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III | ACAD | https://www.nasdaq.com/articles/jjs-jnj-xarelto-aspirin-regimen-positive-in-phase-iii-2017-08-28 | nan | nan | Johnson & Johnson 's JNJ subsidiary, Janssen, announced data from a pivotal phase III study, showing that its blood thinner Xarelto has significantly reduced major cardiovascular events in patients with stable coronary and peripheral artery disease (CAD/PAD).
The study is being currently conducted to expand Xarelto's label (rivaroxaban, 2.5 mg twice-daily) in combination with aspirin (100 mg once daily) versus aspirin alone.
Xarelto is presently marketed as an anticoagulant to reduce the risk of stroke and blood clots in patients with atrial fibrillation (AF), not caused by a heart valve problem. It is also approved in the United States to treat deep vein thrombosis (VTE) and pulmonary embolism.
Shares of J&J have outperformed the industry year to date. The stock increased 14.4% as against the industry's 10.9% gain during the period.
The findings also showed a massive 42% decrease in any stroke and 22% fall in CV death. The trial was conducted at 602 centers in 33 countries. Also, PAD patients treated with the combination therapy had significantly fewer major adverse limb events compared with those taking aspirin alone. However, the risk of major bleeding was found to be significantly higher in patients receiving treatment by Xarelto/aspirin regimen.
Currently, there are eight new indications seeking studies for Xarelto as part of the EXPLORER clinical development program.
notably, Xarelto has been developed by J&J in partnership with Bayer AG BAYRY . The drug is launched in more than 80 countries and is marketed by Bayer outside the United States.
Per the company's press release, CAD is found to be developing among one-third to one-half of all middle-aged populace during their lifetime in developed countries. Per an estimate, approximately 20% of adults aged above 55 years have evidence of PAD. Therefore, approval of Xarelto for these additional indications will provide the company an access to a huge globally potential market.
We remind investors that in June, J&J announced that the FDA has granted priority review to a sNDA of Xarelto for label expansion to include a 10 mg dose to reduce the risk of recurrent VTE.
Xarelto is currently approved in a 20 mg dose formulation. Only last month, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on a label update regarding the use of 15 mg once-daily dose of Xarelto in combination with a P2Y12 inhibitor for treatment of patients with non-valvular atrial fibrillation (AF), who require oral anticoagulation and undergo percutaneous coronary intervention (PCI) with stent placement. The final decision of the European Commission is expected by the end of 2017.
Johnson & Johnson Price
Johnson & Johnson Price | Johnson & Johnson Quote
Zacks Rank & Stocks to Consider
J&J currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Bayer AG (BAYRY): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , each carrying a Zacks Rank #2 (Buy). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. |
36096.0 | 2017-08-28 00:00:00 UTC | Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval | ACAD | https://www.nasdaq.com/articles/minerva-jjs-amendment-of-min-202-contract-wins-eu-approval-2017-08-28 | nan | nan | Minerva Neurosciences, Inc.NERV announced that an amendment to its license agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson JNJ , related to co-development of orexin-2 receptor antagonist, MIN-202 (JNJ 42827922), has been approved of in the EU.
Notably, Minerva entered into the agreement with Janssen in June, the execution of which was dependent on the sanction of its certain term by the EU. Subsequently, each condition has now been met and the amendment is expected to take effect on Aug 29, 2017.
Pursuant to the agreement, Minerva is entitled to receive an upfront payment of $30 million from Janssen. Additionally, Minerva will also receive an amount of $20 million at the start of a phase III insomnia study for MIN-202 and $20 million upon 50% completion of enrollment in the study. Also, an amount of $13 million has been waived by Janssen that was due from Minerva for phase II development of the candidate.
Shares of Minerva have significantly underperformed the industry year to date. The stock has plunged 50.2% compared with the industry's 2.2% decrease during the period.
Minerva's other pipeline candidates include MIN-117, currently in clinical development for major depressive disorder (MDD), MIN-101 (three phase IIb study) for schizophrenia and MIN-301 for Parkinson's disease.
Significantly in July, Minerva completed a public offering, having generated net proceeds of approximately $41.5 million. The company expects that this fund along with finances raised from the public stock offering and current financial resources, will together support five clinical studies projected to take place by 2019-end for other pipeline candidates including MIN-202.
Minerva Neurosciences, Inc Price
Minerva Neurosciences, Inc Price | Minerva Neurosciences, Inc Quote
Zacks Rank & Stocks to Consider
Minerva currently carries a Zacks Rank #2 (Buy). Some other stocks worth considering in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other stocks worth considering in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. | Some other stocks worth considering in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. Some other stocks worth considering in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some other stocks worth considering in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. |
36097.0 | 2017-08-27 00:00:00 UTC | 3 Stocks That Turned $8,000 Into at Least $138,000 in 5 Years | ACAD | https://www.nasdaq.com/articles/3-stocks-turned-8000-least-138000-5-years-2017-08-27 | nan | nan | In a rising market, it's easy for the tide to lift all boats, but it takes a special company and business to far outperform all others. When one stock can soar much further than its rivals, that's a business that investors might want to look at more closely.
MGP Ingredients (NASDAQ: MGPI) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Netflix (NASDAQ: NFLX) are three such companies that did just that, taking a grubstake investment of $8,000 and in just five years time turning it into a colossal $135,000 return.
MGP Ingredients (76.88% annual return for $138,511)
It's probably not so far afield to partially credit the TV show Mad Men for the current popularity of whiskey, bourbon, scotch, and rye, and distilling giants such as Diageo have ridden the wave higher. In its fiscal 2017 fourth-quarter earnings announcement, the company reported 15% rise in net sales, driven in large part by strong growth in North American whiskey, scotch, and tequila sales. In particular, whiskey sales surged 12% on the strength of its Crown Royal and premium Bulleit brands.
What many investors may not know is that Diageo and a number of other distillers source their alcohol from MGP Ingredients, a contract distiller in Indiana, which produces high-quality formulations that customers can tweak to their own specifications. Premium whiskey Bulleit is but one brand that gets its start at MGP. Many so-called craft distilleries are also using MGP for their alcohol, which seems to belie the "craft" image they're trying to maintain.
Business in the premium alcohol market has been good for the contract distiller, with sales rising 14.5% last year, though total sales were dragged down by declines in industrial alcohol, which is used in food and non-food applications.
Whiskey's popularity has driven an investment in MGP Ingredients higher, with total returns of some 1,650% over the past five years. That would have turned an $8,000 investment into one worth more than $138,500. I'll drink to that!
Acadia Pharmaceuticals (77.22%, $139,847)
The ride for commercial-stage biopharma Acadia Pharmaceuticals to outsize performance hasn't been a smooth one, as you'd expect for a biotech that is operating in the rough-and-tumble world of new drug discovery. But with FDA approval last year of its Parkinson's disease psychosis (PDP) drug Nuplazid, Acadia looks as if it might not be looking backward for a long, long time.
The benefit to Acadia from Nuplazid is that there are really no other treatment options on the market for patients suffering from the illness. With approximately a million patients in the U.S. currently suffering from Parkinson's -- a progressive condition of the central nervous system that causes tremors, muscular rigidity, and imprecise movement -- it has a large pool of patients to target as many go on to develop PDP. Its second-quarter earnings report shows how large the potential is, as Acadia reported sales growth of more than $30 million for Nuplazid, far ahead of the $19 million analysts were expecting.
With the possibility the drug could be used for other conditions as well, there doesn't seem to be any reason Acadia can't continue to perform beyond the reaches of the rest of the market. The nearly $140,000 that $8,000 initial investment has turned into may very well be worth a lot more in the years ahead.
Netflix (77.85%, $142,350)
You can probably track Netflix's growth as an investment with the growth in the number of subscribers it has to its service. While there are over 103 million subscribers worldwide right now, with about half in the U.S. alone, five years ago it had only about 26 million.
In its second-quarter earnings report, issued a few weeks ago, Netflix said revenue jumped 32% for the period to $2.8 billion, while profits were soaring 60% higher to $66 million. Of more importance, the movie-streaming service blew away subscriber-growth estimates, adding 5.2 million new members, which was well ahead of the 3.2 million it had forecast. While the bulk of the subscriber growth numbers came from overseas, that's not surprising, because that's where Netflix's future lies -- there, and in original content.
Once upon a time, Netflix was content to rent out other people's movies, but the success of its House of Cards and Orange Is the New Black original series taught it that relying on the kindness of others is second best. Now Netflix is a full-blown content creator, and it's looking to upend how Hollywood works by releasing feature-length movies on its platform rather than in theaters.
With a nearly 80% annual return for the past half-decade, Netflix has been a rocket ship on fire that shows no signs of burning out. An $8,000 investment in the movie-streaming service back in 2012 would be worth $142,350 today, a not-too-shabby result for kicking back with your feet up and eating some popcorn while you watch a few movies.
10 stocks we like better than Acadia Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Rich Duprey has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Netflix. The Motley Fool recommends Diageo. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MGP Ingredients (NASDAQ: MGPI) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Netflix (NASDAQ: NFLX) are three such companies that did just that, taking a grubstake investment of $8,000 and in just five years time turning it into a colossal $135,000 return. Acadia Pharmaceuticals (77.22%, $139,847) The ride for commercial-stage biopharma Acadia Pharmaceuticals to outsize performance hasn't been a smooth one, as you'd expect for a biotech that is operating in the rough-and-tumble world of new drug discovery. But with FDA approval last year of its Parkinson's disease psychosis (PDP) drug Nuplazid, Acadia looks as if it might not be looking backward for a long, long time. | MGP Ingredients (NASDAQ: MGPI) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Netflix (NASDAQ: NFLX) are three such companies that did just that, taking a grubstake investment of $8,000 and in just five years time turning it into a colossal $135,000 return. Acadia Pharmaceuticals (77.22%, $139,847) The ride for commercial-stage biopharma Acadia Pharmaceuticals to outsize performance hasn't been a smooth one, as you'd expect for a biotech that is operating in the rough-and-tumble world of new drug discovery. But with FDA approval last year of its Parkinson's disease psychosis (PDP) drug Nuplazid, Acadia looks as if it might not be looking backward for a long, long time. | MGP Ingredients (NASDAQ: MGPI) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Netflix (NASDAQ: NFLX) are three such companies that did just that, taking a grubstake investment of $8,000 and in just five years time turning it into a colossal $135,000 return. Its second-quarter earnings report shows how large the potential is, as Acadia reported sales growth of more than $30 million for Nuplazid, far ahead of the $19 million analysts were expecting. Acadia Pharmaceuticals (77.22%, $139,847) The ride for commercial-stage biopharma Acadia Pharmaceuticals to outsize performance hasn't been a smooth one, as you'd expect for a biotech that is operating in the rough-and-tumble world of new drug discovery. | MGP Ingredients (NASDAQ: MGPI) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Netflix (NASDAQ: NFLX) are three such companies that did just that, taking a grubstake investment of $8,000 and in just five years time turning it into a colossal $135,000 return. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! Acadia Pharmaceuticals (77.22%, $139,847) The ride for commercial-stage biopharma Acadia Pharmaceuticals to outsize performance hasn't been a smooth one, as you'd expect for a biotech that is operating in the rough-and-tumble world of new drug discovery. |
36098.0 | 2017-08-25 00:00:00 UTC | Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars | ACAD | https://www.nasdaq.com/articles/adamas-adms-dyskinesia-drug-gets-fda-approval-stock-soars-2017-08-25 | nan | nan | Adamas Pharmaceuticals, Inc.ADMS announced FDA approval of its Gocovri for treating dyskinesia in patients with Parkinson's disease who are on levodopa-based therapy. This the first drug to receive approval for this indication in the U.S.
The approved dosage for Gocovri extended release (ER) capsules is 274 mg administered once daily.
With no drug approved for treating dyskinesia, the approval of Gocovri is good news for Adamas. The company expects to make the drug available in the fourth quarter of 2017 and a formal launch is planned in January 2018.
Dyskinesia is a disorder, which causes involuntary and non-rhythmic movements that are purposeless and unpredictable. The disorder occurs in Parkinson's patients due to levodopa-based treatment.
The company's stock soared 38.5% in after-hours trading on Thursday subsequent to the announcement of the news. Moreover, shares of the company have outperformed the industry so far this year. The company's shares are down 15.8% against the industry's decline of 19.9% in the period.
The approval of Gocovri was based on positive data from two phase III studies. In the first study, the drug showed statistically significant and clinically relevant reductions in dyskinesia in Parkinson's disease patients. Treatment with Gocovri led to a reduction in Unified Dyskinesia Rating Scale (UDysRS) total score by 37% compared to 12% for placebo at week 12. Confirming the data from the first study, in the second study, Gocovri achieved 46% reduction in UDysRS total score versus 16% for placebo.
Moreover, Gocovri increased functional time by 3.6 hours in the first study and 4 hours in the second study whereas placebo achieved an increase of 0.8 hours and 2.1 hours, respectively.
Adamas Pharmaceuticals, Inc. Price and Consensus
Adamas Pharmaceuticals, Inc. Price and Consensus | Adamas Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Adamas has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the pharmaceutical sector are Corcept Therapeutics Incorporated CORT , Recro Pharma, Inc. REPH and ACADIA Pharmaceuticals Inc. ACAD . All these stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Corcept's earnings estimates increased from 26 cents to 42 cents for 2017 and from 49 cents to 70 cents for 2018 over the last 30 days. The company delivered an average earnings beat of 29.17% in the four trailing quarters. The stock is up 98.8% so far this year.
Recro Pharma's loss estimates have narrowed from $2.59 to $2.35 for 2017 and from $2.60 to $2.59 for 2018 over the last 60 days. The company delivered an average positive earnings surprise of 21.16% in the trailing four quarters.
ACADIA Pharma's loss estimates have narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company delivered an average earnings beat of 7.97% in the four trailing quarters. The stock is up 13.8% so far this year.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really takes off.
See Stocks Now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
Recro Pharma, Inc. (REPH): Free Stock Analysis Report
Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharmaceutical sector are Corcept Therapeutics Incorporated CORT , Recro Pharma, Inc. REPH and ACADIA Pharmaceuticals Inc. ACAD . ACADIA Pharma's loss estimates have narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report Recro Pharma, Inc. (REPH): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharmaceutical sector are Corcept Therapeutics Incorporated CORT , Recro Pharma, Inc. REPH and ACADIA Pharmaceuticals Inc. ACAD . Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report Recro Pharma, Inc. (REPH): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharma's loss estimates have narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report Recro Pharma, Inc. (REPH): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharmaceutical sector are Corcept Therapeutics Incorporated CORT , Recro Pharma, Inc. REPH and ACADIA Pharmaceuticals Inc. ACAD . ACADIA Pharma's loss estimates have narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharmaceutical sector are Corcept Therapeutics Incorporated CORT , Recro Pharma, Inc. REPH and ACADIA Pharmaceuticals Inc. ACAD . ACADIA Pharma's loss estimates have narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report Recro Pharma, Inc. (REPH): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. |
36099.0 | 2017-08-25 00:00:00 UTC | Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate | ACAD | https://www.nasdaq.com/articles/ultragenyx-files-bla-to-fda-for-hypophosphatemia-candidate-2017-08-25 | nan | nan | Ultragenyx Pharmaceutical Inc.RARE along with Japanese partner Kyowa Hakko Kirin Co., Ltd announced filing of a biologics license application (BLA) to the FDA for its pipeline candidate burosumab (KRN23) to treat patients with X-linked hypophosphatemia (XLH). The FDA informed that a decision on acceptance of the same will be made within 60 days.
Notably, in January, European Medicines Agency (EMA) had accepted the company's marketing application for burosumab for review. The company now expects an opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) in the second half of this year.
Shares of the company have inched up almost 1% following the news release. However, Ultragenyx's share price movement shows that the stock has underperformed the industry so far this year. Specifically, the stock plunged 26.8% as against the industry's 8% gain.
The BLA submission was supported by positive data from a phase III study on adults and a phase II trial on pediatric patients for the aforementioned indication. The data was announced in April. The 24-week phase III study met the primary endpoint as the patients treated with burosumab achieved a statistically significant improvement in serum phosphorus levels compared with placebo. Further, the secondary endpoint of the study was also met as patients administered with burosumab attained a substantial improvement in stiffness as well as witnessed a strong progress in physical function and pain.
On the other hand, the 64-week data from the pediatric phase II study showed better results in serum phosphorus levels, rickets, growth rates and other functional outcomes with use of burosumab, sustained through a prolonged period of treatment.
In fact, in June 2016, the FDA had granted a therapy designation to burosumab for treatment of XLH in pediatric patients aged one year and above.
Currently, burosumab is also being evaluated in a phase II study for treating tumor-induced osteomalacia (TIO).
Importantly, Ultragenyx is making a significant progress with other pipeline candidates as well. Another candidate rhGUS (UX003) is under review in both the U.S. and the EU for treatment of mucopolysaccharidosis 7 (MPS 7). The company expects a response from the FDA by this year-end and the EU's feedback is awaited in the first half of 2018.
In the near term, we expect investors' focus to remain on the opinion of Committee for Medicinal Products for Human Use (CHMP) on burosumab and for regulatory responses to rhGUS.
Ultragenyx Pharmaceutical Inc. Price
Ultragenyx Pharmaceutical Inc. Price | Ultragenyx Pharmaceutical Inc. Quote
Zacks Rank & Stocks to Consider
Ultragenyx currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aerie Pharmaceuticals, Inc. AERI , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Aerie's loss per share estimates narrowed from $2.62 to $2.53 for 2017 over the last 30 days. The company delivered a positive earnings surprise in all three of the trailing four quarters with an average beat of 0.64%. Its share price soared 39.7% so far this year.
Aduro Biotech's loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market's record highs, but picking the best ones to buy can be tough. There's a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now - before the next wave of innovations really takes off.
See Stocks Now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the pharma sector are Aerie Pharmaceuticals, Inc. AERI , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the pharma sector are Aerie Pharmaceuticals, Inc. AERI , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Aerie Pharmaceuticals, Inc. AERI , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Aerie Pharmaceuticals, Inc. AERI , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report To read this article on Zacks.com click here. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.